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Abstract 
In the past decades a significant number of pharmaceuticals emerged from conscious design and 
screening of small molecule drugs, purposely invented and developed by medicinal and 
pharmaceutical chemists. Medicinal chemistry in its most common guise – directed towards small 
organic molecules – has become a vivid interplay of synthetic organic chemistry, computational 
chemistry, chemical biology, enzymology and structural biology, together aiming to discover new 
therapeutic agents. Organic chemists find themselves in the center of this collaboration, as they are 
demanded to create and optimize lead structures and supply material for biological assays. Therefore, 
there is a permanent ambition to create new molecular architectures and methodologies that expand 
the organic chemist’s tool box. 
This thesis summarizes the development of new transformations for the transition metal-catalyzed 
introduction of carbon monoxide and alternative C1-building blocks into molecular scaffolds. The 
developed methodologies provide novel opportunities for the implementation of functional groups and 
ideally expand the molecular space of organic building blocks. 
The first Chapter targets the development of ruthenium-catalyzed carbonylative direct arylation of 
(hetero)arenes via C−H bond activation. A facile three component synthesis of complex aryl-
heteroaryl ketones was enabled upon exploitation of the multifunctional aptitudes of inexpensive 
ruthenium(II)-catalyst precursors that allow for a successive twofold C(sp
2
)−C(sp2) bond formation via 
acetate-assisted C−H bond cleavage on water (Scheme I.1). Starting with simple phenylpyridine 
derivatives, this chemistry was later extended to the preparation of aryl-heteroarylketones including 
examples with cleavable directing groups. The synthetic applicability of the developed methodology is 
showcased in the streamlined synthesis of an unprecedented analog of the top-selling selective 
estrogen receptor modulator Raloxifene (Evista®) and the gram-scale synthesis of a key intermediate 
of marinopyrroles and pyoluteorin (Figure I.1). 
 
Scheme I.1. Regioselective ruthenium-catalyzed carbonylative direct arylation. 
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Figure I.1. Synthetic application of the ruthenium-catalyzed direct aroylation protocol. (a) synthesis of 
a Raloxifene analog. (b) Synthesis of a key intermediate towards the synthesis of marinopyrroles. 
The second Chapter describes the enantioselective masked formylation of phenyldiazo acetates using 
1,3,5-trioxane as C1 source (Scheme I.2). This protocol represents a new application of rhodium(II) 
carbenoid mediated C−H bond cleavage in an enantioselective masked-formylation reaction leading to 
the synthesis of novel alkyl 2-phenyl-2-(1,3,5-trioxan-2-yl)acetates. These compounds demonstrated a 
high stability of the trioxanyl moiety, thus enabling further functionalization in its presence. Because 
of its structural relation to naturally occurring arylpropionates such as atropine and artificial 
methylphenidates, this substance class holds great promise as valuable building blocks for medicinal 
chemistry. 
 
Scheme I.2. Enantioselective masked formylation of rhodium(II) carbenoids using 1,3,5-trioxane. 
In a subsequent work, the rhodium(II)-catalyzed decomposition of 1-(methylsulfonyl)-4-aryl-1H-
1,2,3-triazoles in the presence of 1,3,5-trioxane has been investigated (Scheme I.3). In this reaction, 
ylide formation of the oxygen-heterocycle with the Rh-carbenoid species outcompetes the C−H bond 
functionalization pathway. Successful optimization of the reaction condition allowed for the one-pot 
preparation of unprecedented nine-membered 1,3,5,7-trioxazonine rings. 
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Scheme I.3. Rhodium(II)-catalyzed decomposition of 1-sulfonyl-1,2,3-triazoles in the presence of 1,3,5-
trioxane. 
Finally, a conceptually new approach of a concomitant alkoxylation/formylation of diazo 
compounds through C−O bond activation triggered by rhodium(II) catalysts is described (Scheme I.4). 
The final Chapter summarizes the development of a new strategy for the one step synthesis of 
quaternary carbon centers from inexpensive chemical commodities holding an aryl or alkenyl, alkoxy, 
masked aldehyde and ester functionality.  
 
Scheme I.4. Rhodium(II)-catalyzed alkoxylation-acetalization of donor-acceptor-substituted diazo 
compounds: one-step synthesis of densely functionalized quaternary carbon centers. 
 
 
  Table of Contents 
VII 
 
Table of Contents 
Acknowledgements ........................................................................................................................... II 
Abstract ............................................................................................................................................ IV 
Table of Contents ...........................................................................................................................VII 
List of Abbreviations ........................................................................................................................ X 
1 Regioselective ruthenium-catalyzed carbonylative direct arylation of (hetero)arenes ........1 
1.1 Preface .................................................................................................................................1 
1.2 Project outline .....................................................................................................................1 
1.3 Background .........................................................................................................................2 
1.3.1 Transition metal-catalyzed C−H bond activation ........................................................ 2 
1.3.2 Carbonylative C−H bond functionalization ................................................................ 5 
1.3.3 Benzophenones ............................................................................................................ 9 
1.4 Result and discussion .......................................................................................................10 
1.4.1 Screening of reaction conditions ............................................................................... 11 
1.4.2 Scope and limitations ................................................................................................ 12 
1.4.3 Regioselective ruthenium-catalyzed carbonylative direct arylation of 5-membered and 
condensed heterocycles ............................................................................................... 15 
1.4.4 Application of the developed methodology .............................................................. 21 
1.4.5 Mechanistic considerations ....................................................................................... 26 
1.5 Conclusion and outlook ...................................................................................................31 
2 Rhodium(II)-catalyzed enantioselective masked formylation of push-pull carbenes with 
1,3,5-trioxane ............................................................................................................................32 
2.1 Preface ...............................................................................................................................32 
2.2 Project outline ...................................................................................................................32 
2.3 Background .......................................................................................................................33 
2.3.1 1,3,5-Trioxane in organic synthesis .......................................................................... 33 
2.3.2 C–H Bond functionalization by means of rhodium carbenoid insertion ................... 35 
2.4 Results and discussion ......................................................................................................42 
2.4.1 Optimization and catalyst screening.......................................................................... 42 
2.4.2 Scope of the transformation ...................................................................................... 43 
Table of Contents 
VIII 
 
2.4.3 Product derivatization ................................................................................................ 47 
2.5 Stereoelectronic effects in 1,3,5-trioxane: The Perlin effect ........................................ 50 
2.5.1 Background ................................................................................................................ 50 
2.5.2 Stereoelectronic effects in 1,3,5-trioxane .................................................................. 51 
2.6 Conclusion and outlook ................................................................................................... 53 
3 Rhodium(II)-catalyzed annulation of azavinyl carbenes through ring-expansion of 1,3,5-
trioxane: Rapid excess to 9-membered heterocycles ............................................................ 54 
3.1 Preface .............................................................................................................................. 54 
3.2 Project outline .................................................................................................................. 54 
3.3 Background ...................................................................................................................... 56 
3.4 Results and discussion ..................................................................................................... 59 
3.4.1 Scope and limitations ................................................................................................. 60 
3.4.2 Mechanistic considerations ........................................................................................ 61 
3.5 Conclusion and outlook ................................................................................................... 64 
4 Rhodium(II)-catalyzed alkoxylation-acetalization of donor-acceptor-substituted diazo 
compounds: One-step synthesis of highly functionalized quaternary carbon centers ...... 65 
4.1 Preface .............................................................................................................................. 65 
4.2 Project outline .................................................................................................................. 65 
4.3 Background ...................................................................................................................... 66 
4.3.1 Trialkyl orthoesters in organic synthesis ................................................................... 66 
4.3.2 Synthesis of arylmethoxyacetic acid derivatives ....................................................... 68 
4.3.3 Rhodium(II) catalysis: Ylide formation and C−X/C-C bond forming reactions ....... 70 
4.4 Results and discussion ..................................................................................................... 75 
4.4.1 Optimization of reaction conditions .......................................................................... 75 
4.4.2 Scope and limitations ................................................................................................. 76 
4.4.3 Derivatization of methyl 2-phenyl-2,3,3-trimethoxypropanoates ............................. 79 
4.4.4 Mechanistic considerations ........................................................................................ 81 
4.5 Conclusion and outlook ................................................................................................... 85 
5 Summary .................................................................................................................................. 86 
6 Experimental section ............................................................................................................... 88 
  Table of Contents 
IX 
 
6.1 General remarks ...............................................................................................................88 
6.2 General procedures ..........................................................................................................90 
6.2.1 Experimental part to Chapter 1 ................................................................................. 92 
6.2.2 Experimental part to Chapter 2 ............................................................................... 133 
6.2.3 Experimental part to Chapter 3 ............................................................................... 162 
6.2.4 Experimental part to Chapter 4 ............................................................................... 169 
7 References ...............................................................................................................................179 
8 Curriculum Vitae ...................................................................................................................186 
9 Publications .............................................................................................................................188 
 
  
List of Abbreviations 
X 
 
List of Abbreviations 
[M+] 
Ac   
Ad    
Alk  
aq.   
Ar  
Bn 
Boc    
Bu 
t-Bu   
calcd. 
Cat. 
DBU   
 
DCM  
DFT  
DG 
2,2-DMB 
DMF  
DMSO 
DOSP 
 
d.r.  
Ed.  
ee 
EDG  
e.g. 
EI 
ESI 
Et 
EWG  
equiv. 
EI-MS 
  
OOct 
molecular ion peak 
acetyl  
adamantyl  
alkyl 
aqueous 
aryl 
benzyl 
tert- butyloxycarbonyl 
n-butyl 
tert-butyl 
calculated 
catalytic 
1,8-diazabicyclo[5,4,0]undec-7-
ene 
Dichloromethane 
density function theory 
directing group 
2,2-dimethylbutane  
N,N-dimethylacetamide 
dimethylsulfoxid  
N-(4-dodecylbenzene-sulfonyl) 
prolinate  
diastereomeric ratio 
Editor 
enantiomeric excess 
electron-donating group 
for example 
electron ionization 
electrospray ionization 
Ethyl 
electron-withdrawing group 
equivalent 
electron ionization mass 
spectroscopy 
octanoate 
eV 
g 
GC 
h 
Hex 
HPLC 
 
HRMS  
 
Hz  
IR  
isol. 
J 
L 
m 
m 
[M] 
Me 
MeCN 
MeO 
MeOH 
Mes 
m.p. 
m/z 
min 
mL 
mmol 
MS 
NMR 
 
NOESY 
 
o 
OAc  
OEt 
electron volt 
gramm 
gas chromatography 
hours 
n-hexyl 
high-performance liquid 
chromatography  
high resolution mass 
spectroscopy 
Hertz 
infrared spectroscopy 
isolated 
coupling constant 
ligand  
meta 
multiplet 
metal 
methyl 
acetonitrile 
methoxy 
methanol 
mesityl 
melting point 
mass-to-charge ratio 
minute 
milliliter 
millimol 
mass spectrometry 
nuclear magnetic resonance 
spectroscopy 
nuclear Overhauser effect 
spectroscopy 
ortho 
acetate 
ethoxy 
List of Abbreviations 
XI 
 
p 
Ph 
PhMe 
Piv 
ppm  
iPr  
R  
rt  
sat. 
solv  
t  
T 
 
para 
phenyl 
toluene 
pivalate 
parts per million 
isopropyl 
rest 
room temperature 
saturated 
solved 
time 
temperature 
 
t-AmOH 
TBS  
TFA  
THF  
TISP  
 
TLC  
TM 
TMS  
TPA  
X 
δ 
 
tert-amyl alcohol 
tert-butyldimethylsilyl 
trifluoroacetic acid  
tetrahydrofuran 
2,4,6-tri-iso-propyl-
benzenesulfonyl 
thin layer chromatography 
transition metal 
trimethylsilyl 
triphenylacetate 
halide 
chemical shift 
 
  
 
 
    Chapter 1 
1 
 
1 Regioselective ruthenium-catalyzed carbonylative direct 
arylation of (hetero)arenes 
 “The development of techniques that can predictably modify C−H bonds selectively would 
fundamentally change the logic of organic synthesis.” 
Daniel Morton, Center for Selective C−H Functionalization, Managing Director, Emory University, 
GA, USA. 
(Angew. Chem. Int. Ed. 2014, 53, 10256–10259.) 
1.1 Preface 
The first chapter outlines the development of ruthenium-catalyzed carbonylative direct arylation of 
(hetero)arenes through C−H bond cleavage. Introductory, conceptual key factors of transition metal-
catalyzed C−C bond formation via C−H bond activation are introduced. Special emphasis is put on 
carbonylative versions of this process. A facile three component synthesis of complex aryl-heteroaryl 
ketones was enabled by ruthenium(II) catalysis that allows for a successive twofold C(sp
2
)−C(sp2) 
bond formation via acetate-assisted C−H bond cleavage in water. 
1.2 Project outline 
Aromatic groups are essential and prevailing pharmacophores for medicinal chemistry and drug 
development. In 2007, more than 75% of all phase III APIs contained at least one arene or heteroarene 
moiety.
[1]
 The implementation of arenes in drug-like scaffolds proceeds almost entirely via arene 
coupling chemistry. Thus, the functionalization of arenes depicts an aspirational goal in synthetic 
chemistry. Hence, a main endeavor of our research group is the development of novel carbonylative 
coupling reactions for the transition metal-catalyzed functionalization of aromatic and heteroaromatic 
compounds. In the past years, we succeeded to translate the logic of traditional cross-coupling reaction 
to carbonylative versions of these processes (Figure 1.1).
[2]
 
In the net carbonylative cross-coupling reaction, two new C−C bonds are formed while 
implementing a valuable carbonyl functionality. The major drawback, as it is in non-carbonylative 
cross-coupling reactions, is the concomitant generation of stoichiometric waste products. In recent 
years, the scientific community has made significant progress towards direct C−C coupling strategies 
via transition metal-catalyzed C−H bond activation in which pre-functionalization of one coupling 
partner is dispensed. 
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Figure 1.1. General overview (a) traditional cross-coupling, (b) carbonylative cross-coupling and (c) 
carbonylative direct arylation. 
This trend drew our attention towards the conscious conjunction of carbonylative coupling 
chemistry and C−H bond functionalization (Figure 1.1, below). A facile three component synthesis of 
complex benzophenone derivatives was enabled upon exploitation of the multifunctional aptitudes of 
inexpensive ruthenium(II)-catalyst precursors.
[3]
 The synthetic applicability of the developed 
methodology is showcased in the streamlined synthesis of an analog of the top-selling selective 
estrogen receptor modulator Raloxifene (Evista®). Furthermore, our endeavors towards the synthesis 
of marinopyrrole A and B will be discussed. 
1.3 Background 
1.3.1 Transition metal-catalyzed C−H bond activation 
Transition metal catalyzed activation of C−H bonds is a field of major interest in organic chemistry. 
The C−H bond is the most ubiquitous bond in organic molecules and its regio- and site-selective 
transformation into more sophisticated value-added architectures is a desired aim. However, the 
targeted C−H bonds are thermodynamically strong and kinetically inert and intricate to cleave. 
Homogenous catalysis mediated by transition metal complexes offers a unique opportunity to achieve 
both high activity and high selectivity in C−H bond cleavage and further functionalization. 
 
Figure 1.2. Transition metal-catalyzed C−H bond functionalization. 
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The concept of C−H bond functionalization involves an elementary step wherein a C–H bond is 
transformed into a C−metal bond via a metal insertion process. Important to this definition is that the 
hydrocarbyl species remains attached to the inner-sphere of the metal in the course of the reaction 
versus simple deprotonation of C–H acidic compounds that react as external nucleophile via an outer-
sphere mechanism. The newly formed “activated” C−M bond can then undergo reductive elimination 
with a functional group bound to the transition metal center (Figure 1.2). This functional group can be 
a metalloid such as boron- or silicon-based group, or a halogen-atom, however, the crux of the field 
lies in the ability of subsequent C−C bond formation.[4] In the past years, the concept of direct C−C 
coupling has been applied in the syntheses of increasingly complex natural products and 
pharmaceutical targets, meeting the quest for more atom and step economic syntheses.
[5]
 
The key challenge of any C−H bond functionalization is the selective cleavage of a targeted C−H 
bond preferentially over others present in the molecule.
[6]
 Commonly, regioselectivity is either 
controlled due to (1) conformationally biased and entropically-favored intramolecular direct arylation, 
(2) directed intermolecular C−H bond activation in the presence of Lewis-basic directing-groups or (3) 
site-differentiation by C−H bond acidity (Scheme 1.1). 
 
Scheme 1.1. Representative examples of relevant compounds synthesized by transition metal-catalyzed 
(1) intramolecular, (2) ortho-directed intermolecular and (3) C−H bond acidity-dependent direct 
arylation. 
The cleavage of a σ(C−H) bonds in the coordination sphere of a transition metal complex generally 
results from two synergetic electronic effects: (1) σ-donation from the bonding σC−H bond into a vacant 
orbital of the metal complex (LnM) and π-backdonation from a filled dx-LnM molecular orbital into the 
antibonding σ*C−H MO. Thus, the electronic nature of the reactant, allocation of a vacant site on the 
metal complex and electronic nature of the same contribute to the C−H bond cleavage.[7] The 
pioneering efforts of Bergman, Ellman and others have deepened the understanding of the factors 
which govern regioselective C−H bond activation.[7c,8] The work of Murai and Kakiuchi, in particular, 
had a profound impact on the development of this field. A significant breakthrough of C–C bond 
formation based on C–H bond activation was reported in 1993 with the Ru-catalyzed selective 
hydroarylation of olefins in ortho position to the carbonyl group of aromatic ketones as a directing 
group (Scheme 1.2).
[9]
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Scheme 1.2. Chelate-assisted ruthenium-catalyzed direct arylation of olefins. 
Directing groups contain a lone pair of electrons that can coordinate to the transition metal 
catalyst.
[10]
 Most directing groups bear either nitrogen or oxygen containing functional groups in order 
to achieve regioselective C−H bond activation via a five or six-membered intermediate (Figure 1.3. 
A). 
 
Figure 1.3. Activation mode of directing groups and carboxylate-assisted C‒H bond cleavage. 
Another major advance was the observation that selectivity can likewise be induced by an external 
partner such as carboxylate or phosphate bases.
[11]
 Detailed experimental and computational analysis 
established different models for the assisted C−H bond cleavage: (1) CMD (concerted metalation 
deprotonation),
[12]
 IES (internal electrophilic substitution)
[13]
 and AMLA (ambiphilic metal ligand 
activation).
[14]
 The CMD mechanism is by far the most widely encountered mode of activation by 
carboxylate assistance. The mechanism is postulated to proceed through an innersphere hydrogen 
abstraction by a coordinated carboxylate ligand via a six-membered transition state and simultaneous 
C−M bond formation, depicted in Figure 1.3.B. This mode of activation has been suggested for a 
number of Rh- and Pd-catalyzed C−H bond functionalization reactions, involving N-heterocycles, 
polyfluoroarenes or intramolecular aryl-aryl coupling reactions. A combined directed carboxylate-
assisted bond cleavage (Figure 1.3.C) has been useful in a number of palladium and ruthenium-
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catalyzed protocols. Phosphate bases have also been found to facilitate C−H bond breaking event via 
similar five-membered transition states, (Figure 1.3.D). 
1.3.2 Carbonylative C−H bond functionalization 
“In the beginning God created the heaven and the earth. And the carbonyl group. No other 
functional group can rival its versatility and utility.” 
P . J. Kocienski, “Carbonyl Protecting Groups - Introduction” in Protecting Groups, Thieme, 
Stuttgart, 2005. 
Despite its indisputable value, catalytic carbonylative functionalization of unactivated hydrocarbon 
bonds has only scarcely been studied.
[15]
 This instance is even more surprising, considering that 
carbonylative C–C coupling through the C–H bond cleavage are amongst the pioneering examples in 
the field of transition metal catalyzed C–H bond activation of arenes in general. 
The first ruthenium-catalyzed carbonylative C–H activation reaction was discovered in 1992, by 
Moore and co-workers.
[16]
 Ortho-acylation of pyridine and other nitrogen-containing aromatic 
compounds, used in high excess, was performed in the presence of internal and terminal alkenes and 
CO, using trinuclear Ru3(CO)12 as pre-catalyst (Scheme 1.3). The activation of N-heterocycles is 
commonly believed to proceed through pre-coordination of the transition metal by the nitrogen lone 
pair and subsequent insertion into the adjacent C−H bond (Scheme 1.3).[17] 
 
Scheme 1.3. Catalytic and regioselective acylation of N-heterocyles with carbon monoxide and olefins. 
Murai and co-workers translated the development by Moore to the ortho-acylation of simple arenes 
(Scheme 1.4). Herein, they applied the strategy of directing group assisted ortho-metalation that has 
previously been discovered for the chelat-assisted hydroarylation of olefins, vide infra. In the first set 
of reactions, pyridine and pyrimidine heterocycles were used as directing groups. Mono-ortho-
substitution of the arene was mandatory to prevent from diacylation. 
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Scheme 1.4. Reaction of 2-pyridyl- and pyrimidylarenes with carbon monoxide and ethylene. 
In 1998, the group of Murai extended this methodology towards the site-selective 
carbonylative C–H acylation of aza-heterocycles to aryl-alkylketones.[18] The same catalytic system 
could be used for the functionalization of 1,2-disubstituted benzimidazole and 2-methylimidazo[1,2-
]pyridine (Scheme 1.5). The significant advantage of these substrates was that they allowed for an 
extension of the olefin substrate scope. Besides ethylene, 1-hexene, 2-methylstyrene and vinyl 
cyclohexene were eligible coupling partners and the corresponding ketones were obtained in 25-78% 
yield. 
 
Scheme 1.5. Reaction of aza-heterocycles with carbon monoxide and alkenes. 
The protocol could be further extended to the ortho-acylation of various arenes and heteroarenes, 
triggered by various N-heterocyclic directing groups, such as oxazines, thiazine and pyrazoles 
(Scheme 1.6). 
 
Scheme 1.6. N-heterocyclic directing groups in the ortho-acylation of (hetero)arenes. 
A related activation mode, however, in this case via a 6-membered ruthenacycle has been pursued 
in the C-7 selective acoylation of N-pyridylindolines (Scheme 1.7).
[19]
 The corresponding coupling 
products were obtained in reasonable yields up to 65%. 
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Scheme 1.7. Reaction of N-pyridylindolines in the presence of carbon monoxide and ethylene or propen. 
Thus, in conclusion, the group of Murai and Kakiuchi made an extensive effort and thoroughly 
explored the chemical space of ruthenium-catalyzed direct acoylation of aza-arenes and benzene 
derivatives. However, the harsh reaction conditions render these protocols less applicable on larger 
scale, or as alternative to existing protocols. Surprisingly, no further extensions or variations have 
been investigated to explore the limiting factors of this process. The remainder of ruthenium-catalyzed 
C−H carbonylation protocols concern intramolecular lactonization or lactamization reactions.[15b] 
 
Scheme 1.8. Intramolecular Pd-catalyzed cyclocarbonylation. 
Outside the ruthenium regime, in 2000 and 2001, Larock published the first intramolecular 
palladium-catalyzed carbonylative direct arylation for the synthesis of flurophen-9-ones from ortho-
biaryls (Scheme 1.8).
[20]
 The synthesis proceeded under relatively mild reaction conditions under 
atmospheric carbon monoxide pressure. A catalytic system comprising Pd(PCy)3 and pivalic acid 
suggests a carboxylate-assisted C−H bond cleavage. This reaction conditions proved general for a 
great range of substrates. Besides biphenyls, several heterocyclic starting materials underwent 
carbonylative ring closure, e.g. fused isoquinoline, indole, pyrrole, thiophene, benzothiophene, and 
benzofuran products could be obtained. 
 
Scheme 1.9. Palladium-catalyzed copper-mediated carbonylative direct arylation of heteroarenes. 
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The first example of an intermolecular direct carbonylative coupling of aromatic compounds by 
means of C–H bond activation was described by the group of Beller in 2010.[21] C–H acidic 
heteroarenes such as oxazoles, thiazoles, and imidazoles were found to be suitable nucleophiles in a 
carbonylative coupling reaction with aryl iodides (Scheme 1.9). This reaction applies a palladium 
catalyst and a twofold excess in bidentate dppp ligand and superstochiometric CuI. The cleavage of 
the C−H bond is suggested to proceed via deprotonation at the two position of the heterocycle to form 
a heteroaryl-copper species. This species then undergoes transmetallation with a Pd-aroyl intermediate 
that is formed upon oxidative addition and CO-insertion (Scheme 1.10). Noteworthy, a high CO 
pressure of 40 bar was needed to obviate undesired aryl-heteroaryl coupling. 
 
Scheme 1.10. Proposed mechanism. 
From the literature it is known, that C−H acidic heterocycles can be deprotonated by a strong base 
to form adducts with appropriate Cu(I) salts. These species, have been applied, for instance, in copper-
mediated carboxylation reactions with gaseous CO2.
[22]
 Thus, this reaction does not fully meet the 
introductory described definition of a direct C−H bond functionalization. 
 
Scheme 1.11. Palladium-catalyzed oxidative double C−H functionalization/carbonylation for the 
synthesis of xanthones. 
In 2012, the group of Lei disclosed a protocol on palladium-catalyzed oxidative double C–H bond 
functionalization/carbonylation of diaryl ethers (Scheme 1.11).
[23]
 Pd(TFA)2 formed in situ from 
Pd(OAc)2 in trifluoroacetic acid is a competent catalyst precursor to undergo electrophilic palladation 
of the diarylether starting material, step A in Scheme 1.12. The subsequent CO insertion (B) is 
followed by activation of a second CH bond (C) and reductive elimination of the carbonylation 
product (D). Eventually, the Pd
0
 species is re-oxidized by K2S2O8 as sacrificial oxidant to turn-over the 
catalytic cycle (E). Mechanistic studies suggest that the second C–H bond activation represents the 
rate-determining step. The yield was significantly affected by the electronic nature on the arenes, 
resulting in a broad variation in yield from 27-96%. Electron-rich arenes were generally better 
received in this transformation. 
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Scheme 1.12. Proposed mechanism for the double C−H carbonylation. 
1.3.3 Benzophenones 
Benzophenones constitute widely used building blocks in organic chemistry and are attractive 
targets in pharmaceutical and finechemical industry, exhibiting a plethora of biological activities. 
Prominent examples are Tricor, applied for cholesterol regulation in patients at risk of cardiovascular 
disease, the anti-inflammatory drug Sector and selective estrogen receptor modulation Raloxifen 
(Evista®) (Scheme 1.13). These drugs are listed among the top 200 drugs by sales in 2012 and thus 
are of sever economical interest for the pharma industry.
[24]
 
 
Scheme 1.13. Selected examples of bioactive benzophenone derivatives. 
Benzophenone derivatives provide a broad-spectrum ultraviolet coverage, including UVB and 
short-wave UVA rays.
[25]
 Oxybenzophenones, (2-Hydroxy-4-methoxyphenyl)-phenylmethanone, is 
the most widely applied UVA filter used in sunscreen. Besides medicinal and cosmetic applications, 
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benzophenones are used as photoprotective agents in UV-curing applications such as inks, imaging, 
and clear coatings in the printing industry.
[26]
 
In recent years, classic synthetic routes such as copper-catalyzed oxidation of diphenylmethane or 
Friedel-Crafts acylation face competition by transition-metal catalyzed carbonylative coupling 
reactions of arenes.
[27]
 Carbon monoxide represents an inexpensive and atom economic C1 building 
block, which allows the introduction of a carbonyl group into the desired target molecule by various 
carbonylation reactions. Representative examples include the carbonylative Suzuki-Miyaura,
[28]
 
Negishi,
[29]
 Stille,
[30]
 and Hiyama
[31]
 reactions. However, these processes require pre-functionalized 
reaction partners and lead to concomitant generation of stoichiometric waste which ought to be 
circumvented in times of limited resources and growing environmental awareness. 
1.4 Result and discussion 
The direct arylation of (hetero)arenes by means of C−H bond activation represents an enormously 
growing field in organometallic chemistry and has a tremendous impact on synthetic organic 
chemistry. Our preceding success in the development of carbonylative versions of a plethora of 
traditional cross-coupling reactions
[2a,2c]
 drew our attention towards the conscious conjunction of 
carbonylative coupling chemistry and C−H bond functionalization. 
 
Scheme 1.14. Regioselective ruthenium-catalyzed carbonylative direct arylation of five-membered and 
condensed heterocycles. 
It was our primary goal to develop a methodology for the selective carbonylative direct-arylation of 
simple arenes via successive twofold C(sp
2
)−C(sp2) bond formation for the rapid build-up of complex 
aryl-heteroaryl ketone (Scheme 1.14). Seminal experiments revealed that ruthenium is the metal of 
choice to strive for this endeavour. 
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1.4.1 Screening of reaction conditions 
Initial experiments were carried out using 2-phenylpyridine (1.1a) as model substrate, phenyl iodide 
(1.2a) and 5 mol% of [Ru(cod)Cl2] polymer under carbon monoxide pressure (30 bar) at 120 °C. The 
product formation was determined by calibrated GC after 20 hours reaction time, using hexadecane as 
an internal standard. Various bases, solvents and additives were tested under these conditions (Table 
1.1). Most organic solvents gave no or little conversion of the starting material (Table 1, entries 1-6). 
However, when changing the reaction media to water, selective conversion to the desired carbonylated 
product was observed in 56% yield (entry 7). Variation of the base and carbonate additive further 
improved the yield of 1.3a up to 65% (entry 16). The reaction proofed to be rather sensitive to reduced 
carbon monoxide pressure. Thus, further optimization of the ruthenium-catalyst precursor was 
performed at 30 bar carbon monoxide pressure. 
Table 1.1. Ruthenium-catalyzed carbonylative C‒H bond activation of 2-phenylpyridine: Optimization 
of reaction conditions.
a 
 
Next, we decided to investigate the effect of different ruthenium complexes on the carbonylative 
C−H bond functionalization. In the related direct coupling reaction, weakly coordinating anions had a 
positive effect on transition metal catalyzed activation of C−H bonds. In some instances, generating a 
more cationic metal species may encourage σ-donation from the bonding σ(C−H) molecular orbital to 
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stabilize the vacant orbital on LnM. However, in the present model reaction the addition of silver 
acetate or silver hexafluoroantimonate led to complete inhibition of the catalytic activity of the 
reaction system (Table 1.2, entry 2 and 3). Furthermore, lower conversions and yields were observed 
when other ruthenium precursors were used (Table 1.2, entry 4-9). A low product yield was also 
observed when the related ruthenium dimer dichloro(p-cymene)ruthenium(II) was used (Table 1.2, 
entry 6). This initially surprising result could be rationalized and will be discussed later on. Employing 
other ruthenium catalysts with different oxidation states (0, II and III) gave marginal product 
formation (Table 1.2, entries 7-9). 
Table 1.2. Ruthenium-catalyzed carbonylative C‒H bond activation of 2-phenylpyridine 1.1a: Catalyst 
screening.
a 
 
1.4.2 Scope and limitations 
Having a practical protocol in hand for the ruthenium-catalyzed preparation of benzophenone 
derivatives with a three-component carbonylative direct arylation strategy, we studied the scope of 
iodoarenes (Table 1.3). Many aryl iodides afforded the corresponding products in good yields. 
Electron-donating (1.3a-g) as well as electron-withdrawing (1.3j-l) functionalities were tolerated. The 
electronic nature of the electrophile did not have a crucial impact on the product formation. It is 
important to note that in the case of 4-iodotoluene the optimum yield was obtained with potassium 
carbonate as a base. Other yields were not significantly affected by the choice of carbonate base. Aryl 
iodides substituted with alkyl groups in para-, meta-, or ortho-positions were invariably applicable 
under our reaction conditions (Table 1.3, 1.3b-1.3i).The best result was obtained with 2-iodotoluene as 
a coupling partner. The corresponding ketone 1.3b was obtained in 74% isolated yield (Table 1.3). 
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However, more sterically encumbered 2,6-dimethyl-iodobenzene or electrophiles bearing coordinating 
substituents such as hydroxyl or methoxy groups in the ortho-position were less eligible coupling 
partners. 
Table 1.3. Ruthenium-catalyzed carbonylative direct arylation of phenylpyridine (1.1a).
a 
 
After having observed the general activity with several aryl iodides, we turned our attention to study 
the effect of different directing groups (Table 1.4). To our delight, phenyl derivatives bearing pyrazole 
as a directing group were also suitable. Hence, 3,5-dimethyl-1-phenyl-1H-pyrazole 1.4a was 
successfully converted with 4-ethyliodobenzene as well as with 2-iodotoluene. When 2-iodotoluene 
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was reacted with the monomethylsubstituted pyrazole under carbon monoxide pressure the 
corresponding diarylketone 1.6a was formed. Besides pyridine, 2-(hetero)aryl pyrimide could be 
employed in the carbonylative coupling reaction. In this instance, the methodology was extended to 
the direct arylation of heteroarenes for the first time. 2-(Thiophen-3-yl)pyrimidine was activated 
exclusively in the 2-position. The corresponding heteroaryl-aryl ketone, (3-(pyrimidin-2-yl)thiophen-
2-yl)(o-tolyl)methanone (1.7c), was isolated in satisfying 68% yield (Table 1.4). 
Table 1.4. Variation of directing groups.
a 
 
It is noteworthy to mention that the reaction proved to be rather sensitive towards substituents 
attached to the phenyl core of the nucleophile. On the other hand, this sensitivity displays a positive 
effect on the regioselectivity of the reaction. Although phenylpyridines and related arylpyrazoles 
possess two chemically equal ortho-C−H bonds only one C−C bond is selectively formed. This effect 
is presumably owed to the retarded reactivity of a subsequent bond formation on the now substituted 
phenylpyridine derivative. 
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1.4.3 Regioselective ruthenium-catalyzed carbonylative direct arylation 
of 5-membered and condensed heterocycles 
Heterocycles are ubiquitous structural motifs in natural products and pharmaceuticals (Figure 1.4). 
The reduced symmetry and aromaticity renders the C−H bonds of heterocycles chemically more 
distinguishable which in turn facilitates to selectively address certain sites in the heterocycle. For 
instance as introductory discussed early examples for the carbonylative direct functionalization 
utilized pyridine as substrate. The C−H bond cleavage in the 2-position of the pyridine is facilitate due 
to advantageous resonance effects stemming from the adjacent heteroatom. The C-2 C−H bond 
represents also the most activated position for transition-metal C−H bond insertion in five-membered 
heterocycles because of its high nucleophilicity and C−H bond acidity.[32] 
 
Figure 1.4. Important heterocycle containing pharmaceuticals and reactive site differentiating in 
heteroarenes. 
Unfortunately, the direct carbonylation reaction proved rather sensitive to modifications on the 
phenyl core. Gratifyingly, we found that pyridine-containing bisheteroaryls, such as 3-(2’-
pyridyl)thiophene (1.8), were equally eligible for the directed aroylation (Scheme 1.15). Incited by our 
finding we strived to extent the substrate scope of the direct carbonylative ortho-aroylation. 
A competition experiment between 2-phenylpyridine (1.1a) and 3-(2’-pyridyl)thiophene (1.8) was 
conducted. Using a large excess of the competing nucleophiles revealed a remarkable selectivity in 
favor of exclusive conversion of the thiophenyl nucleophile 1.8 to (3-(pyridin-2-yl)thiophen-2-yl)(o-
tolyl)methanone (1.9) in 87% isolated yield, while 1.1a was re-isolated in quantitative yield (Scheme 
1.15). Further optimization showed that an excess of the nucleophile was beneficial for the aroylation 
of heteroarenes and significantly accelerated the overall process; vice versa resulting in higher yields 
of the desired coupling product. 
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Scheme 1.15. Comparison of the reactivity of 2-phenylpyridine (1.1a) and 3-(2’-pyridyl)thiophene (1.8). 
With this slightly modified reaction conditions, the ruthenium-catalyzed carbonylative direct 
arylation of 3-(2’-pyridyl)heteroarenes, including thiophenyl, furanyl, and pyrrol-based heterocycles, 
was conveniently accomplished. The pendent pyridine moiety selectively biased the carbonylative 
coupling which allowed for a highly regioselective functionalization at the 2-position of five-
membered heterocycles (Table 1.5). The corresponding heteroaryl–aryl ketones were isolated in 
moderate to good yields (10–91 %, Table 1.5). The best result was obtained when 1.8 was reacted with 
2- iodotoluene, resulting in 91% isolated yield of the desired [3-(pyridin-2-yl)thiophen-2-yl](o-
tolyl)methanone (1.9a). In general, ortho-substituted iodoarenes gave superior results compared to 
other substitution patterns. 
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Table 1.5. Scope for C2-directed carbonylative direct arylation of 5-membered heterocycles.
a,b
 
 
The activation of the C3-position of five-membered heterocycles is a more challenging goal because 
of its reduced C−H bond acidity which attenuates its bias to be engaged into C−H activation. 
However, this inherent bias can be evaded by the use of an ortho-directing group. The scope of the 
C3-directed carbonylative direct arylation is shown in Table 1.6. 
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Table 1.6. Scope for C3-directed carbonylative direct arylation of 5-membered and condensed 
heterocycles.
a,b
 
 
Five-membered and condensed S- and O-containing heterocycles were successfully converted to the 
corresponding aryl heteroaryl methanones 1.12-1.15 in good yields (20–71%, Table 1.6). The isolated 
yields for 2-(2-heteroaryl)pyridines are comparable to those that have been obtained for the C2-
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directed carbonylative coupling. However, the aforementioned beneficial “ortho-effect” was not 
observed with this substitution pattern of the nucleophile. Yields up to 68% were obtained (Table 1.6. 
1.12c), whereas 2-furanyl-2’-pyridine proved to be less efficient. Gratifyingly, when condensed 
heteroarenes, such as 2-(benzo[b]thiophen-2-yl)pyridine and 2-(benzo[b]furan-2-yl)pyridine were 
employed, improved yields were achieved with diverse electrophiles (1.14a-d and 1.15a-c). 
Table 1.7. Scope for the C2-selective carbonylative direct arylation of N-arylated heterocycles. 
 
The synthetic applicability of ortho-directed C−H bond functionalization strategies is often 
restricted due to the presence of the directing group. This constraint can be elegantly circumvented by 
the installation of a cleavable directing group. To demonstrate the versatility of the direct 
carbonylation protocol, N-heteroarylated indole-based compounds, 1.17a and 1.17b, as well as 2-(1H-
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pyrrol-1-yl)pyrimidine (1.16) have been prepared according to literature procedures.
[33]
 These 
substrates demonstrated decent reactivity and predictable site-selectivity of the carbonylative coupling 
reaction under our optimized reaction conditions (Table 1.7) and the resulting heteroaryl aryl ketones 
1.16a-1.16d were isolated in moderate to good yields (45–75 %). The C2-aroylation of indole 
proceeded in moderate yields of 55 to 75% (1.17a-d and 1.18a and b). Again, 2-substituted iodoarenes 
were superior coupling partners compared to meta- and para-substituted electrophiles. However, 
strongly chelating di-heteroarenes, such as 2-(1H-pyrazol-1-yl)pyridine and 2-(1H-imidazol-1-
yl)pyridine proofed incompatible as substrate in this reaction. 
The cleavage of the pyrimidine-based directing element was easily accomplished when starting with 
[1-(pyrimidin-2-yl)-1H-pyrrol-2-yl](o-tolyl)methanone (1.16a) and NaOEt in DMSO at 100°°C for 
5°h, yielding (1H-pyrrol-2-yl)(o-tolyl)methanone (1.19) in 91% isolated yield (Scheme 1.16). 
 
Scheme 1.16. Cleavage of the pyrimidine protecting/directing group. 
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1.4.4 Application of the developed methodology 
Di(hetero)aryl ketones constitute a common structural motif in natural products and 
pharmaceuticals, and can be found in the selective estrogen receptor modulator Raloxifene 
(Evista®),
[34]
 in indole-based natural products uvarindole C, calothrixin A and B, as well as 
marinopyrrole A and B (Figure 1.5).
[35]
 To showcase the applicability of the developed reaction we 
drew our attention to the synthesis of a Raloxifene analog and the synthesis of a key intermediate in 
the biosynthesis of marinopyrroles. 
 
Figure 1.5. Selected natural products bearing a heteroaryl–aryl methanone moiety. 
Marinopyrroles are densely-halogenated bipyrrole natural products, produced by a marine-derived 
streptomycetes isolated from ocean sediments.
[36]
 These axially chiral biaryl compounds exhibit a 
unique 1,3’-bipyrrole motif and possess potent antibiotic activity against methicillin-resistant 
staphylococcus aureus.
[37]
 Several total syntheses of racemic marinopyrrole A and B have been 
pursued and were published by a number of research teams.
[35b-d,38]
 In 2012, Moore and co-workers 
contributed to the elucidation of the enzymology pathway for the atropo-selective synthesis of these 
bipyrrole natural products.
[35a]
 According to their results a pair of FADH2- dependent halogenases is 
involved in marinopyrrole biosynthesis. It catalyzes an atropo-selective N,C-biaryl homocoupling 
reaction of (4,5-dichloro-1H-pyrrol-2-yl)(2-hydroxyphenyl)methanone 1.20. Thus, the synthesis of 
this intermediate was elected as target structure (Figure 1.6). 
 
Figure 1.6. Rerosynthetetic analysis of marinopyrroles A and B and key intermediate (4,5-dichloro-1H-
pyrrol-2-yl)-phenylmethanone 1.20. 
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(4,5-dichloro-1H-pyrrol-2-yl)-phenylmethanone (1.20) was prepared in a gram-scale from 2-(1H-
pyrrol-1-yl)pyrimidine and iodobenzene and carbon monoxide following the previously described 
protocol for the ruthenium-catalyzed carbonylative direct arylation. 1.2 g of 1.16e were obtain as a 
colorless solid from a singly run. The directing group was quantitatively cleaved using sodium 
ethoxide in DMSO at elevated temperature. Subsequent dichlorination of the 4,5-position of the 
pyrrole core yielded the desired product 1.20 in 53% over-all yield from 1.15 (Scheme 1.17). 
 
Scheme 1.17. Synthesis of marinopyrrole intermediate 1.20. 
Although the presence of an ortho-hydroxy group is not tolerated in the carbonylative coupling 
reaction, (4,5-dichloro-1H-pyrrol-2-yl)-phenylmethanone (1.20) is an ideal candidate for ketone 
directed ortho-hydroxylation that has been described in manifold variants both by palladium and 
ruthenium-catalyst. 
 
Scheme 1.18. Ketone-directed hydroxylation grants access to pyoluteorin and marinopyrroles A and B. 
Raloxifene, distributed under the trade name Evista® (EllyLilly), is a synthetic, non-steroidal, 
selective estrogen-receptor modulator used for the treatment and prophylaxis of osteoporotic fractures 
in postmenopausal women. It was also evaluated to have a positive effect for the prevention of 
invasive breast cancer. Raloxifen is listed among the top one hundred drugs by sales, ranked highest at 
#77 in 2010 and at #92, post-patent expiration, in 2013. Distinct routes for the syntheses of Raloxifene 
derivatives frequently involve Friedel-Crafts-type acylation of the benzo[b]thiophene followed by 
Kumada–Corriu coupling for the C‒C bond formation at the 2-position. These procedures require the 
use of stoichiometric metal salts, extensive substrate prefunctionalization and necessitate handling of 
air and moisture-sensitive compounds. 
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Scheme 1.19. Traditional synthesis of Raloxifen hydrochloride through sequential Friedel-Crafts 
reaction and Kumada-Currio cross coupling. 
The carbonylative direct arylation ought to offer a considerable advantage in the synthesis of 
Raloxifene derivatives in terms of step- and atom-economy. Moreover, complementing traditional 
routes, the demonstrated approach offers the good opportunity for facile implementation of an 
isotopically labeled ketone functionality upon usage of labeled carbon monoxid which can be 
beneficial for the elucidation of the metabolic pathway of a pharmaceutical. 
 
Scheme 1.20. Retrosynthetic analysis for the symthesis of Raloxifen through carbonylative direct 
arylation. 
The directing-group was directly embedded in the core-structure of the pharmacophore. The 
precursor 4’-methoxy-2-(6-methoxybenzo[b]thiophen-2-yl)pyridine (1.27) was readily prepared by 
Suzuki–Miyaura coupling of 6-methoxybenzo[b]thiophen-2-ylboronic acid and 2-bromo-5-
methoxypyridine (1.26). Noteworthy, unprotected 4’-hydroxy-2-(6-methoxybenzo[b]thiophen-2-
yl)pyridine did not serve as adequate starting material. Under the applied reaction conditions, 3-
hydroxypyridine tautomerizes to a zwitterionic form in which the pyridinium nitrogen atom is 
ineligible for coordination to the metal center.
[39]
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Scheme 1.21. Preparation of precursor 4’-methoxy-2-(6-methoxybenzo[b]thiophen-2-yl)pyridine (1.27). 
Starting from the bismethoxylated substrate 1.27 and 4-fluoro iodobenzene (1.2d), the desired 
diarylketone 1.30 was obtained in 55% isolated yield. When 4’methoxy-2-(6H-benzo[b]thiophen-2-
ylpyridine (1.28) was used as core structure, the C−H bond carbonylation proceeded likewise in 53% 
yield.
30
 The structure of the corresponding product 1.29 was confirmed by X-ray analysis (Figure 1.7). 
Analogous to previous Raloxifene syntheses, the next step of the synthesis was the installation of the 
piperidine ethylether by SNAr reaction onto the aryl C−F bond. Eventually, deprotection of the two 
methoxy groups led to the target compound 1.32 in 42% isolated yield from 1.27. 
 
Scheme 1.22. Synthesis of pyridine-containing Raloxifene analog 1.32. 
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Figure 1.7. X-ray structure of compound 1.29. 
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1.4.5 Mechanistic considerations 
The present work is the first example of intermolecular transition metal-catalyzed carbonylative 
direct arylation. Thus, the elucidation of the mechanism is a complex subject. 
Intensive research efforts paved the way for a deeper understanding of the transition metal catalyzed 
C−H bond cleavage. Ample research articles and reviews comprehensively summarize various aspects 
that ought to be scrutinized to characterize the event of C−H bond activation.[7] The advent of C−H 
bond activation can be classified according to four different processes (Scheme 1.23). 
 
Scheme 1.23. Schematic representation of the different mechanisms for C−H bond activation. 
Oxidative addition (I) is described as the most common mechanism. The oxidative addition consists of 
two steps: (1) coordination of the Lewis-basic C−H bond and (2) actual cleavage of the C−H bond to 
form the new M−C bond (Scheme 1.23). The net increase of the oxidation state of the transition metal 
by two units is accompanied by a change of geometry of the complex upon formation of two new σ-
bonds. This mechanism is most commonly observed for electron-rich, low-valent complexes of the 
late transition metals (Re, Fe, Ru, Os, Ir, Pt) for which the higher oxidation state of the metal in the 
addition product and the necessary change in geometry upon formation of the two new bonds are not 
energetically penalizing. For early transition metals (groups 3 and 4, lanthanides and actinides) with d0 
electronic configuration, an oxidative process is not possible, and the preferred mechanism is σ-bond 
metathesis (II) usually involving an alkyl or a hydride complex (Scheme 1.23). The essential aspect of 
the σ-bond metathesis mechanism is the concerted formation (M−C and C′−H) and breaking (M−C′ 
and C−H) of bonds at the transition state. Late- or post-transition metals (Pd2+, Pt2+ or Pt4+, Hg2+) in a 
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strongly polar medium in which the metal center only acts as Lewis acid, a putative intermediate is 
formed by electrophilic attack of the metal to the substrate. The hydrogen atom of the substrate is 
formally substituted by the metal center. Hence, this mechanism has been formally classified as 
electrophilic substitution (III). Finally, the C−H bond can add across an unsaturated M−X bond in a 
1,2 addition (IV). This mechanism resembles σ-bond metathesis except that the newly formed X−H 
bond does not lead to release of XH because the M−X σ-bond is still present in the product. The 
functional groups X leading to such reactivity are generally amido and alkylidene complexes of early 
to middle transition metals, but alkoxy and alkylidyne complexes have also been shown to activate 
C−H bonds.  
Despite seemingly large differences among the various mechanisms that can be anticipated, there 
are three fundamental aspects to consider: (1) How is the C−H bond brought into the proximity of the 
metal, (2) How is the C−H bond cleaved in the metal coordination sphere and (3) what is the 
thermodynamic stability of the organometallic product featuring the new M−C bond. These questions 
ought to be addressed in the last section of this chapter. 
In well-comprehended palladium-catalyzed traditional cross-coupling reactions as well as in direct 
arylations, the oxidative addition of the electrophile to the metal center depicts the first step within the 
catalytic cycle, and notably precedes the insertion of the metal into a C−H bond. In contrast, 
applicability of ruthenium catalysts in traditional bi(hetero)arenes through traditional cross-coupling 
reactions have been elusive.
[41]
 Yet, versatile ruthenium direct arylations strategies have been 
discovered.
[42]
 Oi and Inoue were the first who postulated that the cyclometalation precedes the 
oxidative addition of the electrophile to the metal-center and is nowadays the generally accepted 
reaction pathway.
[43]
 
In the present system, a successful C−H bond cleavage was evident by full H/D-exchange when 2-
(thiophen-3-yl)pyridine 1.8 was subjected to the standard reaction conditions in D2O in the absence of 
an electrophile. The C-2 deuterated 2-(thiophen-3-yl)pyridine D-4a was isolated from the reaction 
mixture in 60% yield with an H/D-exchange rate of >95% (Scheme 1.24). This result provides strong 
evidence for a reversible C−H bond insertion step. 
 
Scheme 1.24. C-2 Deuteration of 2-(thiophen-3-yl)pyridine 1.8. 
Furthermore, experimental results suggested that the C−H bond insertion is promoted both by the 
nitrogen-containing directing group and acetate-assistance. Generally higher yields have been obtained 
in the presence of carboxylate additives (Table 1.1). Hence, carboxylate-assistance in the C−H bond 
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cleavage is suggested. Furthermore, the Lewis basicity of the N-directing group appeared to be 
especially important for a successful C−H bond cleavage event. An electron donating methoxy group 
in 5-position of the pyridine slightly enhanced the reactivity of the system, whereas electron 
withdrawing substituents, such as bromine or fluorine, significantly attenuated the process relative to 
the unsubstituted pyridyl group (Figure 1.8). A hydroxyl group in 5-position prohibits the involvement 
of the N-heterocycle in the C−H bond cleavage event. Under basic reaction conditions, 5-
hydroxypyridine isomerizes to the zwitterionic pyridium form resulting in complete loss of its Lewis 
basic character.
[39]
 
 
Figure 1.8. Influence of substituents on the N-directing group. 
In the following, a number of mechanistic experiments targeting the key steps of the ruthenium-
catalyzed carbonylative direct arylation have been conducted. Initially the reversibility of the C−H 
bond cleavage by using 3-(2’-pyridyl)thiophene (1.8) was contemplated. Concerning this matter, the 
reaction between 1.8 and 2-iodotoluene (1.2b) was conducted in D2O under otherwise unaltered 
reaction conditions (Scheme 1.25). The process was stopped after 3 h and 65% deuterium 
incorporation at the 2-position of d-1.8 was determined by 
1
H NMR spectroscopy. After 20 h full 
consumption of the electrophile was observed and the H/D-exchange at the 2-position corresponded to 
95% deuterium incorporation and 15% at C4. The H/D-exchange at the 4-position in product 1.9a 
accounted for less than 7%. This observation is a strong evidence for the reversibility of the 
ruthenium-catalyzed C−H bond cleavage. 
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Scheme 1.25. H/D exchange at C2 of 1.8. 
The influence of the electronic nature of the electrophile on the rate of the oxidative addition was 
probed by an intermolecular competition experiment between electron-rich 4-methoxyiodobenzene 
(1.2c) and electron-poor 4-fluoroiodobenzene (1.2d) (Scheme 1.26). The substrates were employed in 
a 1:2:2 ratio that corresponds to an eightfold excess of electrophile relative to the optimized reaction 
conditions (with nucleophile 1.2 as the limiting reactant). The reaction was quenched after 4 h in order 
to secure low conversion. The product distribution of 1.9f and 1.9g in a 1.2:1.0 ratio according to 
1
H 
NMR spectroscopy. Consequently, the oxidative addition should not represent the rate-determining 
step in the catalytic cycle. 
 
Scheme 1.26. Intermolecular competition experiment between electron-rich and poor electrophiles. 
The metalated arene which is formed in course of the C−H bond can be contemplated as 
nucleophile which attacks an electrophilic metal-acyl species to generate a new C−C bond. The carbon 
based nucleophile might face competition from stronger nucleophiles such as hydroxyl groups or 
amines. 
From a reaction between 4-(pyridin-2-yl)phenol (1.1b) and 2-iodotoluene (1.2b) it was indeed 
evident that the phenol is indeed capable to attack the metal-acyl species. From the analysis of the 
crude mixture of products the occurrence of two side-products 1.33b and 1.1c have been observed. 
The benzoylation of the phenol indicated that (1) the phenol competes in the in abstraction of the acyl 
species via intermolecular attack and (2) the carbon monoxide-insertion in the ruthenium-aryl bond of 
the electrophile subsequent to the oxidative addition is relatively fast. However, the combined product 
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yield for the desired carbonylative direct arylation accounted for 74% isolated yield. Thus, (3) the 
formally intramolecular insertion of the carbon nucleophile is the privileged pathway. 
 
Scheme 1.27. Competitive attack of C- and O-nucleophiles. 
Eventually, a plausible catalytic cycle for the ruthenium-catalyzed carbonylative direct arylation is 
proposed as illustrated in Figure 1.9. The C−H bond is brought into the proximity of the metal by 
coordination of the nitrogen lone-pair of the directing group (A). Subsequently, the C−H bond is 
cleaved in the metal coordination sphere (B). In the following, the electrophile oxidatively adds to the 
chelated ruthenium species (C) to form D, which in turn readily reacts with carbon monoxide to form 
of Ru-acyl complex (E). Eventually, the second C(sp
2
)−C(sp2) bond formation proceeds via reductive 
elimination and extrusion of the coupling product along with regeneration of the active Ru(II)-catalyst 
(F). 
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Figure 1.9. Proposed mechanism for the carboxylate-assisted carbonylative direct arylation 
(hetero)arenes bearing an N-directing group. 
1.5 Conclusion and outlook 
In summary, we have developed the first ruthenium-catalyzed carbonylative direct arylation of 
(hetero)arenes by means of C−H bond activation. This facile three component synthesis of complex 
aryl-heteroaryl ketones via successive twofold C(sp
2
)−C(sp2) bond formation in water describes a 
conceptually new path for the construction of benzophenone derivatives. 
Starting with simple phenylpyridine derivatives, this chemistry could be extended to the preparation 
of aryl-heteroarylketones including examples with cleavable directing groups. The synthetic 
applicability of the developed methodology has been demonstrated in the streamlined synthesis of an 
analog of the top-selling selective estrogen receptor modulator Raloxifene (Evista®) and the gram-
scale synthesis of a key intermediate of marinopyrroles and pyoluteorin. 
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2 Rhodium(II)-catalyzed enantioselective masked 
formylation of push-pull carbenes with 1,3,5-trioxane 
2.1 Preface 
A significant drawback of reactions applying gaseous carbon monoxide as C1-building block is the 
necessity to operate with special apparatuses, such as autoclaves, high-pressure and multi-vessel 
glassware, in addition to imperative safety restrictions that come into play when compared to classic 
bench chemistry. In this chapter the development of an operational methodology for the 
enantioselective introduction of an inexpensive, crystalline C1-building block, 1,3,5-trioxane by 
means of rhodium(II)-catalyzed C‒H insertion, will be outlined and discussed. 
2.2 Project outline 
Intensive studies by Doyle,
[44]
 Davies
[45]
 and others have established dirhodium(II) carbene 
chemistry as a useful means for site- and stereoselective functionalization of sp
3C‒H bonds. It has 
been shown that the choice of the dirhodium(II) catalyst in combination with appropriate carbene 
precursors is pivotal to trigger the desired reactivity (C‒H bond insertion vs. cyclopropanation vs. 
ylide formation), which can be accomplished even in highly functionalized substrates. In this respect, 
it has been demonstrated that donor/acceptor dirhodium(II) carbene complexes permit intermolecular 
insertion into sp
3
-C‒H bond. A comparison of the relative rates of the C‒H bond insertion, shown in 
Figure 2.1, highlights the superior reactivity of secondary C‒H bonds which can best stabilize a 
positive charge build up during the C‒H bond cleavage event, e.g. C‒H bonds in allylic position 
and/or in the vicinity of a heteroatom.
[2a] 
 
Figure 2.1. Relative rates of reactivity for rhodium carbene C−H functionalization.[45a] 
This project was outlined to investigate the functionalization of 1,3,5-trioxane as alternative C1 
building block by means of dirhodium(II) carbene chemistry, derived from diazo compounds, for the 
stereoselective implementation of a versatile masked formyl functionality (Scheme 2.1). 1,3,5-
Trioxane, a solid, easily handled formaldehyde surrogate, combines several features which suggest 
advantageous for an efficient sp
3C‒H bond functionalization. Six chemically equal C‒H bonds are 
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positioned in -position to two oxygen heteroatoms. Additionally, the cyclic structure minimizes the 
steric congestion, thus rendering the targeted reaction site conveniently accessible.
[3]
 Subsequent 
cleavage of the acetal, under oxidative, acidic or reductive conditions, respectively, ought to grant 
access to optically active carboxylic acids, aldehydes and readily protected primary alcohols. 
 
Scheme 2.1. Rhodium(II)-catalyzed enantioselective masked formylation of push-pull carbenes with 
1,3,5-trioxane. 
Cyclic ethers are broadly appreciated for their non-peptidic hydrogen binding abilities and ring 
flexibility in pharmaceutical chemistry and other life sciences.
[46,47]
 In addition, 2-aryl-2-(1,3,5-
trioxan-2-yl)acetates are structurally closely related to biologically active methylphenidates and 
atropine yet providing orthogonal hydrogen-bonding abilities (Scheme 2.2). Providing access to this 
class of compounds is likely to contribute to expand the current tool box in medicinal chemistry. 
 
Scheme 2.2. Selected pharmaceuticals and natural products containing cyclic ethers and α-
arylpropionic acid derivatives, respectively. 
2.3 Background 
2.3.1 1,3,5-Trioxane in organic synthesis 
1,3,5-Trioxane or s-trioxane has been employed as clean and convenient anhydrous source of 
formaldehyde. Trioxane is of very low toxicity following single-dose administration. The oral LD50 
values for rats ranges from 7.7 to 9.5 g/kg body weight. Single dermal treatment of rabbits with 4.0 or 
15 g/kg does not cause irritation or any clinical signs of toxicity.
[48]
 In combination with hexamine, 
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trioxane can be compressed to solid fuel bars, used as outdoor stove fuels. Furthermore, 1,3,5-trioxane 
is used as restorative chemical for the conservation of postmortem tissue. 1,3,5-Trioxane is formed 
from formaldehyde under thermolysis or acid-mediated cyclotrimerisation (Figure 2.2).
[49]
 
 
Figure 2.2. Formation of 1,3,5-trioxane by cyclotrimerisation of formaldehyde. 
Although the 1,3,5-trioxane congener paraldehyde (Figure 2.3) is long known as central nervous 
system depressant for the treatment of acute status epilepticus, the 1,3,5-trioxane motif is essentially 
absent in medicinal chemistry. A related yet structurally off 1,2,4-tiroxanyl motif is found in the 
antimalarial Artemsinin.
[50]
 The reason for the limited appearance of 1,3,5-trioxane rings is likely 
caused due to the lack of methods to append the trioxanyl motif into drug-like scaffolds. Accordingly, 
very few chemical transformations for its installation are reported in the literature.
[51]
 Such examples 
almost exclusively describe the installation of the trioxane onto sp
2
-hybridized carbons via radical 
chemistry.
[52]
 Hence, these approaches inherently do not allow for generation of a stereogenic centers. 
 
Figure 2.3. Pharmaceuticals bearing a trioxane motif. 
Early examples for the functionalization of trioxane can be found in the midst of the scope of a 
protocol for the photoalkylation of cyclic ethers described by Rosenthal and Elad in 1968 (Scheme 
2.3).
[51a]
 However, the yields of alkyltrioxacyclohexanes were poor accounting only for 10-20% yield. 
 
Scheme 2.3. Ketone-initiated photoaddition of olefines to cyclic ethers. 
Almost twenty years later, the group of Inanaga reported a SmI2-induced masked formylation of 
carbonylcompounds. α-Hydroxyacetals were attained by the reduction of iodobenzene with SmI2 in a 
solution of 1,3-dioxolane-MeCN-HMPA (20:2:1) in the presence of carbonyl compounds.
[51b]
 
However, the substitution of 1,3-dioxolane with 1,3,5-trioxane gave rise to the corresponding adducts 
only in poor yields (Scheme 2.4). 
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Scheme 2.4. SmI2-induced masked formylation of carbonyl compounds. 
Crabtree and Brown particularly emphasized the synthetic high value of the trioxanyl moiety as a 
masked formyl group. In their studies the authors described the functionalization of cyclohexane by 
mercury-photosensitized cross-dehydrodimerization which generated 2-cyclohexyl-1,3,5-trioxane 
(Scheme 2.5).
[53]
 They stressed the opportunity to cleave the acetal upon hydrolysis, however the 
report is lacking further details concerning this transformation. 
 
Scheme 2.5. Alkane functionalization by mercury-photosensitized cross-dimerization. 
A fourth reaction in which the 1,3,5-trioxane motif is fully implemented into a molecular scaffold is 
the Minisci-type functionalization of N-heterocycles such as chinoline
[52b]
 or benzonaphthyridine 
(Scheme 2.6).
[52a]
 
 
Scheme 2.6. Minisci-type functionalization of heterocycles using 1,3,5-trioxane. 
Besides the above mentioned examples, in the vast majority of reactions with 1,3,5-trioxane, the O-
heterocycle is used as formaldehyde source. Practical applications are aldol reactions,
[54]
 Blanc 
chloromethylation,
[55]
 Pictet-Spengler-cyclization
[56]
 or Eschweiler-Clarke aminomethylations and 
Mannich reactions.
[27]
 
2.3.2 C–H Bond functionalization by means of rhodium carbenoid 
insertion 
The C−H bond functionalization by a metal-bound carbene, nitrene or oxo species has become a 
powerful branch in the field of C−H bond functionalization methodologies in recent years.[57] In 
particular, chiral catalysis using dirhodium(II) catalysts has experienced immense growth since the 
discoveries in the early 1980’s.[58] Dirhodium(II) carboxylate complexes are inherently stable to heat, 
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moisture and can be handled and stored under ambient atmosphere. They are highly reactive catalysts 
for the decomposition of diazo compounds (Scheme 2.7). 
 
Scheme 2.7. Rhodium(II)-mediated decomposition of diazo compounds. 
The resulting rhodium carbenoids are exceptionally versatile in their reactivity, while displaying 
high selectivities in reactions such as C–H bond insertions, cyclopropanation/propenation reactions 
and ylide formation, cycloadditions
[59]
 and cross-coupling reactions.
[60]
 This section will highlight 
selected examples of rhodium(II)-catalyzed C–H bond insertion reactions with an emphasize on the 
application in small molecule activation. 
The reactivity is particularly dependent on the stability of the carbenoid and C−H bond strength of 
the reaction partner. Variation of the electron demand of the substituents on the carbene precursor 
proved particularly helpful to affect the chemoselectivity (Figure 2.4). A wide array of experimental 
data displayed considerably enhanced chemo- and stereoselectivity when donor/acceptor rhodium 
carbenoids where employed in cyclopropanation
[61]
 and C−H bond insertion reactions. A 
computational study conducted by Hansen, Autschbach and Davies demonstrated that stabilized 
donor/acceptor rhodium carbenoids display significantly higher potential energy activation barriers 
which vice versa leads to an increased selectivity due to lower reactivity compared to the traditionally 
used acceptor carbenoids derived from unsubstituted diazo esters.
[57b]
 
 
Figure 2.4. Classification of carbenoid intermediates. 
The C−H bond functionalization by donor/acceptor rhodium carbenes is a powerful method that has 
impacted profoundly on complex chemical synthesis. Amongst the most notable developments in this 
field is the highly site and stereoselective intermolecular direct functionalization of unactivated sites in 
a multitude of molecules. This has proven advantageous to streamline the synthesis of numerous 
natural products and pharmaceutical targets. 
Chiral rhodium-prolinate complexes, initially invented by McKervey
[62]
 and further developed by 
the group of Davies,
[63]
 display excellent catalytic activity in intra- and intermolecular C−C bond 
forming reactions via C−H bond insertion of donor-acceptor carbenoids in a highly stereoselective 
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fashion. The highest stereoinduction was commonly achieved in apolar solvents. However, 
McKervey’s Rh2(S-BNP)4 catalyst was poorly soluble in this medium. Introducing a dodecyl side-
chain significantly enhanced the solubility and broadened the applicability of the catalyst system 
(Figure 2.5). The S-DOSP (dodecylsulfonylprolinate) backbone of Rh2(S-DOSP)4 is synthesized from 
chiral pool amino acid S-proline and dodecylsulfonyl chloride. Dodecylsulfonyl chloride is accessed 
from sodium dodecylsulfonate which is a bulk chemical commonly used as surfactant and constitutes a 
major component in laundry detergent.
[64]
 Hence, this powerful catalyst consists of inexpensive and 
abundant commodities. Irrespective of the substitution pattern, the carboxylate ligands undergo 
thermal ligand exchange with the acetate ligands of Rh2(OAc)4 to form the corresponding rhodium(II) 
carboxylate complex. 
 
Figure 2.5. Chiral rhodium(II)-prolinate complexes Rh2(S-BNP)4 (left) and Rh2(S-DOSP)4 (middle). 
Rh2(S-DOSP)4 is arguably the most widely applied chiral rhodium catalysts and has been used in a 
multitude of enantioselective C−H bond insertion reactions. The site selectivity is controlled by a 
delicate balance of steric and electronic effects. Highly substituted sites are electronically favored as 
they stabilizes build up of the positive charge at the carbon centre during the C−H insertion event. 
Nonetheless this contribution is counterbalanced by the steric demands of the carbene complex. Thus, 
dirhodium tetraprolinate catalyst Rh2(S-DOSP)4 operate most efficiently in C−H bond 
functionalization reactions at secondary C−H bonds, although a few examples of functionalization of 
sterically accessible tertiary C−H bonds[45b,57c] and electronically activated primary C−H bonds have 
been reported.
[65]
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Figure 2.6. Simplified model of the dirhodium prolinate complex Rh2(S-DOSP)4. 
Kinetic studies have demonstrated that only one of the two metal atoms is catalytically competent 
while the other metal center functions as an electron sink to stabilize the carbenoid structure.
[66]
 The 
selectivity of the chiral dirhodium(II) paddlewheel carboxylate can be illustrated as depicted in Figure 
2.6. The core of the complex is represented as a disc-like shape. The dirhodium(II) complex can be 
separated into quadrants, defined by the O−Rh−O bonds. In the Rh2(S-DOSP)4 model, tetraprolinate 
DOSP is thought to reside in a D2-symmetric conformation. An alternating up-down arrangement 
minimizes the net dipole induced by the N-sulfonyl groups.
[67]
 The donor/acceptor carbenoid arranges 
itself in a way that the donor group (e.g. aryl or vinyl moiety) is in the plane of the rhodium bound 
carbene, whereas the electron withdrawing group (e.g. alkyl ester) adopts an arrangement 
perpendicular to the plane of the carbene. The stereo-electronic demand of the ester shields an 
additional quadrant. Hence, the incoming substrate has merely one possible trajectory to approach the 
carbenoid. These features dictate the stereochemistry of the resulting coupling product (Figure 2.7). 
Calculations at a B3LYP/6-31G*[Rh-RSC+4f] level of theory suggested that the C−H bond insertion 
is highly asynchronous for activated C−H bonds. In these cases, the formation of the new C−H bond 
slightly precedes the C−C bond formation between the carbenoid and the substrate. This is also evident 
in a 165° C−H−C angle in the optimized transition state geometry. Hence, the substrate penetrates the 
metal carbenoid in an almost orthogonal trajectory as illustrated in Figure 2.6. The Newman 
projection, as shown below, serves as good model for the prediction of the stereochemical outcome of 
the reaction. 
 
Figure 2.7. Newman projection as predictive model for the stereoselective C−H bond insertion. 
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Noteworthy, small molecule activation, naturally depending on its definition, is relatively scarce in 
rhodium-carbenoid catalysis. Examples that provide a formal C1 extension of the carbenoid are even 
less widespread. 
Two examples in this area have been studied and published by the group of Davies. In the first 
example, stereoselective insertion of methylphenyl diazoacetates into the methyl group of silyl-
protected methylamine was accomplished in the presence of Rh2(S-DOSP)4 (Scheme 2.8). The 
corresponding chiral β-amino esters were synthesized in good yields and high enantiomeric excess. 
Acidic treatment eventually liberated the free amine. This reaction was applied to a rapid 
enantioselective synthesis of the antidepressant venlafaxine (Scheme 2.8).
[68]
 
 
Scheme 2.8. C–H functionalization strategy for the preparation of venlafaxine. 
The C‒H functionalization of a primary center alpha to the nitrogen atom of N,N-dimethylanilines 
was further applied to the preparation of C2-symmetric anilines, by using an excess of methyl 
aryldiazoacetate in reported yields of 41-60% and 85-95% ee (Scheme 2.9).
[65a]
 Blocking of the para-
position of the aniline arene was mandatory to avoid site-product formation by competing electrophilic 
aromatic substitution. 
 
Scheme 2.9. Double C–H activation strategy for the asymmetric synthesis of C2-symmetric anilines. 
Besides these two examples for the stereoselective activation of formal C1-building blocks, the 
broad applicability of stereoselective C−H bond insertion by means of rhodium(II) carbenoid 
chemistry has certainly been showcased. In particular, the site-selective activation of C−H bonds α to 
heteroatoms proved to be a fruitful pathway to create valuable architectures and supplies alternative 
strategies to traditional synthetic routes. For example, β-hydroxy esters, traditionally prepared by an 
aldol reaction have been stereoselectively accessed by α-C–H functionalization of silyl ethers (Scheme 
2.10).
[69]
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Scheme 2.10. Catalytic asymmetric C‒H activation α to oxygen as a surrogate to the aldol reaction. 
Almost one decade later, in 2003, this approach was implemented in the sequential synthesis of 
functionalized 2,3-dihydrobenzofurans based on C−H bond functionalization in a collaborative project 
jointly published by the groups of Huw Davies and Jin-Quan Yu (Scheme 2.11). 
 
Scheme 2.11. Sequential C−H functionalization reactions for the enantioselective synthesis of highly 
functionalized 2,3-dihydrobenzofurans. 
Similarly, β-amino esters, products of the Mannich reactions, are obtained by C–H activation α to 
nitrogen.
[70]
 This reaction provided access of threo-methylphenidates, the active form of the 
psychostimulant drug Ritalin
®
 (Scheme 2.12). 
 
Scheme 2.12. Catalytic asymmetric C‒H activation α to nitrogen as a surrogate to the Mannich 
reaction. 
A strategically surrogate for the Claisen condensation has been proposed by the insertion of donor-
acceptor substituted carbenoids into C–H bonds of acetals (Scheme 2.13).[71] The resulting protected β-
keto esters were formed in up to 65% yield and maximum 91% ee. However, the average yields and 
enantiomeric excesses were moderate. 
 
Scheme 2.13. Asymmetric C–H insertion of Rhodium(II) stabilized carbenoids into acetals. 
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In line with these examples, we aimed to exploit small molecule-activation by means of 
rhodium(II)-catalyzed C−H bond activation to provide an equivalent for asymmetric formylation 
outside the range of thoroughly studied hydroformylations. 
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2.4 Results and discussion 
The direct functionalization of inexpensive, crystalline, and safe to handle cyclic ether 1,3,5-
trioxane by means of enantioselective rhodium(II) carbenoid insertion into one of six chemically 
equivalent C−H bonds is presented. The applied method allowed for the unprecedented 
implementation of stable, chiral trioxanyl acetals. 
2.4.1 Optimization and catalyst screening 
Methyl phenylacetate 2.1a was used as standard substrate for the optimization of the reaction 
conditions for the rhodium-catalyzed stereoselective insertion into 1,3,5-trioxane 2.2 (Table 2.1). The 
conversion to the desired product was determined by 
1
H NMR analysis of the crude mixtures after 
evaporation of the solvent. Mesitylene was used as an internal standard. Isolated yields are shown in 
parenthesis. Where appropriate, the enantiomeric excess was determined by chiral HPLC analysis (ee 
of (S)-enantiomer). The stereochemistry was assigned according to the predictive model for Rh2(S-
DOSP)4 C−H bond insertion as described in Figure 2.7. Later the prediction was confirmed by x-ray 
analysis of an enantiomerically pure probe and cross-checked with its chiral HPLC trace and optical 
rotation values. 
 
Figure 2.8. Tested achiral and chiral rhodium carboxylate complexes. 
Although most tested chiral rhodium(II) carboxylate complexes, Rh2(S-ptad)4, Rh2(S-pttl)4, Rh2(S-
nttl)4 (Figure 2.8) efficiently catalyzed the C−H bond insertion of phenyl acetate derived carbenoids 
into 1,3,5-trioxane (Table 2.1, entry 13-22). Rh2(S-DOSP)4 imparted both the highest selectivity for 
the productive C‒H insertion pathway and highest enantioselectivity amongst the chiral catalysts 
tested (36% isol. 92% ee (S), yield of 2.3a; Table 2.1, entry 18). The modest yields owing to the high 
reactivity of diazoesters, which are prone to participate in side reactions such as dimerization, in 
expense of product yield. For instance, (2Z,2'Z)-dimethyl 2,2'-(hydrazine-1,2-diylidene)bis(2-
phenylacetate) was formed and isolated in 18% yield as major side product (Table 2.1, entry 12). 
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None-the-less, a higher yield of 54% and improved enantioselectivity (99% ee, (R)) was observed 
when methyl 4-bromophenyldiazo acetate 2.1b was used as the substrate (entry 23). Thus, after an 
exploratory screening, optimal results were obtained when a solution of methyl phenyl diazoacetate 
2.1 in 1,2-dichloroethane was added dropwise to a styrring solution of the Rh2(S-DOSP)4 (1.0 mol%) 
and 1,3,5-trioxane (2.3) in 1,2,-dichloroethane over the course of 90 min. 
Table 2.1. Optimization and catalyst screening.
a 
 
2.4.2 Scope of the transformation 
The electronic nature of the substituents on the phenyl ring had a crucial impact for the efficiency of 
the reactions. The reactivity of the substrates correlated well and can be predicted with corresponding 
Hammett values.
[72]
 Substrates with positive σm/p values proved to benefit from the product-forming 
C−H insertion pathway, whereas substituents with negative σm/p values gave less satisfying results in 
terms of product yields. Thus, the scope of this reaction could be explored in a predictable manner, 
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comprising a reasonably broad variety of functional groups, including halides (Table 2.2, entries 2-5), 
sulfonates (entries 6-7) and cyclopropylcarbonyl (entry 8) in moderate yields and excellent 
enantiomeric excesses (91-99% ee). The stereochemistry of all products was assigned according to 
their optical rotation in comparison with the confirmed configuration of (R)-2.3b (entry 3) which is in 
analogy with the stereochemistry of the predictive model for chiral Rh2(DOSP)4 catalysts. 
Table 2.2. Scope of the reaction: para-substituted phenyl diazo acetates (2.1). 
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Table 2.2. (continued) Scope of the reaction: para-substituted phenyl diazo acetates (2.1). 
 
In the presence of meta-substituents the isolated yields of racemic products (method B) were 
comparable with those obtained for para-substituted phenyldiazoacetates (Table 2.3, entries 1-5). The 
corresponding enantioenriched products were formed in comparably lower yields (21-35%) and 
moderate enantiomeric excess (67-77% ee, entries 1-4). 
 
Figure 2.9. Conformers A and B of Rh2(S-DOSP)4 carbenoids bearing a meta-substituent. 
 The diminished enantiomeric excess ought to originate from either one of two possible 
conformations of the corresponding rhodium carbenoid species, A or B (Figure 2.9). As illustrated, an 
adverse steric repulsion between the substrate and the ligand backbone are conceivable in both 
instances, which might lead to an out-of plain-bend of the phenyl ring. Thus, the usually unfavorable 
C−H insertion from the quadrant that is shielded by the ester group is now permitted. This 
disadvantageous steric repulsion is even more pronounced when the methyl 3,5-
dimethoxyphenyldiazoacetate is used and the corresponding product (R)- was isolated in a low yield 
(17%), when compared to its racemate (56%), and in lower enantioselectivity (53% ee, entry 5). 
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Table 2.3. Scope of the reaction: meta-substituted phenyl diazo acetates. 
 
Gratifyingly, the structurally related yet more sterically congested acetaldehyde trimer, paraldehyde 
(2.4), was an equally eligible coupling partner, showcased in Scheme 2.14. In this sequence, methyl 2-
(4-bromophenyl)-2-((4R,6S)-2,4,6-trimethyl-1,3,5-trioxan-2-yl)acetate (2.5), bearing an acetal-
protected ketone quaternary center, was isolated in a 50% yield as racemic mixture of the (4R,6S)-
diastereomer, in excellent diastereoselectivity (99:1). When chiral Rh2(S-DOSP)4 was used, formation 
of the desired product accounted for 11% (NMR-yield) only led to unsatisfactory low yields with we 
attribute to disfavourable steric repulsion between paraldehyde 2.4 and the bulky chiral DOSP-ligands. 
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Scheme 2.14. Formation of a quaternary carbon center by regioselective insertion of 1b into the α-C‒H 
bond of paraldehyde. 
It is noteworthy to mention, that in most related reports, the purification of the C−H insertion 
products have been difficult to achieve and yields were often documented as calculated yield from a 
crude mixtures of products.
[73]
 In the present work, all products were isolated and almost exclusively 
obtained as colorless, crystalline material. Yields are given for the analytically pure material. In two 
cases, crystals suitable for x-ray analysis were attained (Figure 2.10). This instance was pivotal to 
unambiguously support the successful enantioselective C−H bond insertion and the absolute 
configuration of the formed products. The stereochemistry could be assigned from the crystal structure 
of enantiomerically pure (-)-(S)-ethyl 2-(4-bromophenyl)-2-(1,3,5-trioxan-2-yl)acetate (2.3b) from the 
reaction of ethyl 2-(4-bromophenyl)-2-diazoacetate (2.1b) and 1,3,5-trioxane (2.2) in the presence of 
chiral Rh2(S-DOSP)4. Subsequently, the enantiomerically pure crystal was subjected to HPLC analysis 
to confirm that it represents the major component. Another crystal structure of racemic methyl 2-(2,5-
difluorophenyl)-2-(1,3,5-trioxan-2-yl)acetate (2.3j) could be resolved. 
 
Figure 2.10. X-ray structures of (-)-(S)-ethyl 2-(4-bromophenyl)-2-(1,3,5-trioxan-2-yl)acetate 2.3b and 
(rac)-methyl 2-(2,5difluorophenyl)-2-(1,3,5-trioxan-2-yl)acetate 2.3j. 
2.4.3 Product derivatization 
Methyl 2-aryl-2-(1,3,5-trioxan-2-yl)acetates 2.3 were found to be surprisingly robust compounds. 
The high stability of the trioxane moiety could be exploited in terms of product derivatization. For this 
purpose a sufficient amount of starting material was required. 2-(4-bromophenyl)-2-diazoacetate 
(2.1b) was chosen as substrate for a gram-scale synthesis of (R)-methyl 2-(4-bromophenyl)-2-(1,3,5-
trioxan-2-yl)acetate ((R)-2.3b) as it is easily accessible and proved more stable than the parent 2-
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phenyl-2-diazoacetate (2.1a). The corresponding coupling product of diazo 2.1b and 1,3,5-trioxane 
(2.2) catalyzed by Rh2(R-DOSP)4 was obtained in 39% isolated yield comparable to the outcome of 
the small scale reaction. With enough material in hand, we turned our attention to further 
transformations. 
Ester 2.3b was efficiently reduced by lithium aluminium hydride. Alcohol 2.6 was obtained in a 
90% isolated yield with full retention of the absolute configuration. Subsequent functionalization of 
the free alcohol allowed for the synthesis of (S)-2-(4-bromophenyl)-N,N-dimethyl-2-(1,3,5-trioxan-2-
yl)ethanamine (2.7) in 71% isolated yield and 94% ee over two steps (Scheme 2.15). 
 
Scheme 2.15. Reduction of (R)-methyl 2-(4-bromophenyl)-2-(1,3,5-trioxan-2-yl)acetate and synthesis of 
phenethylamine 2.7. 
Treatment of alcohol 2.6 with sodium hydride and iodomethane yielded methyl ether 2.8 in 85% 
yield (Scheme 2.16). Hence, alcohol 2.6 serves as valuable building block which can be treated either 
as nucleophile or pre-electrophile. 
 
Scheme 2.16. Synthesis of chiral ether 2.8. 
As previously mentioned, methyl 2-aryl-2-(1,3,5-trioxan-2-yl)acetates 2.3 proved to be rather 
stable. A number of conditions listed in Scheme 2.17 were tested in order to cleave the trioxanyl 
acetal. In contrast to commonly used acetals that are cleaved at low pH, 1,3,5-trioxane is exceedingly 
stable under acidic conditions. Methyl 2-(4-bromophenyl)-2-(1,3,5-trioxan-2-yl)acetate (2.3b) can be 
stored in 10% HCl in THF for several days (>7 days) without any evidence of degradation.
[74]
 
Furthermore, ester 2.3b proved to be stable under reflux in several solvents (MeOH, THF, 1,4-
dioxane/MeOH, H2O/MeOH/THF) in the presence of concentrated hydrochloric acid, pyridinium p-
toluenesulfonate (ptts) and amberlyst 15. Also other conditions that are usually applied for the 
cleavage of acetal groups did not affect the degradation of the cyclic ether (Scheme 2.17).
[75]
 This 
unexpected behavior arguably originates from a conformational stabilization due to the syn-periplanar 
alignment of the oxygen lone pairs. Moreover, the 5-oxygen ought to significantly alter the electronic 
nature of the acetal oxygens, rendering them less prone to protonation. Alternatively, treatment of 
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ester 2.3b with lithium hydroxide in THF/H2O led to rapid cleavage of the O-heterocycle selectively 
yielding the free aldehyde 2.9 in a 70% isolated yield. However, under these alkaline conditions it was 
noted that (R)-methyl 2-(4-bromophenyl)-3-oxopropanoate (2.9) readily racemizes. Nevertheless, the 
corresponding alcohol 2.6 and ether 2.8 derivative of 2.3b were stable under the same reaction 
conditions. Notably, in situ reduction of the aldehyde with NaBH4 could not prevent the racemization. 
This result indirectly substantiates that the aldehyde-enol tautomerization is faster compared to the 
reduction step. 
 
Scheme 2.17. Cleavage of the trioxanyl acetal 2.3b. 
Indeed, the apparently anomalous behavior of 1,3,5-trioxane compared to 1,3-dioxane has been 
previously reported in a related context. Jenkins and co-workers studied the reaction of tert-butoxyl 
radicals with cyclic ethers by the radical trapping technique.
[76]
 They have evaluated 14 cyclic alkanes 
and cyclic ethers in terms of their reactivity pattern and relative rate of abstraction of tert-butoxyl 
radicals. It was observed that oxygen α to C−H strongly enhances the abstraction, whereas oxygen 
located β to C−H generally retards the abstraction. According to this supposition, the reactivities of 
1,3,5-trioxane and of 1,3-dioxane are comparable, and arguably enhanced in case of the trioxane. 
However, the hydrogen atoms exhibited much reduced reactivity, accounting for less than half 
compared to 1,3-dioxane. By comparison of the bond lengths of both cyclic ethers from x-ray data (co-
crystallized with a zinc porphyrin complex)
[77]
 no significant dissimilarities in the C−H bond lengths 
was observed. Conversely, it was hypothesized that the differences ought to be of electronic origin. 
The obvious difference between 1,3,5-trioxane and 1,3-dioxane is the 5-oxygen versus 5-methylene 
substituent. Thus, whereas each methylene group of the trioxane is subjected to electron withdrawal by 
two flanking oxygen atoms, the analogous methylene of the dioxane experiences a slightly electron 
donation by the trimethylene chain. In Jenkins study it is comprehensible that a reduced accumulation 
of electron density results in a reduced rate of hydrogen abstraction by the (electrophilic) tert-butoxyl 
radical (Figure 2.11., left). 
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Figure 2.11. Comparison of 1,3-dioxane and 1,3,5-trioxane in radical hydrogen abstraction and acetal 
cleavage of 2-(1,3-dioxanyl) and 2-(1,3,5-trioxanyl) acetals. 
Extrapolated to the objected acetal cleavage, the electronic influence of the oxygen atom in the 
backbone of the 1,3,5-trioxanyl acetal has a similarly perturbing effect (Figure 2.11, left). The acetal 
oxygens possess a diminished electron density compared to the 1,3-dioxanyl acetal oxygen atoms. 
Hence, protonation is excessively more difficult. In addition, the oxygen atoms in trioxane seem also 
less eligible to interact with Lewis-acids which ought to facilitate the cleavage. 
2.5 Stereoelectronic effects in 1,3,5-trioxane: The Perlin effect 
“The longer C‒H bond has the lower one-bond C‒H coupling constants” 
Saul Wolfe et al., Department of Chemistry, Queen's University, Ontario, Canada. 
(Can. J. Chem. 1990, 68, 1051‒1062.) 
2.5.1 Background 
The stereochemical non-equivalence of axial and equatorial bonds in cyclohexane derivatives in the 
chair conformation manifests itself in a number of ways, and is particularly evident in the NMR 
spectra. Typically, the chemical shift of axial protons is 0.1-0.7 ppm upfield compared to the 
equatorial protons (
3
JH(ax)/H(ax) = 8-10 Hz, while 
3
JH(eq)/H(eq) = 2-3 Hz). The C−H bond length and 
strength and therefore, the chemical reactivity is reflected by its coupling constant and chemical shift 
in the NMR spectrum and is significantly influenced upon its stereochemical relationship to vicinal 
electron lone pairs. In cyclohexanes and derived saturated heterocycles having one or more first row 
heteroatoms attached to the carbon of interest, the 
1
JC−H(eq) coupling constant is always larger than the 
axial one (
1
JC−H(ax) < 
 1
JC−H(eq)). In literature this effect is generally referred to as Perlin Effect.
[78]
 This 
interrelation is reminiscent of an infrared effect known as Bohlmann bands. The magnitude of a one-
bond C−H coupling constant expectedly varies inversely with the bond length, i.e. the longer, thus 
weaker, the C−H bond exhibits a smaller one-bond coupling constant. This correlation has been 
confirmed due to numerous experimental studies and has been rationalized by quantitative 
perturbational molecular orbital (PMO) theory. 
1
JC−H values from undecoupled 
13
C NMR spectra are 
commonly addressed to determine the anomeric configuration in carbohydrate derivatives (Scheme 
2.18). 
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2.5.2 Stereoelectronic effects in 1,3,5-trioxane 
1,3,5-Trioxane is a 6-membered heterocycle consisting of three alternating -CH2O- units. All axial 
oxygen lonepairs of the C3-symmetric molecule are arranged in a 1,3-syn-periplanar fashion. This 
interrelation stabilizes the chair structure of the heterocycle. Moreover, the axial lone-pairs perturb the 
contiguous axial C−H bonds via nO → σ*C‒H interactions. As a result, the axial C−H bond is weakened 
while the C−O bonds are strengthened and thus shortened. These geometric features ought to lead to a 
superior reactivity of the axial C−H bond and enhanced stabilization of the carbenium intermediate 
which is formed during the rhodium-carbenoid triggered C−H bond-cleavage. 
  
Scheme 2.18. (A) Decoupled and (B) undecoupled 
13
C-NMR spectra of 1,3,5-trioxane (2.2). 
In contrary, a reverse Perlin-effect for all C−H bonds is met in 1,3-dithiane (1JC−H(ax) > 
1
JC−H(eq)) 
suggesting the existence of a dominant σC‒S → σ*C‒H stereoelectronic interaction which leads to a 
weakening of the equatorial C−H bond in this heterocycle. A similar stereoelectronic relation can be 
assumed to be present in 1,3,5-trithiane. 
When 1,3,5-trithiane was tested in the catalytic reaction with methyl phenyldiazo acetate 2.1a no 
product formation could be observed. Instead a color change from green to purple was noticed when 
1,3,5-trithiane was added to a solution of Rh2(S-DOSP)4 which most likely originates from ligation of 
the sulfur lone-pairs to the vacant axial position of the rhodium complex. Scheme 2.19 shows the UV-
vis spectra of solutions of (A) Rh2(S-DOSP)4, (B) Rh2(S-DOSP)4 and 1,3,5-trioxane and (C) Rh2(S-
DOSP)4 and 1,3,5-trithiane in 1,2-dichloroethane (5x10
-4
 M). Spectra A shows an absorption maxima 
at 237 cm
-1
 which is unaffected by the presence of 1,3,5-trioxane. In the presence of 1,3,5-trithiane 
UV-vis spectra shows two maxima at 243 cm
-1
 and 317 cm
-1
 strongly shifted towards higher wave 
numbers which clearly supports a strong substrate-catalyst interaction in the presence of sulfur 
containing-heterocycles. A similar catalyst deactivating effect is encountered when urotropin was 
tested as coupling partner in the rhodium-mediated C−H bond insertion, emphasizing the well-known 
lone-pair donor binding  affinity of nitrogen atoms to the  rhodium metal center. 
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Scheme 2.19. UV-vis spectra of (A) Rh2(S-DOSP)4, (B) Rh2(S-DOSP)4 and 1,3,5-trioxane and (C) Rh2(S-
DOSP)4 and 1,3,5-trithiane in 1,2-dichloroethane (5x10
-4
 M). 
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2.6 Conclusion and outlook 
The developed methodology for the enantioselective masked-formylation of push-pull carbenes by 
means of rhodium(II) carbenoid mediated C−H bond insertion provides access to a new substance 
class of chiral alkyl 2-phenyl-2-(1,3,5-trioxan-2-yl)acetates (Scheme 20). This scaffold is the first of 
its kind in which a 1,3,5-trioxane moiety is attached to an optically active sp
3
-hybridized carbon atom. 
Owing to the structural relation to naturally occurring arylpropionates such as atropine and artificial 
methylphenidates, this substance class holds great promise to be used as valuable building blocks for 
medicinal chemistry. The demonstrated high stability of the O-heterocycle towards strong acidic 
conditions is advantageous in view of oral administration of potential drug candidates. 
However, the selective cleavage of the 1,3,5-trioxanyl acetal remains an explicit goal. Liberation of 
the free aldehyde while maintaining the optical purity would provide a formylation strategy beyond 
traditional asymmetric hydroformylation chemistry. 
 
Scheme 2.20. Enantioselective masked formylation of rhodium(II) carbenoids using 1,3,5-trioxane.
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3 Rhodium(II)-catalyzed annulation of azavinyl 
carbenes through ring-expansion of 1,3,5-trioxane: 
Rapid excess to 9-membered heterocycles 
3.1 Preface 
Besides donor-acceptor substituted carbenes that have been studied in depth, 1-sulfonyl-1,2,3-
triazoles depict another promising class of carbene precursors. This section describes the 
decomposition of 1-sulfonyl-1,2,3-triazoles in the presence of rhodium(II) catalysts and the reactivity 
of the corresponding azavinyl carbenes with 1,3,5-trioxane. 
3.2 Project outline 
Intermolecular insertions of highly reactive metalbound carbenes have emerged as a powerful 
strategy for the functionalization of seemingly inert sp
3 
C−H bonds and activated and unactivated 
alkanes.
[5a,45a,79]
 However, although diverse C−H bonds have been successfully functionalized, this 
strategy has been mainly limited to donor-acceptor substituted rhodium(II) carbenes derived from 
phenyl or vinyl diazoesters (Figure 3.1). 
 
Figure 3.1. Overview of the reactivity of rhodium-carbenoids derived from 1-sulfonyl-1,2,3-triazoles. 
The group of Valery Fokin has strikingly demonstrated that 1-sulfonyl-1,2,3-triazoles can serve as 
direct precursors to azavinyl carbenes in the presence of rhodium(II) catalysts in the transannulation of 
nitriles.
[80]
 Azavinyl carbenes are electronically closely related to donor-acceptor substituted carbenes 
and share many reactivity features. Subsequent to the seminal discovery that 1-sulfonyl-1,2,3-triazoles 
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serve as formidable carbene precursor, triazoles were tested in a variety of reactions that have been 
previously reserved to diazo acetates, such as cyclopropanation, dimerization, insertion, dipolar 
addition, ylide generation, and rearrangement reactions (Figure 3.1).
[81]
 The most important 
precedence to this end was the reactivity of azavinyl carbenes derived from 1-sulfonyl-1,2,3-triazoles 
towards unactivated C−H bonds. In 2011, Fokin and Chuprakov published a protocol on a highly 
enantioselective C−H insertion into unactivated alkanes that allowed for the synthesis of various chiral 
β-sulfonamides (Scheme 3.1).[57e] 
 
Scheme 3.1. Catalytic asymmetric C−H insertions of Rhodium(II) azavinyl carbenes into unactivated 
alkanes. 
Based on these findings and to further explore the synthetic potential of 1,3,5-trioxane, we 
envisioned to study the rhodium(II)-catalyzed decomposition of 1-sulfonyl-1,2,3-triazoles in the 
presence of 1,3,5-trioxane. The C−H insertion of the azavinyl carbene into 1,3,5-trioxane would 
supply direct to chiral protected β-amino carbonyl compounds derived from phenethylamines. 
However, in this reaction, ylide formation of the oxygen-heterocycle with the Rh-carbenoid species 
outcompetes the C−H bond functionalization pathway (Scheme 3.2). Successful optimization of the 
reaction condition allowed for the one-pot preparation of a seemingly illusive nine-membered 1,3,5,7-
trioxazonine ring. 
 
Scheme 3.2. Rhodium(II)-catalyzed decomposition of N-sulfonyl-triazoles in the presence of 1,3,5-
trioxane. 
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3.3 Background 
The formations of medium-sized rings depict a synthetic challenge since their synthesis is often 
impeded by adverse entropic or unfavorable transannular interactions.
[82]
 However, their synthesis 
gains considerable attention, not least because of the broad abundance of medium-sized rings natural 
products and the huge therapeutic success of agents derived from that substance class, such as taxol
[83]
 
or a number of polycyclic ethers shown in Figure 3.2.
[84]
 7- to 11-membered cyclic structures are most 
frequently obtained via macrocyclization,
[85]
 fragmentation, ring expansion and ring-closing 
metathesis reactions.
[86]
 
 
Figure 3.2. Natural products containing medium-sized rings, (-)-taxol and E,F,G,J-rings of Ciguatoxin. 
The influence of ethers upon carbenes has been investigated both experimentally and 
computationally. Whereas phosphonium ylides
[87]
 and sulfur ylides
[88]
 are readily formed and widely 
used in organic synthesis, depending on the electrophilic nature of the carbene, oxygen ylides between 
carbenes and ether oxygen atoms are reputed to undergo rather weak interactions.
[89]
 More 
nucleophilic carbenes, e.g. derived from push-pull diazo compounds, are associated with interactions 
of C–H bonds of carbon α to oxygen atoms. However, reactive electrophilic carbenes such as azavinyl 
carbenes are known to form oxygen ylide intermediates that are prone to undergo C–O bond insertion 
reactions.
[90]
 
In 2010, the group of Lacour and co-workers observed that the transition-metal-catalyzed 
decomposition of diazo compounds in the presence of cyclic ethers is a powerful method for the 
regioselective condensation of two α-diazo-β-ketoesters and two cyclic ethers to yield functionalized 
16- to 18-membered macrocycles in up to 75% yield (Scheme 3.3).
[91]
 
 
Scheme 3.3. Rhodium(II)-catalyzed synthesis of functionalized polyether macrocycles. 
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According to Baldwin’s rule, the intramolecular 5-endo-tet cyclization of the ylide intermediate 3.A 
is disfavored.
[92]
 The authors suggested that the key step of the proposed mechanism involves a 
synchronous “concerted” dimerization of two oxonium ylide intermediates 3.A (Scheme 3.3).[93] The 
developed methodology was later further expanded to the non-templated macrolactonization of methyl 
diazoacetoacetates and substituted ethers.
[94]
 
In 2012, again the group of Lacour demonstrated that α-diazo β-ketoesters and diketones react with 
cyclic acetals yielding polyoxygenated 8- and 9-membered, which was unprecedented at that time 
(Scheme 3.4).
[95]
 
 
Scheme 3.4. Synthesis of medium-sized rings versus macrocycles through rhodium-catalyzed ring- 
expansion reactions of cyclic acetals. 
The synthesis of medium-sized rings versus macrocycles proceeded with perfect regioselectivity. 
The standard reaction conditions stipulate a 20-fold excess of cyclic acetal. Of particular interest, 
1,3,5-trioxane was also was also used as a substrate, yielding the corresponding insertion products in 
34-85% yield. The authors proposed a mechanistic rational in direct application of Baldwin's rules. 
Accordingly, the reaction pathway encompasses the formation of an oxonium ylide (A), its 
transformation into an electrophilic unsaturated acyclic oxocarbenium intermediate and subsequent 
intramolecular nucleophilic attack. This reaction had precedence and was previously reported in 1999 
by Tollari and co-workers for the synthesis of polyoxygenated coumarins.
[96]
 
 
Figure 3.3. Proposed catalytic cycle for the rhodium-catalyzed medium-sized ring synthesis from diazo 
acetoacetates and cyclic acetals. 
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After we have started to investigate the rhodium-catalyzed decomposition of 1-sulfonyl-1,2,3-
triazoles in the presence of 1,3,5-trioxane, the group of Lacour published a closely related work on the 
insertion of 1-arylsulfonyl-1,2,3-triazoles into cyclic acetals, 1,3-dioxane and 1,3-dioxolane (Scheme 
3.5).
[97]
 
 
Scheme 3.5. One-step synthesis of nitrogen-containing medium-sized rings via α-imino diazo 
intermediates. 
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3.4 Results and discussion 
At the outset of our studies of the rhodium(II)-catalyzed decomposition of sulfonyl-triazoles in the 
presence of 1,3,5-trioxane a number of achiral rhodium(II) catalysts were screened to evaluate their 
catalytic activity (Table 3.1, entry 1-6). Rh2(Opiv)4 gave the best result and a coupling product was 
obtained in 60% isolated yield in 1,2-dichloroethane (entry 3). A brief solvent screening revealed that 
the yield could be enhanced to 70% in chloroform (entry 9). Hence, the best results for the annulation 
of 1-(methylsulfonyl)-4-phenyl-1H-1,2,3-triazole 3.1 with 1,3,5-trioxane 3.2 was obtained at 40 °C in 
the presence Rh2(Opiv)4 using chloroform as a solvent (entry 3). Under these reaction conditions the 
corresponding product (Z)-7-(methylsulfonyl)-9-phenyl-6,7-dihydro-1,3,5,7-trioxazonine 3.3 was 
isolated in 70% yield after flash chromatography. Increasing the temperature to 60 °C and 80 °C did 
not lead to significant increase of the product yield (entry 16 and 17, respectively). Thus, the scope 
was explored at 40 °C. 
Table 3.1. Optimization of reaction conditions. 
 
Owing to the unusual atomic constitution of the molecule, structural elucidation on the basis of 
1
H-
NMR spectroscopy proved challenging. Gratifyingly, the structure of the 9-membered N,O-
heterocycle could be unambiguously assigned by help of X-ray analysis of compounds 3.3b and 3.3d 
(Figure 3.4). 
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3.4.1 Scope and limitations 
Having assessed a practical protocol for the rhodium-catalyzed ring expansion of 1,3,5-trioxane 3.2, 
we studied the scope of 1-(methylsulfonyl)-4-phenyl-1H-1,2,3-triazole 3.1 derivatives that could be 
used under these conditions (Table 3.2). 
Table 3.2. Scope of the Rhodium(II)-catalyzed ringexpansion of 1,3,5-trioxane (3.2). 
 
All reactions proceeded smoothly at 40 °C with different aryl-substituted 1,4-disubstituted 1-
sulfonyl-1,2,3-triazoles 3.1 in good yields (60-80% ). Hereby, the outcome was largely unaffected by 
the electronic nature of the substituents on the aromatic ring of the triazole. The structure of the 
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obtained compounds is unusual to say the least and may appear illusive at first sight. Yet, we found 
that these compounds are highly stable and without exception obtained as colorless crystalline solids. 
Hence, we were grateful for obtaining crystals that were suitable for crystal structure analysis. This 
technic enabled us to unambiguously assign the configuration of the heterocycle. The reaction 
products shown in Figure 3.4 are composed of a nine-membered heterocycles consisting of two sp
2
-
hybridized carbon atoms, respectively, along with an alternating carbon-heteroatom chain following a 
N-C-O-C-O-C-O- sequence. The 9-position of 6,7-dihydro-1,3,5,7-trioxazonine 3.3 core harbors the 
aryl substituents of the former 4-aryl-1,2,3-triazol. 
 
Figure 3.4. X-ray structures of compounds 3.3d and 3.3b. 
The reaction was optimized for 1-(methylsulfonyl)-4-phenyl-1H-1,2,3-triazoles (3.1a). However, 
one major drawback of 1-(methylsulfonyl)-1H-1,2,3-triazoles 3.2 is the relatively high sensitive 
towards hydrolysis. The free 1H-1,2,3-triazole strongly binds to the vacant axial positions of the 
dirhodium complex and is thus poisonous for the catalytic activity. Therefore, it is especially 
important to operate with pure starting material to supply with good reactivity.  
 
Scheme 3.6. Reaction of N-1-tosyl-1,2,3-triazole with 1,3,4-trioxane. 
Noteworthy, the corresponding 1-tosyl-1,2,3-triazoles 3.4 displayed no reactivity in the 
transformation with 1,3,5-trioxane (Scheme 3.6), demonstrating that the presented reaction is 
orthogonal to the recently published protocol by Lacour.
[97]
 To this end the reaction scope is rather 
limited and sensitive to substituents other than aryls. However, the reaction product depicts a novel 
class of organic compounds that possesses a unique arrangement of carbon and heteroatoms. 
3.4.2 Mechanistic considerations 
The encountered reaction pathway seems particularly intriguing with regard to the energy profile of 
ring-opening versus degradation of 1,3,5-trioxane. The energy required for the ring-opening event 
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accounts for ca. 80 kcal/mol, considerably higher compared to the activation energy required to initiate 
the thermal decomposition with 49.1 kcal/mol.
[98]
 Quantum chemical calculation suggest that the 
thermal fragmentation of 1,3,5-trioxane into three formaldehyde molecules proceeds through a 
concerted mechanism. Thus, the unimolecular decomposition pathway to formaldehyde ought to be 
both entropically and kinetically favored. Nonetheless, the ring expansion products, 6,7-dihydro-
1,3,5,7-trioxazonine 3.3, have been obtained in high yields under mild reaction conditions. 
An reasonable explanation for the different reactivity of cyclic ethers that preferentially form 16- 
and 18-membered macrocycles
[91,94]
 versus the selective formation of medium-sized rings in the 
presence of acetals,
[95,97]
 was provided by the group of Lacour and co-workers. 
 
Figure 3.5. Mechanistic explanation for macrocyclization versus medium-sized ring synthesis. 
SN2 reactions whether inter- or intramolecular proceed via a transition state in which the incoming 
nucleophile and the leaving group are concerted in a trajectory somewhat close to 180°. Both cyclic 
ethers and cyclic acetals form reactive ylide intermediates with electrophilic carbenes. In the case of 
acetylacetonate derived carbenes an enolate species is formed. However, in ylides derived from cyclic 
ethers the geometry prohibits a nucleophilic attack on the electrophilic α carbon atom (Figure 3.5). In 
these species the chemical tension is released upon dimerization of two ylides. Oxygen-ylides formed 
from cyclic acetals, on the other hand, are mesomerically stabilized. The ring opening of the ether to 
the carbenium intermediate provides a scenario that allows for nucleophilic attack of the oxygen 
nucleophile on the electron-deficient carbon to form 8- and 9-membered oxygen-heterocycles, 
respectively. 
An equal situation is encountered in azavinyl carbenes. The acetal ylide is similarly stabilized by its 
open-chain mesomer. The negative charge of the zwitterion is located on the sulfony amine which is in 
the right angle to attack the carbenium cation to form 6,7-dihydro-1,3,5,7-trioxazonine 3.3 (Figure 
3.6). 
 
Figure 3.6. Rational for 9-membered ring synthesis from 1-sulfonyl-triazoles and 1,3,5-trioxane. 
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The proposed reaction mechanism is depicted in Scheme 3.7, below. The catalytic cycle 
commences with the decomposition of the triazole I from its open-chain isomer II (A). In the 
following, the reaction pathway involves the generation of an electrophilic metal carbenoid (B). 
Nucleophilic attack of an oxygen atom from 1,3,5-trioxane generates the corresponding oxonium ylide 
(C). Electron-shift of one adjacent oxygen lone-pair forms a trigonal sp
2
-hybridized carbon center 
which is amenable to intramolecular nucleophilic attack from the sulfonyl amine (E) that 
accommodated negative charge in course of the extrusion of the rhodium catalyst. This rational 
supplies an adequate explanation for the synthesis of the 6,7-dihydro-1,3,5,7-trioxazonine and the 
complete regioselectivity. 
 
Scheme 3.7. Proposed catalytic cycle. 
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3.5 Conclusion and outlook 
In summary, we have developed a methodology for the rhodium(II)-catalyzed annulation of 
azavinyl carbenes derived from 1-(methylsulfonyl)-1,2,3-triazoles through ring-expansion of 1,3,5-
trioxane. This examples further highlights the synthetic value of 1,3,5-trioxane as building block in 
organic chemistry apart from its role as a formaldehyde surrogate. Thus, unlike the common sense, 
this study could further invigorate the strength and stability of trioxane. The chemical structure of the 
product is unprecedented. The further functionalization of the nine-membered 1,3,5,7-trioxazonine 
rings and the evaluation of their stability under certain reaction conditions depict a field of future 
research. Notably, hydrogenation of the double bond ought to grant access to potentially bio-active 
phenethylamines. 
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4 Rhodium(II)-catalyzed alkoxylation-acetalization of 
donor-acceptor-substituted diazo compounds: One-
step synthesis of highly functionalized quaternary 
carbon centers 
4.1 Preface 
This chapter summarizes the development of a new strategy for the rapid build-up of densely 
functionalized quaternary carbon centers from inexpensive chemical commodities. A rhodium(II)-
catalyzed alkoxylation-acetalization of donor-acceptor-substituted diazo compounds by trimethyl 
orthoformate has been discovered and is the subject of the following section. This reaction allows for 
the one step synthesis of quaternary centers holding an alkene or arene, alkoxy, aldehyde and ester 
functionality. 
4.2 Project outline 
Encouraged by our previous results, we were intrigued to further expand the logic of implementing 
a C1-building block by means of rhodium(II)-catalyzed C−H bond insertion of carbenes. An initial 
survey of a suitable precursor drew our attention to trimethyl orthoformate. 
 
Figure 4.1. C−H bond length and O-basicity in 1,3,5-trioxane and trimethyl orthoformate. a Hydrogen 
bond basicity, statistically corrected value is shown in parenthesis.
[46a]
 
In chapter 2, the bond-weakening effect of the oxygen lone-pairs in 1,3,5-trioxane has been 
discussed. In further expansion of this effect, a priori, the C−H bond insertion ought to be even more 
pronounced when an additional lone-pair impairs the bond strength. However, a significantly different 
hydrogen bond affinity and thus higher nucleophilicity of the oxygen atoms in these structures may 
contribute to a deviant reactivity of 1,3,5-trioxane and the trimethyl orthoester. 
An initial experiment of the reactivity of trimethyl orhoformate (4.2) and 4-bromophenyl 
diazoacetate (4.1a) in the presence of Rh2(esp)2 yielded a product with suitable spectroscopic and mass 
spectrometric data, suggesting the successful incorporation of trimethyl orhoformate into the rhodium 
carbenoid species. However, based on the analytic data, ambiguous assignment of the molecular 
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structure of the reaction product proved difficult. Gratifyingly, crystals suitable for X-ray analysis 
elucidated a surprising structure featuring a quaternary center holding an alkane or arene, alkoxy, 
aldehyde and ester functionality. 
 
Scheme 4.1. Rhodium(II)-catalyzed reaction of 4-bromophenyl diazo acetate 4.1a and trimethyl ortho 
formate 4.2. 
This unexpected reaction outcome could be rationalized via a ylide formation/[1,2]rearrangement 
mechanism. To the best of our knowledge, this transformation is the first reaction of trimethylortho 
formate in which a simultaneous C−C and C−O bond formation has been observed. The extrusion of 
nitrogen as a sole by-product and otherwise full atom-economy renders this process particularly 
valuable and environmentally benign. The optimization of reaction conditions, scope and limitations 
and mechanistic investigation will be discussed after a preceding overview of relevant related 
transformations involving orthoesters and related applications of rhodium(II) catalysis. 
4.3 Background 
4.3.1 Trialkyl orthoesters in organic synthesis 
Trimethyl orthoformate or trimethoxymethane is the simplest orthoester. It is a versatile reagent 
widely used in synthetic organic chemistry.
[99]
 Orthoformates are bench-stable, yet highly reactive 
compounds. Reactions of orthoesters can be classified in reactions which result in (1) carbon−oxygen 
bond formation, (2) carbon−heteroatom bond forming transformations and (3) carbon−carbon bond 
formation. 
Typical examples for C−O bond forming reactions with trialkyl orthoformates are protection of 
diols,
[100]
 acetalization of carbonyl compounds,
[101]
 and esterification of acids (Scheme 4.2). The 
conversion of orthoformate to formate is energetically favored. Hence, trialkyl orthoformates are 
excellent esterification reagents as they function both as a water scavenger and as a source of alcohol 
for the esterification. This dual role limits reaction reversibility. Thus, trialkyl formats are especially 
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useful in lipase-catalyzed kinetic resolution of racemic carboxylic acids wherein orthoesters allow for 
enhanced enantiomeric excess of the resolved acids relative to alternative protocols.
[102]
 A similar 
effect accounts in acetalization reactions, allowing the formation of acetals under exceedingly mild 
conditions, making the additional use of acids obsolete. Thus, irrespective of the great number of 
different reaction condition for the acetalization of aldehydes, common features are high yields over a 
broad range of substrates, high selectivities for aldehydes versus ketones and tolerance of acid-
sensitive functionalities. 
 
Scheme 4.2. Reactions of orthoformates in which C−O bonds are formed. 
One of the most common applications of trialkyl orthoformates is in the condensation with 2-amino 
alcohols or vicinal diamines to afford heterocycles.
[103]
 Two representative examples include facile 
acid-catalyzed preparation of asymmetric 2-oxazolines from chiral amino alcohols (Scheme 4.3),
[103d]
 
as well as high yielding conversion of substituted ortho-phenylenediamines to benzamidazoles or 2-
aminophenols to benzoxazoles catalyzed by ytterbium triflate under solvent-free conditions (Scheme 
4.3). Noteworthy, the ytterbium catalyst can be recycled and is reusable without loss of activity. 
 
Scheme 4.3. Reactions of orthoformates in which C−heteroatom bonds are formed. 
C−C bond forming reactions with trialkyl orthoformates encompass formylation of carbanions,[104] 
formylation of electron-rich species, such as arenes and alkynes (Scheme 4.4).
[105]
 These reactions are 
synthetically particularly interesting as they add molecular complexity to simple carbon frameworks 
and supply with a useful handle for further transformations. 
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Scheme 4.4. Reactions of orthoformates in which C−C bonds are formed. 
Besides applications of trialkyl orthoformates in organic synthesis, they are also used in inorganic 
and organometallic chemistry. For instance, trimethyl orthoformate is often used as dehydrating 
reagent in the synthesis of transition metal complexes.
[106]
 
4.3.2 Synthesis of arylmethoxyacetic acid derivatives 
Arylmethoxyacetic acids (AMAAs) represent a versatile class of synthetic intermediates and serve 
as potent precursor for a plethora of highly valuable pharmaceuticals (Scheme 4.5). 
 
Scheme 4.5. Arylhydroxy acetic acids and derivatives. 
Arylmethoxyacetic acids are employed as auxiliary reagents for the determination of the absolute 
configuration of organic compounds by NMR as chiral derivatisation reagents.
[107] 
 Phenylpropionic 
acid derivatives, ibuprofen and naproxen, are immensely appreciated as non-steroidal analgesic and 
non-steroidal anti-inflammatory agents.
[108]
 Moreover, α-carbonyl-α-hydroxy arylpropionic acids have 
the potential to revise current syntheses of essential drugs, such as powerful antifungal fluconazole
[109]
 
and severe pain-relieving agent tramadol.
[109,110]
 
There are basically no straightforward procedures known that supply synthetic excess to α-
carbonyl-α-hydroxy arylpropionic acids. In practice, commonly reported procedures require a 
multistep reaction sequence. Hence, build-up of this substance class remains a challenge within the 
synthetic community. 
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Hegedus and co-workers followed a chiral-pool approach for the generation of optically active 
quaternary carbon centers.
[111]
 Photoaddition of stoichiometric chromium-alkoxycarbene complexes to 
optically active valine-derived thiazolines generated penam intermediate 4.A. Alcoholysis of the β-
lactam followed by solvolysis of the thiazolidine ring produced highly functionalized optically active 
quaternary centers holding an alkane or arene, alkoxy, aldehyde and ester functionality. However, this 
approach demanded a tedious synthesis of the chiral thiazoline precursor that was only reliably 
produced on large scale. 
 
Scheme 4.6. Synthesis of optically active carbon centers from photoaddition of chromium-
alkoxycarbene complexes and chiral thiazolines. 
Another approach for the preparation of arylmethoxyacetic acids by the group of Massanet involves 
a sequence of asymmetric dihydroxylation and further oxidation of the resulting glycol with 
TEMPO/NaClO/NaClO2, concerted around a tedious protection/deprotection sequence (Scheme 
4.7).
[112]
 
 
Scheme 4.7. Sequential enantioselective synthesis of arylmethoxyacetic acid derivatives from α-styrenes. 
An interesting organocatalytic approach was reported by Fernandez, Lassetta and co-workers. 
Therein, they investigated an asymmetric formal carbonyl-ene reaction of formaldehyde tert-butyl 
hydrazone with α-keto esters by dual activation by bis-urea catalysts.[113] The corresponding tertiary 
carbinols were obtained in excellent yields and high to excellent regioselectivities (Scheme 4.8). 
 
Scheme 4.8. Asymmetric formal carbonyl-ene reactions of formaldehyde tert-butyl hydrazone with α-
keto esters: dual activation by bis-urea catalysts. 
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4.3.3 Rhodium(II) catalysis: Ylide formation and C−X/C-C bond forming 
reactions 
The carbenoid intermediate formed in the course of transition metal catalyzed decomposition of 
diazo compounds are highly electrophilic in nature and readily react with various heteroatom 
nucleophiles.
[114]
 The corresponding ylides are eligible to undergo a wide variety of transformations, 
ranging from simple proton transfer to more complex [2,3]-sigmatropic rearrangement, [1,2]-Stevens-
rearrangement and 1,3-cycloaddition reactions.
[58,79,114c]
 
Since their discovery in the 1970s, dirhodium carboxylates have been applied as highly efficient 
catalysts in the carbenoid O–H and N–H insertion reactions.[115] The most notable industrial 
application of this reaction is the Rh2(OAc)4-catalyzed intramolecular insertion into a β–lactam N–H 
bond, a key step in MERCK’s thienamycin synthesis (Scheme 4.9).[116] The cyclic ketoester 4.4 was 
formed in quantitative yield.  
 
Scheme 4.9. Rhodium-catalyzed N–H insertion step in MERCK’s thienamycin synthesis. 
However, the excellent level of stereoinduction of chiral dirhodium catalyst that has been achieved 
in asymmetric cyclopropanation and C–H insertion reactions could not be translated to asymmetric O–
H and N–H insertion reactions.[117] The reaction of phenyldiazoacetates with alcohols was catalyzed by 
various chiral dirhodium catalysts in excellent yield, however exclusively as racemic mixtures.
[118]
 
Better results in terms of stereoselectivity have been achieved by Fu and co-workers who applied a 
copper/planar-chiral ligand (-)-bpy* catalyst system that accomplished N–H insertion of carbamate 
with a wide range of aryldiazoacetates in good yields and enantioselectivities (Scheme 4.10).
[17b]
 This 
logic could further be extended to O-nucleophiles, supplying efficient excess to chiral α-amino and α-
hydroxy acids, respectively.
[119]
 
 
Scheme 4.10. Asymmetric copper-catalyzed N–H insertion of aryldiazoacetates and tert-butyl 
carbamate. 
The orthogonal selectivity of rhodium versus copper carbenoids was later addressed by Yu and co-
workers by application of density functional theory (DFT).
[120]
 In both cases a water-catalyzed [1,2]-
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proton shift process was found to be much more energetically favored over a direct [1,2]-proton shift. 
However, while the copper-associated ylide B’ is the reactive species for the [1,2]-proton shift in the 
copper-catalyzed O–H insertion, the Rhodium(II)-catalyzed O–H insertion operates via free ylide A’’ 
(Scheme 4.11). 
 
Scheme 4.11. Rhodium(II) and Cu(I) catalyzed O–H insertion. 
Mechanistically, the presented rhodium(II)-catalyzed alkoxylation-acetalization of donor-acceptor-
substituted diazo compounds by trimethyl orthoformate features an ylide formation and a subsequent 
rearrangement resulting in concomitant C–O and C–C bond formation. This type of reactivity has 
precedence in rhodium(II) catalysis and has been exploited to create a number of interesting 
transformations and molecular frameworks.
[114c,121]
 
A tandem ylide formation/[2,3]-sigmatropic rearrangement between methyl phenyldiazoacetates 
and methyl styryldiazoacetates was discovered and studied by Huw Davies and co-workers (Scheme 
4.12). The two-step ylide formation and rearrangement competes favorably with the conventional O–H 
insertion under the premise that highly substituted allyl alcohols are used. Tertiary α–
hydroxycarboxylate derivatives were synthesized in 53-70% isolated yield and >98% ee with 
dirhodium tetraprolinate Rh2(S-DOSP)4.
[122]
 
 
Scheme 4.12. Tandem oxonium ylide formation/[2,3]-sigmatropic rearrangement between 
donor/acceptor carbenoids and allylic alcohols. 
The same group succeeded in synthesizing tertiary α–hydroxycarboxylate containing vicinal stereo 
centers.
[123]
 They found that the stereochemistry of the tertiary alcohol is governed by the 
configuration of the catalyst, whereas the adjacent stereocentre is controlled by the chirality of the 
allylic alcohol (Scheme 4.13). 
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Scheme 4.13. Stereoselective C−C Bond formation by rhodium-catalyzed tandem ylide formation/[2,3]-
sigmatropic rearrangement between donor/acceptor carbenoids and chiral allylic alcohols. 
The same catalytic system was used for the stereoselective synthesis of allene derivatives. These 
substances arose when propagylic alcohols were used in conjunction with push-pull carbenes (Scheme 
4.14).
[124]
 A considerably broad substrate scope could be created by this strategy. Furthermore, chiral 
resolution of racemic propagylic alcohols could be achieved, leading to an enantioenrichment of the 
unreactive enantiomer of 65-95%. Computational studies reveiled that a highly organized transition 
state structure contributes to the excellent enantiodiscrimination. 
 
Scheme 4.14. Tandem oxonium ylide formation/[2,3]-sigmatropic rearrangement between 
donor/acceptor carbenoids and propargylic alcohols. 
Donor-acceptor substituted rhodium-carbenoids are electrophilic at the carbon atom. However, in 
the case of vinyl derivatives two mesomeric structures can be postulated possessing divergent reactive 
sites. In the preceding section reactivity was exclusively observed on the α-carbon, however, the 
reactivity can be altered towards a favorably vinylogous reactivity (Figure 4.2).
[125]
 
 
Figure 4.2. Electrophilic sites in aryl- and vinyl push-pull carbenes. 
In many cases the vinylogous reactivity of rhodium carbenoids was only observed when the vinylic 
position of the carbenoid is unsubstituted.
[126]
 Other factors to favor vinylogous reactivity were 
electron-deficient dirhodium catalysts, polar solvents, and bulky esters on the carbenoid. Recently, the 
group of Davies
[127]
 and others
[128]
 have studied the vinylogous reactivity in a variety of 
transformations. It was found that chiral bulky dirhodium catalysts could enhance vinylogous 
reactivity, especially in combination with sterically demanding nucleophiles.
[129]
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One example for the vinylogous functionalization of diazo compounds, published by Davies and co-
workers, is the highly diastereoselective methodology for the rapid access to functionalized 2-
alkynoates in a single step using cyclic silyl enol ethers and siloxy vinylcarbenoids under rhodium(II) 
catalysis (Scheme 4.15).
[130]
 It has been clearly shown that bulky tert-butyl esters in conjunction with 
sterically demanding silyl protecting groups on the diazo compound was advantageous for a high 
yielding functionalization in γ-position of the vinyl ester. An exploratory study concerning the 
enantioselectivity of the reaction was conducted. However, only moderate levels of enantiomeric 
excess of up to 70% ee could be achieved. 
 
Scheme 4.15. Alkynoate synthesis through the vinylogous reactivity of rhodium(II) carbenoids 
As an extension to this protocol, the same group later published an asymmetric vinylogous addition 
of acyclic silyl enol ethers to siloxyvinyldiazoacetate (Scheme 4.16).
[127d]
 The reaction proceeds 
through a diastereoselective 1,4-siloxy group migration event and the products were obtained in up to 
97% ee. The reaction pathway proved to be dependent on the steric congestion of the silyl enol ether. 
In this instance, bulky silyl enol ether provoked an enantioselective formal [3+2] cycloaddition. 
 
Scheme 4.16. Asymmetric vinylogous addition of acyclic silyl enol ethers to siloxyvinyldiazo acetate. 
There are manifold examples of formal [3+3] cycloaddition reactions employing vinyldiazo aceates 
and 1,3-dipols.This reaction pattern has been exploited for the synthesis of a number of heterocycles. 
These reactions feature concomitant C−C/C−heteroatom bond formations which is conterminous with 
the presented reaction. 
In this context, Doyle and co-workers have developed a direct formal [3+3] cycloaddition that 
provides an effective access to bicyclic and tricyclic 1,2,3,6-tetrahydropyridazine derivatives.
[128d]
 The 
reaction sequence is triggered by rhodium(II)-catalyzed dinitrogen extrusion from enol diazoacetates 
followed by vinylogous addition with N-acyliminopyridinium ylides. Intramolecular asymmetric 
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addition of the 1,3-dipol to the zwitterionic vinyl ether complex II forms the [3+3] cycloaddition 
product (Scheme 4.17). 
 
Scheme 4.17. Enantioselective dearomatizing formal [3+3] cycloaddition reactions of N-
acyliminopyridinium ylides with electrophilic enol carbene intermediates. 
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4.4 Results and discussion 
4.4.1 Optimization of reaction conditions 
Starting from the encouraging result of the initial experiment between trimethyl orthoformate (4.2) 
and 4-bromophenyl diazoacetate (4.1a) in the presence of Rh2(esp)2, the influence of crucial reaction 
parameters was targeted. Other achiral catalyst gave inferior results (Table 4.1, entries 1-6). However, 
further optimization of the reaction conditions led to improved isolated yields of up to 77% when 
Rh2(S-pttl)4 was used as catalyst in chloroform (entry 12). Optimal results were achieved by dropwise 
addition of a 0.2 molar solution of 4.1 in dichloromethane to a stirring solution of 4.2 in 
dichloromethane in the presence of Rh2(S-pttl)4 (1.0 mol%) at ambient temperature. However, to this 
end, all products were obtained as racemic mixture. This observation suggests an extrusion of the 
chiral catalyst to take place prior to the formation of the desired coupling product. 
Table 4.1. Optimization of reaction conditions for the rhodium(II)-catalyzed tandem 
alkoxylation/acetalization of 4.1a with trimethyl orthoformate (4.2).
a
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Figure 4.3. Crystal structure of compound 4.3a 
The elucidation of chemical structure of the reaction product was not ambiguous. Gratifyingly, 
crystals suitable of x-ray analysis could be obtained from the screening product. To our surprise, one 
of the methoxy groups of the trimethyl orthoformate (4.2) was bound to the former carbenoid carbene 
in 2-position of the methyl 2-(4-bromophenyl)-2-diazoacetate (4.1a). In addition, a new C−C bond 
was formed between C-2 and central carbon atom of 4.1a. In summary, the coupling product possesses 
a highly functionalized quaternary center holding an arene, alkoxy, protected aldehyde and ester 
functionality. 
4.4.2 Scope and limitations 
Having a practical protocol in hand for the rhodium-catalyzed alkoxy-acetalization of methyl 2-(4-
bromophenyl)-2-diazoacetate (4.1a), we studied the scope with respect to phenyl-2-diazoacetate 4.1 
derivatives under the evaluated reaction conditions. A variety of methyl and ethyl phenyl-2-
diazoacetate afforded the corresponding products in high yield. Electron-withdrawing substituents 
benefit the desired reaction pathway (entries 1-7). Thus, valuable product bearing bromo- (entry 1 and 
2), chloro- (entry 3 and 4) and flouro-substituents (entry 5 and 6) as well as ester and alkoxy-
functionalities (entry 7) were well tolerated. When ethyl aryldiazo acetates, 4.1b and 4.1c, slightly 
diminished yields of the desired coupling products, 4.3b and 4.3c, were obtained. In these cases, 
intramolecular C‒H bond insertion into the ester side-chain yielding a 4-membered lactone, is 
competitive with the ylide formation pathway. The modest yield of methyl 2,3,3-trimethoxy-2-
phenylpropanoate (4.3h) from electron-neutral methyl 2-phenyl-2-diazoacetate (4.1h) of 40% in 
dichloromethane at ambient temperature could be increased to reasonable 65% isolated yield when the 
reaction was conducted in chlorobenzene at 60 °C (Table 4.2, entry 8). Electron-donating substituents 
are less suitable and resulted in complex mixtures of products. However, versatile alkoxy groups were 
well tolerated in the meta-position in which the negative inductive effect prevails the otherwise 
dominant positive mesomeric effect (Table 4.2, entry 9). 
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Table 4.2. Scope of the reaction of rhodium(II)-carbenoids with trimethyl orthoformate (4.2).
a
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As previously mentioned, donor-acceptor-substituted carbenoids derived from vinyldiazo acetates 
4.5 harbor two potential electrophilic reaction sites. Thus, formation of two different products 
resulting from (A) α-functionalization and (B) vinylogous addition are conceivable (Figure 4.4). 
 
Figure 4.4. α-Functionalization vs. vinylogous addition. 
We were delighted to find that vinyldiazo acetate 4.5 depicted equally potent coupling partners in 
the alkoxylation/acetalization reaction sequence. The coupling product of dimethyl glutaconoate 4.5a 
was obtained in 53%. According to the 
1
H NMR spectrum the reaction was judged to proceed via the 
α-functionalization mechanism (A) evident from the trans-coupling constants of 15.1 Hz. 
 
Scheme 4.18. Rhodium-catalyzed alkoxylation-acetalization of dimethylglutaconoate. 
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4.4.3 Derivatization of methyl 2-phenyl-2,3,3-trimethoxypropanoates 
The crux of the developed methodology lies in the diverse opportunities for the derivatization of the 
C−C/C−O coupling products. The different functional groups of the molecule possess orthogonal 
reactivity and can thus be transformed independently from each other (Figure 4.5). The ester group 
can be selectively reduced, saponificated or manipulated upon nucleophilic attack. A halide, or related 
functional group, attached to the phenyl moiety can be subjected to a vast number of cross-coupling 
reactions to trigger C−C bond forming reactions or functionalization with heteroatoms. The probably 
most valuable reactive site of the molecule is the protected formyl group. The free aldehyde serves as 
excellent chemical anchor for a myriad of transformations. 
 
Figure 4.5. Functionalization strategies. 
The screening substrate methyl 2-(4-bromophenyl)-2-diazoacetate (4.1a) was used as it is easily 
accessible in high yields. The corresponding coupling product methyl 2-(4-bromophenyl)-2,3,3-
trimethoxypropanoate (4.3a) is equally straightforward to make and its purification is facile. Thus, 
4.3a was produced in gram-scale from a 5.0 mmol reaction. Analytically pure product was obtained 
after filtration and recrystallization from Et2O/n-heptane in 76% isolated yield (Scheme 4.19). 
 
Scheme 4.19. Gramm-scale synthesis of methyl 2-(4-bromophenyl)-2,3,3-trimethoxypropanoate (4.3a). 
A convenient and rapid deprotection of the dimetylacetal was achieved under neutral reaction 
conditions in the presence of iodine (Scheme 4.20).
[75e]
 The corresponding aldehyde 4.7a was obtained 
in excellent yield. 
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Scheme 4.20. Dimethylacetal cleavage by molecular iodine in acetone. 
The general reaction mechanism of the molecular iodine catalyzed deprotection of dialkylacetal 
cleavage is presumed to go through a substrate exchange mechanism, rather than a hydrolysis 
mechanism as encountered in acid-catalyzed cleavage. The deprotection initially involves a 
polarization of the carbonyl group in acetone by molecular iodine. The full mechanism is depicted in 
Scheme 4.21. 
 
Scheme 4.21. Exemplified mechanism for the iodine-mediated deprotection of acetals. 
The free aldehyde 4.7 is an excellent starting point for versatile further functionalization. Just to 
mention a few opportunities arising at this juncture, the aldehyde is amenable to participate in C−N 
bond forming reactions such as reductive amination supplying access to phenethylamines,
[131]
 C−C 
bond generating allylation and crotylation,
[132]
 or combined C−C/C−N bond formation via an 
aminoallylation sequence for the synthesis of homoallylic primary amines (Scheme 4.22).
[4f,133]
 
 
Scheme 4.22. Potential for further functionalization of the aldehyde 4.7. 
The ester functionality of 4.3a could be efficiently reduced with LiAlH4 in THF at 0 °C. The 
reaction was complete within 30 min and the corresponding alcohol (4.8a) was isolated in 90% yield 
(Scheme 4.23, (a)). Saponification of the methyl ester at elevated temperature resulted the formation 
of carboxylic acid 4.9a in quantitative yield after aqueous work-up (Scheme 4.23, (b)). 
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Scheme 4.23. (a) Reduction of methyl 2-(4-bromophenyl)-2,3,3-trimethoxypropanoate (4.3a) with 
LiAlH4; (b) saponification with LiOH in THF/H2O. 
Derivatization of the phenyl moiety of 4.3a can be conveniently achieved under Suzuki-Miyaura 
cross-coupling conditions. When bromo arene 4.3a was reacted with benzo[d][1,3]dioxol-5-ylboronic 
acid (4.10) in the presence of tetrakistriphenylphosphine palladium(II) the corresponding cross-
coupling product methyl 2-(4-(benzo[d][1,3]dioxol-5-yl)phenyl)-2,3,3-trimethoxypropanoate (4.11) 
was isolated in 90% yield (Scheme 4.24). Recrystallization of 4.11 afforded crystals in a quality 
suitable for x-ray crystallography. 
 
Scheme 4.24. Suzuki-Miyaura cross-coupling of 4.3a and 4.10 and crystal structure of the reaction 
product. 
4.4.4 Mechanistic considerations 
As mentioned in the Project outline at the beginning of this chapter, we initially attempted to pursue 
a similar C−H insertion pathway (Figure 4.6, (1)) for the introduction of trimethyl orthoformate as an 
alternative C1-building block similar to the reaction described with 1,3,5-trioxane (Chapter 2). 
Though, trimethyl orthoformate could indeed be implemented into phenyl and vinyl actetate scaffolds 
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via C−C bond formation, the pathway was divergent from the postulated C−H bond insertion 
mechanism (Figure 4.6, (2)). 
 
Figure 4.6. Schematic overview for the activation mode of 1,3,5-trioxane versus trimethyl orthoformate. 
A comparison of the physicochemical of trimethyl orthoformate 4.3 and 1,3,5-trioxane (2.2) aids to 
rationalize the opposed reactivity. Berthelot and co-workers compared the hydrogen bond basicity 
pKHB of various cyclic ethers using 4-fluorophenol as a reference hydrogen-bond donor.
[46a]
 
Equilibrium constants, Kf, for the formation of 1:1 hydrogen bonded complexes have been derived 
from FTIR spectroscopic data. According to their results, 1,3,5-trioxane possesses a medium hydrogen 
bond basicity of 0.5 (0.02)
[134]
 (Figure 4.7). The oxygen lone-pairs in trimethyl orthoformate impart a 
significantly higher hydrogen bond basicity of 1.02 (0.55). This feature significantly contributes to the 
affinity for ylide formation. 
 
Figure 4.7. C−H bond length and O-basicity in 1,3,5-trioxane and trimethyl orthoformate. a Hydrogen 
bond basicity, statistically corrected value is shown in parenthesis. 
However, the ylide formation represents only one step of a sequence that accounts to the product 
formation and different reaction pathways are conceivable for the alkoxylation/acetalization of donor-
acceptor substituted carbenes triggered by rhodium(II) complexes (Scheme 4.25.). Pending the initial 
formation of the reactive rhodium(II) carbenoid species via rhodium(II) carboxylate catalyzed 
decomposition of the diazo compound, the electrophilic attack of the carbenoid on the oxygen electron 
lone pairs forms the oxonium species 4.12 which then undergoes a formal 1,2-shift to form product 
4.3. A direct 1,2-Stevens rearrangement from a chiral catalyst-bound intermediate (A), ought lead to 
product with some enantioselection. In addition, breakdown of the ylide and subsequent stereospecific 
attack of the metal bound tight ion pair (pathway B) would also lead to stereochemical induction. As 
no enantiomeric excess is observed using the chiral Rh catalyst, pathways A and B can be disregarded. 
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Pathways C and D involve reversible formation of a planar enolate, thereby losing all stereochemical 
information.
[120]
 C‒C bond formation can either occur through a [1,2]-Stevens rearrangement[135] or a 
stepwise process involving formation of an ion pair.
[136]
 We initially favoured separation of the 
intermediate, as three component couplings, involving interception of the ylide by external 
electrophiles, are well established and thermodynamically feasible considering the high stability of 
dialkylcarbonium ions.
[137]
 
 
Scheme 4.25. Migration of the oxonium ylide and abstraction of the rhodium catalyst. 
We reasoned that a simple cross-over experiment, employing a 1:1 mixture of undeuterated ([
2
H]0-
2) and fully deuterated ([
2
H]10-2) trimethyl ortho ester, could elucidate this difference as observation 
of mixed products, such as D3-methoxy/dimethylacetal ([
2
H]3-3a) and methoxy/D7-dimethylacetal 
([
2
H]7-3a), would indicate a separation of the catalytic intermediate into an ion pair. We tested the 
reaction in four different solvents of varying polarity, which would affect the tightness of the ion pair 
and thus the degree of cross-over, and found (ESI-MS) no evidence of any mixed products. Therefore, 
this strongly indicates that the concerted pathway C is operational. 
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Scheme 4.26 depicts a plausible catalytic cycle for the rhodium(II)-catalyzed 
methoxylation/acetalization of donor/acceptor substituted diazo compounds. At the outset of the 
catalytic cycle the vacant axial site of the rhodium(II) catalyst coordinates to the zwitterionic form of 
diazo compound 4.1 (A). Nitrogen extrusion (B) results in the formation of carbenoid species I and II 
(C) which exist in equilibrium. In step D, the Lewis-basic oxygen atom attacks the electron-deficient 
carbenium of complex II and forms oxonium species 4.12. Eventually, liberation of the rhodium 
catalyst closes the catalytic cycle (E1). The final C‒C bond formation (E2) proceeds in an off cycle 
process via a zwitterionic enolate species that can rearrange to racemic product 4.3 through a an  
intramolecular 1,2-shift. 
 
Scheme 4.26. Proposed catalytic cycle. 
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4.5 Conclusion and outlook 
The developed methodology allows for the rapid creation of highly value-added molecular 
architectures from inexpensive chemical commodities. Academically the intermolecular C−O/C−C 
bond formation of trimethyl formate reveals a novel reactivity of this vastly used compound. In the net 
reaction almost full atom-economy is achieved. The only expelled waste product is nitrogen gas. From 
an industrial point of view, the created scaffolds offer new opportunities for revised syntheses of 
important pharmaceuticals and their derivatives. Tramadol, a sever pain-relieving agent often used in 
cancer therapy and anti-fungal fluconazole that was listed among the essential drugs by the world 
health organization (WHO) represent only two examples for potential applications (Scheme 4.27). As 
a future endeavor, it is desirable to develop a chiral version of the presented transformation. 
 
Scheme 4.27. Proposed retrosynthetic analysis for the synthesis of O-methyl tramadol from 4.3i and O-
methyl fluconazole from 4.3f. 
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5 Summary 
In times of growing environmental awareness and shortage of resources, sustainable synthesis of 
chemical commodities constitutes a primary goal. In the past decades, transition metal catalysis 
undoubtedly largely contributed to streamline the synthesis of organic molecules, especially in the 
field of direct C−C coupling chemistry, thus often supplying a more sustainable approach than 
traditional coupling reactions 
This thesis summarizes the development of new transformations for the transition metal-catalyzed 
introduction of carbon monoxide and alternative C1-building blocks into molecular scaffolds via the 
direct functionalization of C−H and C−O bonds. The developed methodologies provide with novel 
opportunities for the implementation of functional groups and expand the molecular space of organic 
buildings block synthesis. The presented strategies are characterized by their (i) high over-all atom-
economy, (ii) minimal waste generation and (iii) capability to supply rapid access value-added 
molecular architectures. 
The first chapter described the development of carbonylative arylations of (hetero)arenes through 
direct sp
2
-C−H bond activation, initiated by an inexpensive ruthenium catalyst precursor. This facile 
three component synthesis of complex aryl-heteroaryl ketones proceeded via successive twofold 
C(sp
2
)−C(sp2) bond formation in an aqueous reaction medium and describes a conceptually new path 
for the construction of benzophenone derivatives. Starting with simple phenylpyridine derivatives, this 
chemistry was later extended to the preparation of aryl-heteroaryl ketones including examples with 
cleavable directing groups. The synthetic applicability of the developed methodology has been 
demonstrated in the streamlined synthesis of an unprecedented analog of the top-selling selective 
estrogen receptor modulator Raloxifene (Evista®) and the gram-scale synthesis of a key intermediate 
of marinopyrroles and pyoluteorin. 
In the next part, a conceptually different approach for the implementation of a formal C1-building 
block in an aldehyde oxidation state by means of sp
3
-C−H bond activation has been investigated. The 
rhodium(II)-catalyzed insertion of donor-acceptor substituted carbenoids into one of the six 
chemically equivalent C−H bonds of 1,3,5-trioxane provided access to a novel substance class of 
chiral alkyl 2-phenyl-2-(1,3,5-trioxan-2-yl)acetates. Because of its structural relation to naturally 
occurring arylpropionates such as atropine and artificial methylphenidates, this substance class holds 
great promise as valuable building blocks for medicinal chemistry. 
In a subsequent work, the rhodium(II)-catalyzed decomposition of methyl-sulfonyl-1,4-triazoles in 
the presence of 1,3,5-trioxane was studied. In this reaction, ylide formation of the oxygen-heterocycle 
with the rhodium-carbenoid species outcompetes the C−H bond functionalization pathway. Successful 
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optimization of the reaction condition allowed for the one-pot preparation of unprecedented nine-
membered 1,3,5,7-trioxazonine rings.  
Finally, a conceptually new approach for the concomitant alkoxylation/formylation of diazo 
compounds, mediated by rhodium(II) catalysts has been developed. There are basically no 
straightforward procedures known that supply direct synthetic access to α-carbonyl-α-methoxy 
arylpropionic acids. Hence, the developed methodology for the one step synthesis of quaternary 
carbon centers bearing an aryl or alkenyl, alkoxy, masked aldehyde and ester functionality from 
inexpensive chemical commodities, constitutes a conceptual advancement compared to existing 
procedures. 
Noteworthy, besides the relatively high costs of rhodium, the reactions described in Chapter 2, 3 
and 4 proceed with almost full atom-economy, generating nitrogen as the sole by-product. 
The presented results are expected to stimulate further research interest for the development of 
powerful methodologies for the straightforward functionalization of organic molecules.
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6 Experimental section 
6.1 General remarks 
All reactions involving moisture- or air-sensitive reagents or products were performed under an 
atmosphere of dry argon using standard Schlenk techniques and predried glassware. Syringes for 
handling of dry solvents or liquid reagents were flushed with dry argon prior to use. Analytical data of 
substances that are known in literature (marked by corresponding references) were compared with 
those described in the literature. 
Solvents 
All solvents for reactions containing moisture-sensitive reagents were dried, distilled and stored 
under inert atmosphere (argon or nitrogen) according to following standard procedures. 
N,N-Dimethylacetamide was dried over KH and distilled under ambient pressure. 
N,N-Dimethylformamide was dried over CaH2 for 8 h, degassed and distilled under reduced pressure.  
Methanol was dried over Mg and refluxed prior to distillation. 
N-Methyl-2-pyrrolidone was stirred at 150 °C for 4 h and subsequently distilled under reduced 
pressure. 
Tetrahydrofuran using a SPS solvent purification system by MBRAUN. 
Toluene was pre-dried over KH and distilled over sodium/benzophenone. 
Water was degassed for 2 h and ultrasonicated. 
1,2-Dichloroethane was pre-dried over molecular sieves 4Å, distilled and stored over molecular 
sieves. 
Commercially available dry solvents were purchased from SIGMA-ALDRICH and ACROS ORGANICS. 
Chromatography  
Analytical thin layer chromatography (TLC) was performed on 0.25 mm silica gel 60F plates 
(MACHEREY-NAGEL) with 254 nm fluorescent indicator from MERCK. Plates were visualized under 
ultraviolet light (254 nm) and developed by treatment with the KMnO4 solution or  Chromatographic 
purification of products was accomplished by flash column chromatography on MERCK silica gel, 
grade 60 (0.063-0.200 mm, 70–230 mesh ASTM).  
Vacuum 
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Following pressures were measured on the used vaccuum pump and are not corrected: membrane 
pump vacuum (MPV): 3.1 mbar, oil pump vacuum (OPV): 0.05 mbar. 
Analytical Data  
Analytical data of substances that are known in literature (marked by corresponding references) 
were compared with those described in the literature.  
Infrared Spectroscopy  
Infrared spectra were recorded using a BRUKER ALPHA-P spectrometer. Liquid probes were 
measured as film, solid probes were measured neat. Absorption is given in wave numbers (cm-1). 
Spectra were recorded in the range of 4000–400 cm-1. Following abbreviations were used for 
characterization: s (strong), m (medium), w (weak). 
Nuclear Magnetic Resonance Spectroscopy  
Nuclear magnetic resonance (NMR) spectra were recorded at 300 or 600 MHz (1H-NMR) and 75 or 
125 MHz (13C-NMR, APT (Attached Proton Test) on BRUCKER AM 250, VARIAN Unity-300 and 
Inova 500 instruments. Chemical shifts are reported as δ-values in ppm relative to the residual proton 
peak of the deuterated solvent or its carbon atom, respectively.  
1
H-NMR  
13
C-NMR 
d1-Chloroform   7.26 ppm,  77.0 ppm  
d6-DMSO    2.49 ppm 7 7.0 ppm  
For characterization of the observed signal multiplicities the following abbreviations were applied: s 
(singlet), d (doublet), t (triplet), q (quartet), m (multiplet). Coupling constants J are reported in Hertz 
(Hz). 
Mass spectroscopy 
Mass spectra were measured on FINNIGAN MAT 95 (200 eV, EI-MS) or LCQ (70 eV, ESI-MS). 
The ratio of mass to charge are indicated, intensities relative to the base peak (I = 100) are written in 
parentheses. High resolution mass spectras (HRMS) were recorded on BRUKER APEX IV (7 T, 
Transform Ion Cyclotron Resonance (FTICR) mass spectrometer). 
Melting Points 
Melting points were measured using a BÜCHI melting point apparatus. Reported values are 
uncorrected. 
Crystallographic data 
Crystallographic data were collected on a BRUKER KAPPA APEX II DUO diffractometer. The 
structure was solved by direct methods and refined by full-matrix least-squares procedures on F
2
 with 
the SHELXTL software package (Sheldrick, G. M. Acta Crystallogr. 2008, A64, 112.). XP (BRUKER 
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AXS) was used for graphical representation. Displacement ellipsoids are drawn at the 30% probability 
level. 
High-pressure reactions 
High-pressure reactions were carried out in WEATHON screw capped glass vials (5 mL) with 
silicone/PTFE septum, equipped with a magnetic stirring bar and a needle. The reaction mixtures were 
placed in a PARR 300 mL stainless steel autoclave and pressurized with carbon monoxide (LINDE). 
6.2 General procedures 
General procedure A: Ruthenium-catalyzed carbonylative direct arylation 
A glass vial (4 mL) was charged with [RuCl2(cod)] polymer (5.0 mmol%), NaHCO3 (2.0 equiv.) and 
KOAc (20 mol%) and a stirring bar. The vial was placed into an alloy plate, equipped with a septum 
and an inlet needle, evacuated and backfilled with argon before 2-(aryl)pyridine (2.0 equiv.), 
iodoarene 1.2 (1.0 equiv.) and degassed H2O (1.0 mL) were added. The alloy plate with six vials was 
then placed in an autoclave (300 mL, Parr Instruments 4560 series). At room temperature, the 
autoclave was flushed with CO (3 x 5 bar) and finally pressurized with CO (30 bar). The autoclave 
was heated to 120 °C for 16 , cooled to room temperature, and the remaining CO was released slowly. 
The apparatus was flushed with nitrogen with vigorous stirring. The reaction mixture was further 
diluted with EtOAc (5 mL) and H2O (5 mL). The phases were separated and the aqueous layer was 
extracted with EtOAc (3 x 3 mL). The combined organic layer were washed with brine (10 mL) and 
dried over Na2SO4. The solvent was removed under reduced pressure and the crude product was 
purified by flash-chromatography (n-heptane/EtOAc). 
General procedure B: Ruthenium-catalyzed carbonylative direct arylation of 
heteroarenes 
A glass vial (4 mL) was charged with [RuCl2(cod)] polymer (5.0 mmol%), NaHCO3 (2.0 equiv.) and 
KOAc (20 mol%) and a stirring bar. The vial was placed into an alloy plate, equipped with a septum 
and an inlet needle, evacuated and backfilled with argon before 2-(heteroaryl)pyridine (1.0 equiv.), 
iodoarene 1.2 (2.0 equiv.) and degassed H2O (1.0 mL) were added. The following procedures is 
analogues to general procedure A. 
General Procedure C: Synthesis of 2-(aryl)-2-diazoacetates 
1,8-Diazabicyclo[5.4.0]undec-7-ene (DBU) (1.5 equiv.) was added dropwise to a stirring solution 
methyl phenyl acetate (1.0 equiv.) and TsN3 (1.2 equiv.) in MeCN (0.3 M) at 0°C under inert 
atmosphere. The reaction was allowed to warm to ambient temperature and stirred over night. All 
volatiles were removed under reduced pressure and the crude product was purified by flash 
chromatography (n-pentane:EtOAc). All diazo compounds were stored at -18°C. 
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General Procedure D: Rhodium-catalyzed synthesis of alkyl 2-aryl-2-(1,3,5-trioxan-2-
yl)acetates 
A solution of methyl 2-aryl-2-diazoacetate 2.1 (1.0 equiv.) in 1,2-dichloroethane (5.0 mL) was 
added dropwise to a styrring solution of Rh2(S-DOSP)4 (1.0 mol%) and 1,3,5-trioxane (10 equiv.) in 
1,2-dichloroethane (5.0 mL) at 0°C within 90 min. The reaction mixture was stirred for additional 
30 min. Volatiles were removed under reduced pressure. Mesitylene (20 L) was added as internal 
standard. Purification by flash chromatography (n-pentane:EtOAc) yielded the desired product 2.3. 
A racemic sample was prepared using Rh2(esp)2 (1.0 mol%) at 40°C under otherwise identical 
reaction conditions. 
General procedure E: Rhodium-catalyzed synthesis of 6,7-dihydro-1,3,5,7-
trioxazonines 
To a solution of triazole 3.1 (1.0 equiv.) in CHCl3 (0.5 M) was added 1,3,5-trioxane 3.2 (5.0 equiv.). 
The mixture was stirred for 2 min at ambient temperature before Rh2(Opiv)4 (0.5 mol%) was added. 
The reaction mixture was stirred at 40 °C for 16 hours. The crude mixture was concentrated under 
reduced and purified by column chromatography on silica gel (n-pentane/EtOAc), concentrated and 
dried under reduced pressure. 
General Procedure F: Rhodium-catalyzed synthesis of methyl 2-(aryl)-2,3,3-
trimethoxypropanoates 
Over the course of one hour, 2 mL of a 0.2 M solution of alkyl 2-(aryl)-2-diazoacetate 4.1 (1.0 
equiv.) and trimethyl orthoformate 4.2 (2.5 equiv.) in dichloromethane was added dropwise to a 
stirring solution of Rh2(S-pttl)4 (1.0 mol%) and trimethyl orthoformate 4.2 (2.5 equiv.) in 
dichloromethane (0.3 mL) at room temperature. The crude mixture was concentrated and purified by 
flash chromatography (n-pentane/EtOAc = 20:1). The desired product 4.3 was concentrated and dried 
under reduced pressure.  
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6.2.1 Experimental part to Chapter 1 
This project has been done in collaboration with Dr. Anis Tlili. 
Synthesis of (2-phenyl(2-(pyridin-2’-yl)phenyl)methanone (1.3a) 
 
Following general procedure A, 1.3a was isolated as white solid (80 mg, 0.30 mmol, 62%). 
1
H NMR (300 MHz, Chloroform-d) δ = 8.36 (ddd, J = 4.9, 1.8, 1.0 Hz, 1H, CH), 7.79–7.74 (m, 1H, 
CH), 7.71–7.65 (m, 2H, CH), 7.64–7.46 (m, 5H, CH), 7.38 (ddt, J = 8.2, 6.7, 1.4 Hz, 1H, CH), 7.30–
7.22 (m, 2H, CH), 7.01 (ddd, J = 7.3, 4.9, 1.3 Hz, 1H, CH). 
13
C NMR (75 MHz, Chloroform-d) δ = 198.3 (CO), 156.8 (Cq), 149.1 (CH), 139.7 (Cq), 139.5 (Cq), 
137.9 (Cq), 136.3 (CH), 132.4 (CH), 130.2 (CH), 129.5 (CH), 129.1 (CH), 128.8 (CH), 128.5 (CH), 
128.1 (CH), 122.7 (CH), 122.0 (CH). 
HR-MS (EI) m/z calcd. for C18H14NO [M+H]
+
: 260.1069; found: 260.1074. 
Synthesis of (2-(pyridin-2’-yl)phenyl)(o-tolyl)methanone (1.3b) 
 
Following general procedure A, 1.3b was isolated as yellow oil (101 mg, 0.37 mmol, 74%). 
1
H NMR (300 MHz, Chloroform-d) δ = 8,43 (ddd, J = 4.9, 1.8, 0.9 Hz, 1H), 7.68–7.51 (m, 5H), 7.41 
(dt, J = 7.9, 1.1 Hz, 1H), 7.16 (d, J = 7.5 Hz, 2H), 7.11–7.06 (m, 1H), 7.01 (ddd, J = 7.5, 4.9, 1.2 Hz, 
1H), 6.97–6.90 (m, 1H), 2.58 (s, 3H). 
13
C NMR (75 MHz, Chloroform-d) δ = 199.2 (CO), 157.5 (Cq), 148.8 (CH), 140.7 (Cq), 140.2 (Cq), 
139.2 (Cq), 138.1 (Cq), 136.2 (CH), 131.2 (CH), 131.0 (CH), 130.5 (CH), 130.5 (CH), 129.8 (CH), 
129.1 (CH), 128.5 (CH), 124.8 (CH), 122.6 (CH), 121.8 (CH), 21.1 (CH3). 
HR-MS (EI) m/z calcd. for C19H16NO [M+H]
+
: 274.1226; found: 274.1226. 
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Synthesis of (2-(pyridin-2’-yl)phenyl)(m-tolyl)methanone (1.3c) 
 
Following general procedure A, 1.3c was isolated as yellow oil (71 mg, 0.26 mmol, 52%). 
1
H NMR (300 MHz, Chloroform-d) δ = 8.39 (ddd, J = 4.9, 1.8, 1.0 Hz, 1H), 7.79–7.73 (m, 1H), 7.63–
7.43 (m, 8H), 7.23–7.10 (m, 2H), 7.02 (ddd, J = 7.4, 4.9, 1.3 Hz, 1H), 2.27 (d, J = 0.9 Hz, 3H). 
13
C NMR (75 MHz, Chloroform-d) δ = 197.3 (CO), 155.9 (Cq), 147.9 (CH), 138.6 (Cq), 138.5 (Cq), 
136.7 (Cq), 136.7 (Cq), 135.3 (CH), 132.2 (CH), 129.1 (CH), 128.9 (CH), 128.0 (CH), 127.9 (CH), 
127.4 (CH), 126.9 (CH), 125.9 (CH), 121.8 (CH), 120.9 (CH), 20.2 (CH3). 
HR-MS (EI) m/z calcd. for C19H16NO [M+H]
+
: 274.1226; found: 274.1223. 
Synthesis of (2-(pyridin-2’-yl)phenyl)(p-tolyl)methanone (1.3d) 
 
Following general procedure A, 1.3d was isolated as yellow oil (73 mg, 0.27 mmol, 54%). 
1
H NMR (300 MHz, Chloroform-d) δ = 8.40 (ddd, J = 4.9, 1.7, 0.9 Hz, 1H, CH), 7.77 (dt, J = 7.6, 1.0 
Hz, 1H, CH), 7.63–7.54 (m, 4H, CH), 7.53–7.46 (m, 3H, CH), 7.10–7.01 (m, 3H, CH), 2.32 (s, 3H, 
CH3). 
13
C NMR (75 MHz, Chloroform-d) δ = 197.9 (CO), 156.9 (Cq), 149.1 (CH), 143.1 (Cq), 136.3 (CH), 
135.3 (Cq), 130.1 (Cq), 130.1 (CH), 129.8 (CH), 128.9 (CH), 128.8 (CH), 128.5 (CH), 122.9 (CH), 
122.0 (CH), 21.6 (CH3). 
HR-MS (EI) m/z calcd. for C19H16NO [M+H]
+
: 274.1226; found: 274.1225. 
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Synthesis of (3,5-dimethylphenyl)(2-(pyridin-2’-yl)phenyl)methanone (1.3e) 
 
Following general procedure A, 1.3e was isolated as yellow oil (79 mg, 0.27 mmol, 55%). 
1
H NMR (300 MHz, Chloroform-d) δ = 8.43 (ddd, J = 4.9, 1.8, 1.0 Hz, 1H, CH), 7.76 (dt, J = 7.6, 1.0 
Hz, 1H, CH), 7.72–7.49 (m, 5H, CH), 7.45 (dt, J = 7.9, 1.1 Hz, 1H, CH), 7.36–7.28 (m, 2H, CH), 
7.08–7.00 (m, 2H, CH), 2.23 (q, J = 0.7 Hz, 6H, CH3). 
13
C NMR (75 MHz, Chloroform-d) δ = 198.5 (CO), 157.1 (Cq), 149.0 , 139.8 (Cq), 139.7 (Cq), 137.7 
(Cq), 136.3 (CH), 134.3 (CH), 130.2 (CH), 129.1 (CH), 129.1 (CH), 128.4 (CH), 127.6 (CH), 123.0 
(CH), 122.0 (CH), 21.1(CH3). 
HRMS (EI, m/z) calcd. For C20H18NO [M+H]
+
: 288.1382; found: 288.1382. 
Synthesis of (2-naphthalen-1-yl(2-(pyridin-2-yl)phenyl)methanone (1.3f) 
 
Following general procedure A, 1.3f was isolated as white solid (86 mg, 0.28 mmol, 56%). 
1
H NMR (300 MHz, Chloroform-d) δ = 8.90 (dq, J = 8.7, 0.9 Hz, 1H, CH), 8.20–8.12 (m, 1H, CH), 
7.80–7.68 (m, 4H, CH), 7.66–7.60 (m, 2H, CH), 7.59–7.50 (m, 2H, CH), 7.43–7.32 (m, 3H, CH), 7.16 
(dd, J = 8.2, 7.2 Hz, 1H, CH), 6.77 (ddd, J = 6.8, 4.9, 1.9 Hz, 1H, CH). 
13
C NMR (75 MHz, Chloroform-d) δ = 199.6 (CO), 157.0 (Cq), 148.9 (CH), 140.3 (Cq), 136.3 (Cq), 
136.2 (CH), 133.6 (Cq), 132.4 (CH), 131.0 (CH), 130.7 (CH), 130.2 (CH), 129.7 (CH), 129.0 (CH), 
128.6 (CH), 128.1 (CH), 127.7 (CH), 126.5 (CH), 126.3 (CH), 123.8 (CH), 122.4 (CH), 121.5 (CH). 
HR-MS (EI) m/z calcd. for C22H15NO [M+H]
+
: 309.1148; found: 309.1139. 
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Synthesis of (4-ethylphenyl)(2-(pyridin-2’-yl)phenyl)methanone (1.3g) 
 
Following general procedure A, 1.3g was isolated as yellow oil (87 mg, 0.30 mmol, 61%). 
1
H NMR (300 MHz, Chloroform-d) δ = 8.40 (ddd, J = 4.8, 1.8, 1.0 Hz, 1H, CH), 7.77 (dt, J = 7.7, 1.0 
Hz, 1H), 7.66–7.45 (m, 7H, CH), 7.13–7.07 (m, 2H, CH), 7.03 (ddd, J = 7.4, 4.9, 1.3 Hz, 1H, CH), 
2.61 (q, J = 7.6 Hz, 2H, CH2), 1.18 (t, J = 7.6 Hz, 3H, CH3). 
13
C NMR (75 MHz, Chloroform-d) δ = 197.7 (CO), 157.0 (Cq), 149.3 (Cq), 149.1 (CH), 139.7 (Cq), 
139.7 (Cq), 136.3 (CH), 135.5 (Cq), 130.1 (CH), 129.9 (CH), 129.0 (CH), 128.4 (CH), 127.6 (CH), 
122.9 (CH), 121.9 (CH), 28.9 (CH2), 15.2 (CH3). 
HR-MS (EI) m/z calcd. for C20H17NO [M+H]
+
: 288.1382; found: 288.1381. 
Synthesis of (2-(3-methoxyphenyl)(2-(pyridin-2’-yl)phenyl)methanone (1.3i) 
 
Following general procedure A, 1.3i was isolated as yellow oil (59 mg, 0.20 mmol, 41%). 
1
H NMR (300 MHz, Chloroform-d) δ = 8.37 (ddd, J = 4.9, 1.8, 1.0 Hz, 1H, CH), 7.82–7.72 (m, 1H, 
CH), 7.63–7.47 (m, 5H, CH), 7.33 (ddd, J = 2.7, 1.4, 0.6 Hz, 1H, CH), 7.20–7.09 (m, 2H, CH), 7.02 
(ddd, J = 7.4, 4.9, 1.3 Hz, 1H, CH), 6.94 (ddd, J = 7.3, 2.7, 1.8 Hz, 1H, CH), 3.77 (s, 3H, CH3). 
13
C NMR (75 MHz, Chloroform-d) δ = 198.0 (CO), 159.4 (Cq), 156.8 (Cq), 149.1 (CH), 139.6 (Cq), 
139.5 (Cq), 139.3 (Cq), 136.4 (CH), 130.2 (CH), 129.1 (CH), 129.0 (CH), 128.8 (CH), 128.5 (CH), 
122.7 (CH), 122.6 (CH), 122.0 (CH), 119.2 (CH), 113.1 (CH), 55.4 (CH3). 
HR-MS (EI) m/z calcd. for C19H15NO2 [M+H]
+
: 289.1097; found: 289.1096. 
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Synthesis of (4-fluorophenyl)(2-(pyridin-2-yl)phenyl)methanone (1.3j) 
 
1 Following general procedure A, 1.3j was isolated as yellow oil (55 mg, 0.20 mmol, 40%). 
1
H NMR (300 MHz, Chloroform-d) δ = 8.35 (ddd, J = 4.9, 1.8, 1.0 Hz, 1H, CH), 7.76 (dt, J = 7.7, 1.0 
Hz, 1H, CH), 7.76–7.63 (m, 2H, CH), 7.68–7.52 (m, 2H, CH), 7.57–7.44 (m, 3H, CH), 7.03 (ddd, 
J = 7.4, 4.8, 1.2 Hz, 1H, CH), 7.00–6.84 (m, 2H, CH). 
13
C NMR (75 MHz, Chloroform-d) δ = 196.8 (CO), 165.1 (d, 1JC−F = 253.5 Hz, Cq), 156.6 (Cq), 149.1 
(CH), 139.4 (d, 
2
JC−F = 23.0 Hz, Cq), 136.4 (CH), 134.4 (d, 
4
JC−F = 3.0 Hz, Cq), 132.0 (d, 
3
JC−F = 9.2 
Hz, CH), 130.35 (CH), 129.01 (CH), 128.78 (CH), 128.64 (CH), 125.0 (Cq), 122.4 (d, JC-F = 41.7 Hz, 
CH), 115.3 (CH), 115.0 (CH). 
HR-MS (EI) m/z calcd. for C18H12NOF [M+H]
+
: 277.0897; found: 277.0896. 
Synthesis of (2-(pyridin-2’-yl)phenyl)(3-(trifluoromethyl)phenyl)methanone (1.3k) 
 
Following general procedure A, 1.3k was isolated as yellow oil (88 mg, 0.27 mmol, 54%). 
1
H-NMR (300 MHz, Chloroform-d) δ = 8.27 (ddd, J = 4.9, 1.7, 1.0 Hz, 1H, CH), 7.92 (tt, J = 1.7, 0.8 
Hz, 1H, CH), 7.82 (dddd, J = 7.9, 1.9, 1.3, 0.7 Hz, 1H, CH, CH), 7.78 (dt, J = 7.7, 1.0 Hz, 1H, CH), 
7.66–7.52 (m, 6H, CH), 7.37 (ddt, J = 8.5, 7.0, 0.7 Hz, 1H), 6.99 (ddd, J = 6.7, 4.9, 1.9 Hz, 1H, CH). 
13
C NMR (75 MHz, Chloroform-d) δ = 196.7 (CO), 156.3 (Cq), 148.9 (CH), 139.6 (Cq), 138.8 (Cq), 
138.6 (Cq), 136.6 (CH), 132.3 (CH), 130.7 (CH), 130.5 (q, 
2
JC−F = 32.7 Hz, Cq), 130.3 (Cq), 129.3 
(CH), 128.9 (CH), 128.6 (CH), 128.5 (CH), 128.4 (q, 
4
JC−F = 3.5 Hz, CH ), 125.83 (q, 
4
JC−F = 3.9 Hz, 
CH), 122.3 (CH), 122.2 (CH). 
HR-MS (EI) m/z calcd. for C19H15NOF3 [M+H]
+
: 327.0863; found: 327.0865. 
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Synthesis of (2-(pyridin-2’-yl)phenyl)(4-(trifluoromethyl)phenyl)methanone (1.3l) 
 
Following general procedure A, 1.3l was isolated as yellow oil (75 mg, 0.23 mmol, 46%). 
1
H NMR (300 MHz, Chloroform-d) δ = 8.28 (ddd, J = 4.9, 1.7, 1.1 Hz, 1H), 7.78 (dddd, J = 6.8, 5.9, 
1.8, 0.9 Hz, 3H), 7.67–7.56 (m, 3H), 7.56–7.48 (m, 4H), 7.01 (ddd, J = 6.7, 4.9, 1.9 Hz, 1H). 
13
C NMR (75 MHz, Chloroform-d) δ = 197.0 (CO), 156.1 (Cq), 148.9 (CH), 141.1 (Cq), 139.4 (Cq), 
138.9 (Cq), 136.7 (CH), 133.3 (d, J = 32.5 Hz, CH), 130.6 (CH), 129.4 (CH), 129.2 (CH), 128.8 (CH), 
128.4 (CH), 125.0 (q, JC-F = 3.5 Hz, Cq), 122.2 (CH), 122.2 (CH). 
HR-MS (EI) m/z calcd. for C18H12NOF3 [M+H]
+
: 327.0865; found: 327.0862. 
Synthesis of 2-(3,5-dimethyl-1H-pyrazol-1-yl)phenyl)(4-ethylphenyl)-methanone (1.5a) 
 
Following general procedure A, 1.5a was isolated as a colorless oil (64 mg, 0.21 mmol, 42%). 
1
H NMR (300 MHz, Chloroform-d) δ = 7.65–7.57 (m, 1H), 7.54–7.46 (m, 2H), 7.43 (ddd, J = 7.7, 
1.3, 0.6 Hz, 1H), 7.13–7.07 (m, 1H), 5.6 –5.59 (m, 1H), 2.62 (q, J = 7.6 Hz, 1H), 2.13 (d, J = 0.8 Hz, 
2H), 2.00 (s, 1H), 1.19 (t, J = 7.6 Hz, 1H). 
13
C NMR (75 MHz, Chloroform-d) δ = 195.5 (CO), 149.6 (Cq), 149.2 (Cq), 140.5 (Cq), 138.1 (Cq), 
136.9 (Cq), 134.5 (Cq), 131.1 (CH), 129.9 (CH), 129.4 (CH), 128.1 (CH), 127.3 (CH), 126.9 (CH), 
106.4 (CH), 29.0 (CH2) , 15.4 (CH3), 13.2 (CH3), 11.8 (CH3). 
HR-MS (EI) m/z calcd. for C20H19ON2 [M+H]
+
: 303.14919; found: 303.1494. 
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Synthesis of (2-(3‘-Methylpyrazol-1‘-yl)phenyl)(o-tolyl)methanone (1.6a) 
 
Following general procedure A, 1.6a was isolated as a colorless oil (55 mg, 0.20 mmol, 40%). 
1
H NMR (300 MHz, Chloroform-d) δ = 7.68 (ddd, J = 7.5, 1.6, 0.6 Hz, 1H), 7.59 (td, J = 7.7, 1.6 Hz, 
1H), 7.50–7.41 (m, 2H), 7.41–7.38 (m, 1H), 7.19 (ddd, J = 7.5, 6.9, 1.6 Hz, 1H), 7.14–7.09 (m, 1H), 
6.99 (dd, J = 7.8, 1.6 Hz, 1H), 6.92 (dddd, J = 8.4, 6.9, 1.5, 0.6 Hz, 1H), 5.89–5.81 (m, 1H), 2.60 (s, 
3H), 2.08 (s, 3H). 
13
C NMR (75 MHz, Chloroform-d) δ = 197.2 (CO), 150.4 (Cq), 139.3 (Cq), 139.1 (Cq), 137.0 (Cq), 
135.1 (Cq), 131.5 (CH), 131.2 (CH), 131.1 (CH), 130.6 (CH), 129.7 (CH), 129.5 (CH), 127.4 (CH), 
124.6 (CH), 123.0 (CH), 107.5 (CH), 21.1 (CH3), 13.2 (CH3); HRMS 
HR-MS (EI) m/z calcd. for C19H15ON2 [M+H]
+
: 275.1180; found: 275.1180. 
Synthesis of (3-(pyridin-2-yl)thiophen-2-yl)(o-tolyl)methanone (1.9a) 
 
m.p.: 76-77 °C 
1
H NMR (500 MHz, Chloroform-d) δ = 8.40 (ddd, J = 4.9, 1.8, 1.0 Hz, 1H), 7.64 (d, J = 5.0 Hz, 1H), 
7.40 (ddd, J = 7.7, 7.7,1.8 Hz, 1H), 7.39 (d, J = 5.0 Hz, 1H), 7.20 (ddd, J = 7.8, 1.1, 1.0 Hz, 2H), 7.12 
(ddd, J = 7.5, 7.5, 1.4 Hz, 1H), 7.06 (ddt, J = 7.7, 1.4, 0.7 Hz, 1H), 6.99 (ddd, J = 7.6, 4.9, 1.1 Hz, 
1H), 6.88 (ddd, J = 7.8, 7.7,1.7 Hz, 1H), 2.45 (s, 3H). 
13
C NMR (126 MHz, Chloroform-d) δ = 191.3 (Cq), 153.4 (Cq), 149.0 (CH), 146.1 (Cq), 140.7 (Cq), 
138.6 (Cq), 137.5 (Cq), 135.4 (CH), 131.2 (CH), 130.7 (CH), 130.6 (CH), 130.5 (CH), 129.2 (CH), 
124.7 (CH), 124.2 (CH), 122.0 (CH), 20.1 (CH3). 
MS (GC-MS) m/z (relative intensity) = 279 (18, [M
+
]), 250 (69), 236 (100), 217 (11), 188 (20), 160 
(15), 116 (10), 91 (31). 
HR-MS (EI) m/z calcd for C17H13NOS
+
 [M+H]
+
 279.0712, found 279.0711. 
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IR (ATR, neat, cm-1): 1632 (m), 1578 (m), 1465 (w), 1402 (m), 1377 (m), 1279 (m), 1255 (m), 
863 (m), 791 (m), 749 (s), 737 (s), 646 (s). 
Synthesis of [1,1'-biphenyl]-2-yl(3-(pyridin-2-yl)thiophen-2-yl)methanone (1.9b) 
 
1.9b was synthesized according to representative procedure B, using 2-iodo-1,1'-biphenyl (132 mg, 
0.47 mmol) and 2-(thiophen-3-yl)pyridine (1.3 µL, 1.0 mmol). Purification by flash chromatography 
(PhMe:EtOAc = 20:1 → 15:1) yielded 1.9b (116 mg, 0.34 mmol, 72%) as a white solid. 
m.p.: 128-129 °C 
1
H NMR (300 MHz, Chloroform-d) δ = 8.30 (ddd, J = 4.9, 1.8, 0.9 Hz, 1H), 7.48 – 7.38 (m, 3H), 
7.30 – 7.07 (m, 10H), 6.96 (ddd, J = 7.6, 4.9, 1.1 Hz, 1H). 
13
C NMR (75 MHz, Chloroform-d) δ = 191.1 (CO), 153.2 (Cq), 148.9 (CH), 145.8 (Cq), 140.8 (Cq), 
140.6 (Cq), 140.0 (Cq), 139.1 (Cq), 135.5 (CH), 131.6 (CH), 130.7 (CH), 130.5 (CH), 130.0 (CH), 
129.6 (CH), 129.1 (CH), 128.1 (CH), 127.4 (CH), 126.6 (CH), 124.2 (CH), 122.1 (CH). 
MS (GC-MS) m/z (relative intensity) = 341 (25) [M
+
], 312 (29), 280 (100), 236 (65), 188 (30), 160 
(17), 152 (65), 89 (15). 
HR-MS (ESI-TOF) m/z calcd for C22H15NOS
+
 [M+H]
+
 341.0869, found 341.0868. 
IR (ATR, neat, cm
-1
): 1626 (m), 1469 (w); 1429 (w); 1397 (m), 1296 (w), 1268 (w), 1255 (w), 1246 
(w), 861 (m), 743 (s), 737 (s), 704 (m), 646 (m). 
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Synthesis of naphthalen-1-yl(3-(pyridin-2-yl)thiophen-2-yl)methanone (1.9c) 
 
1.9c was synthesized according to representative procedure B, using 1-iodonaphthalene (128 mg, 
0.50 mmol) and 2-(thiophen-3-yl)pyridine (1.3 µL, 1.0 mmol). Purification by flash chromatography 
(n-pentane:Et2O = 10:1 → 1:1) yielded 1.9c (93 mg, 0.30 mmol, 59%) as a pale yellow oil. 
1
H NMR (300 MHz, Chloroform-d) δ = 8.4 (ddd, J = 8.5, 1.4, 0.7 Hz, 1H), 8.1 (ddd, J = 4.9, 1.7, 1.0 
Hz, 1H), 7.8 – 7.7 (m, 2H), 7.7 (d, J = 5.1 Hz, 1H), 7.6 – 7.4 (m, 3H), 7.4 (d, J = 5.1 Hz, 1H), 7.2 – 
7.0 (m, 3H), 6.8 (ddd, J = 6.8, 4.9, 1.7 Hz, 1H). 
13
C NMR (75 MHz, Chloroform-d) δ = 190.8 (CO), 153.4 (Cq), 148.9 (CH), 146.4 (Cq), 141.3 (Cq), 
136.5 (Cq), 135.3 (CH), 133.4 (Cq), 131.7 (CH), 131.5 (CH), 130.9 (Cq), 130.5 (CH), 128.5 (CH), 
128.2 (CH), 127.5 (CH), 126.3 (CH), 125.7 (CH), 123.9 (CH), 1239 (CH), 121.9 (CH). 
MS (GC-MS) m/z (relative intensity) = 315 (23) [M
+
], 286 (100), 254 (8), 237 (18), 188 (9), 127 (15). 
HR-MS (ESI-TOF) m/z calcd for C20H13NOS
+
 [M+H]
+
 315.0712, found 315.0715. 
IR (ATR, neat, cm
-1
): 1630 (m), 1586 (m), 1507 (w), 1431 (w), 1401 (w), 1284 (m), 1239 (m), 1195 
(m), 1148 (w), 884 (m), 781 (s), 768 (s), 741 (s), 613 (m). 
Synthesis of (2,4-dimethylphenyl)(3-(pyridin-2-yl)thiophen-2-yl)methanone (1.9d) 
 
1.9d was synthesized according to representative procedure B, using 1-iodo-2,4-dimethylbenzene 
(120 mg, 0.52 mmol) and 2-(thiophen-3-yl)pyridine (1.3 µL, 1.0 mmol). Purification by flash 
chromatography (PhMe/Et2O = 10:1 → 5:1) yielded 1.9d (61 mg, 0.21 mmol, 41%) as a yellowish oil. 
1
H NMR (300 MHz, Chloroform-d) δ = 8.42 (ddd, J = 4.9, 1.7, 0.9 Hz, 1H), 7.60 (d, J = 5.0 Hz, 1H), 
7.44 – 7.35 (m, 2H), 7.18 (ddd, J = 7.9, 7.9, 1.0 Hz, 1H), 7.12 (d, J = 7.9 Hz, 1H), 7.00 (ddd, J = 7.6, 
4.9, 1.2 Hz, 1H), 6.88 (d, J = 1.9 Hz, 1H), 6.67 (ddd, J = 7.8, 1.7, 0.9 Hz, 1H), 2.42 (s, 3H), 2.20 (s, 
3H). 
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13
C NMR (75 MHz, Chloroform-d) δ = 191.2 (CO), 153.6 (Cq), 149.1 (CH), 145.8 (Cq), 141.1 (Cq), 
140.9 (Cq), 138.0 (Cq), 135.8 (CH), 135.5 (Cq), 131.7 (CH), 130.8 (CH), 130.6 (CH), 130.0 (CH), 
125.5 (CH), 124.3 (CH), 121.9 (CH), 21.3 (CH3), 20.2 (CH3). 
MS (GC-MS) m/z (relative intensity) = 293 (24, [M
+
]), 264 (63), 250 (100), 188 (20), 160 (15), 116 
(10), 103 (16), 77 (25). 
HR-MS (EI) m/z calcd for C18H15NOS+ [M+H]+ 293.0869, found 293.0865. 
IR (ATR, neat, cm
-1
): 1632 (s), 1610 (m), 1587 (m), 1432 (m), 1401 (m), 1376 (m), 1278 (s), 1231 (s), 
1150 (w), 858 (w), 813 (m), 759 (s), 743 (s), 606 (s). 
Synthesis of (4-methoxyphenyl)(3-(pyridin-2-yl)thiophen-2-yl)methanone (1.9f) 
 
1.9f was synthesized according to representative procedure B, using 4-iodoanisole (117 mg, 
0.50 mmol) and 3-(thiophen-2-yl)pyridine (164 mg, 1.0 mmol). Purification by flash chromatography 
(n-hexane/EtOAc = 7:1 → 2:1) yielded 1.9f (83 mg, 0.28 mmol, 56%) as a off-white solid. 
m.p.: 121 °C 
1
H NMR (500 MHz, Chloroform-d) δ = 8.44 (ddd, J = 4.9, 1.8, 1.0 Hz, 1H), 7.67 (d, J = 8.9 Hz, 2H), 
7.56 (d, J = 5.1 Hz, 1H), 7.47 (d, J = 5.1 Hz, 1H), 7.42 (ddd, J = 7.8, 1.8, 1.8 Hz, 1H), 7.23 (dd, 
J = 7.8, 1.0 Hz, 1H), 7.01 (ddd, J = 7.5, 4.9, 1.2 Hz, 1H), 6.69 (d, J = 8.9 Hz, 2H), 3.75 (s, 3H). 
13
C NMR (126 MHz, Chloroform-d) δ = 188.9 (CO), 163.2 (Cq), 153.5 (Cq), 149.3 (CH), 144.2 (Cq), 
138.9 (Cq), 135.8 (CH), 132.1 (CH), 130.6 (Cq), 129.4 (CH), 129.0 (CH), 124.1 (CH), 122.0 (CH), 
113.3 (CH), 55.4 (OCH3). 
MS (EI) m/z (relative intensity) = 295 (32) [M
+
], 266 (100), 223 (13), 188 (14), 92 (8). 
HR-MS (EI) m/z calcd for C17H13NO2S
+
 [M+H]
+
 296.0740, found 296.0740. 
IR (ATR, neat, cm
-1
): 1634 (m), 1593 (s), 1573 (m), 1463 (m), 1421 (m), 1288 (m), 1265 (m), 1250 
(s), 1173 (s), 1017 (m), 923 (w), 888 (m), 848 (m), 763 (s), 742 (s), 646 (m), 612 (m). 
Synthesis of (4-methoxyphenyl)(3-(pyridin-2-yl)thiophen-2-yl)methanone (1.9g) 
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1.9g was synthesized according to representative procedure B, using 1-fluoro-4-iodobenzene 
(117 mg, 0.50 mmol) and 3-(thiophen-2-yl)pyridine (164 mg, 1.0 mmol). Purification by flash 
chromatography (n-hexane/EtOAc = 7:1 → 2:1) yielded 1.9g (83 mg, 0.28 mmol, 55%) as a pale 
yellow oil. 
1
H NMR (500 MHz, Chloroform-d) δ = 8.38 (ddd, J = 4.8, 1.8, 1.0 Hz, 1H), 7.67 (dd, J = 8.8, 5.5 Hz, 
2H), 7.62 (d, J = 5.0 Hz, 1H), 7.46 – 7.42 (m, 2H), 7.23 (ddd, J = 7.9, 1.0, 1.0 Hz, 1H), 7.02 (ddd, 
J = 7.6, 4.8, 1.1 Hz, 1H), 6.85 (dd, J = 8.7 Hz, 2H). 
13
C NMR (126 MHz, Chloroform-d) δ = 189.1 (CO), 165.5 (d, J = 254.2 Hz, Cq), 153.6 (Cq), 149.7 
(CH), 145.5 (Cq), 139.0 (Cq), 136.3 (CH), 134.6 (d, J = 2.9 Hz, Cq), 132.4 (d, J = 9.2 Hz, CH), 130.2 
(CH), 129.8 (CH), 124.3 (CH), 122.5 (CH), 115.4 (d, J = 22.0 Hz, CH). 
19
F{
1
H} NMR (282 MHz, Chloroform-d) δ = -105.94 (s). 
MS (EI) m/z (relative intensity) = 283 (17) [M
+
], 254 (100), 188 (16), 116 (5), 95 (15). 
HR-MS (EI) m/z calcd for C16H10FNOS
+
 [M+H]
+
 284.0540, found 284.0544. 
IR (ATR, neat, cm
-1
): 1634 (m), 1594 (s), 1504 (m), 1411 (m), 1282 (m), 1232 (s), 1153 (s), 907 (m), 
907 (m), 878 (m), 725 (s), 602 (s). 
Synthesis of (2,4-dimethylphenyl)(3-(pyridin-2-yl)thiophen-2-yl)methanone (1.9h) 
 
1.9h was synthesized according to representative procedure B, using 1-iodo-3,5-dimethylbenzene 
(110 mg, 0.47 mmol) and 2-(thiophen-3-yl)pyridine (1.3 µL, 1.0 mmol). Purification by flash 
chromatography (n-pentane:EtOAc = 10:1 → 5:1) yielded 1.9h (65 mg, 0.22 mmol, 47%) as a 
brownish oil. 
1
H NMR (300 MHz, Chloroform-d) δ = 8.37 (ddd, J = 4.9, 1.8, 0.9 Hz, 1H), 7.55 (d, J = 5.0 Hz, 1H), 
7.40 – 7.36 (m, 1H), 7.32 (ddd, J = 7.7, 1.8, 1.8 Hz, 1H), 7.18 (q, J = 1.2 Hz, 2H), 7.10 (ddd, J = 7.9, 
7.9, 1.0 Hz, 1H), 6.94 (ddd, J = 7.5, 4.9, 1.1 Hz, 1H), 6.89 (dd, J = 2.4, 0.9 Hz, 1H), 2.09 (s, 6H). 
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13
C NMR (75 MHz, Chloroform-d) δ = 190.3 (CO), 153.8 (Cq), 149.2 (CH), 145.2 (Cq), 139.3 (Cq), 
137.7 (Cq), 137.6 (Cq), 135.7 (CH), 134.1 (CH), 130.0 (CH), 129.9 (CH), 127.6 (CH), 124.3 (CH), 
122.1 (CH), 21.0 (CH3). 
MS (GC-MS) m/z (relative intensity) = 293 (16, [M
+
]), 264 (100), 250 (18), 188 (26), 160 (9), 116 (8), 
103 (8), 77 (15). 
HR-MS (EI) m/z calcd for C18H15NOS+ [M+H]
+
 293.0869, found 293.0873. 
Synthesis of (3-(pyridin-2-yl)furan-2-yl)(o-tolyl)methanone (1.10a) 
 
1.10a was synthesized according to representative procedure B, using 2-iodotoluene (109 mg, 
0.5 mmol) and 3-(furan-2-yl)pyridine (145 mg, 0.5 mmol). Purification by flash chromatography (n-
heptane/EtOAc = 20:1 → 5:1) yielded 1.10a (71 mg, 0.27 mmol, 54%) as a colorless oil. 
1
H NMR (300 MHz, Chloroform-d) δ = 8.61 (ddd, J = 4.9, 1.8, 0.9 Hz, 1H), 7.97 (dt, J = 8.0, 1.0 Hz, 
1H), 7.68 – 7.58 (m, 2H), 7.41 – 7.27 (m, 2H), 7.24 – 7.08 (m, 4H), 2.37 (s, 3H). 
13
C NMR (75 MHz, Chloroform-d) δ = 187.0 (CO), 150.7 (Cq), 149.4 (CH), 148.2 (Cq), 145.5 (CH), 
138.5 (Cq), 137.1 (Cq), 136.1 (CH), 134.9 (Cq), 130.9 (CH), 130.7 (CH), 128.8 (CH), 125.3 (CH), 
125.1 (CH), 123.0 (CH), 114.8 (CH), 19.8 (CH3). 
MS (GC-MS) m/z (relative intensity) = 263 (26, [M
+
]), 234 (100), 220 (58), 206 (44), 191 (8), 116 
(13), 91 (35). 
HR-MS (ESI-TOF) m/z calcd for C17H13NO2
+
 [M+H]
+
 264.1019, found 264.1018. 
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Synthesis of (3-(pyridin-2-yl)furan-2-yl)(o-tolyl)methanone (1.10b) 
 
1.10b was synthesized according to representative procedure B, using 2-iodo-1,1’-biphenyl (88 µL, 
0.5 mmol) and 3-(furan-2-yl)pyridine (144 mg, 1.0 mmol). Purification by flash chromatography (n-
heptane/EtOAc = 20:1 → 5:1) yielded 1.10b (106 mg, 0.33 mmol, 65%) as a yellow oil. 
1
H NMR (300 MHz, Chloroform-d) δ = 8.55 (ddd, J = 4.9, 1.8, 1.0 Hz, 1H), 7.92 (dt, J = 8.0, 1.1 Hz, 
1H), 7.67 – 7.58 (m, 2H), 7.52 (td, J = 7.5, 1.5 Hz, 1H), 7.42 (td, J = 7.5, 1.5 Hz, 1H), 7.37 (ddd, 
J = 7.6, 1.4, 0.6 Hz, 1H), 7.29 – 7.13 (m, 7H), 6.80 (d, J = 1.8 Hz, 1H). 
13
C NMR (75 MHz, Chloroform-d) δ = 187.5 (CO), 150.4 (Cq), 149.2 (CH), 147.9 (Cq), 145.0 (CH), 
141.5 (Cq), 140.1 (Cq), 138.9 (Cq), 136.1 (CH), 133.9 (Cq), 130.9 (CH), 129.9 (CH), 129.0 (CH), 128.8 
(CH), 128.2 (CH), 127.5 (CH), 127.2 (CH), 124.7 (CH), 122.9 (CH), 114.3 (CH). 
MS (GC-MS) m/z (relative intensity) = 324 (1, [M
+
]), 296 (100), 268 (11), 220 (5), 152 (17), 104 (8). 
HR-MS (EI) m/z calcd for C22H14NO2
+
 [M+H]
+
 324.1019, found 324.1015. 
Synthesis of ((3-(pyridin-2-yl)-1H-pyrrol-2-yl)(o-tolyl)methanone (1.11a) 
 
1.11a was synthesized according to representative procedure B, using 2-iodotulene (112 mg, 
0.51 mmol) and 2-(1H-pyrrol-3-yl)pyridine (144 mg, 1.00 mmol). Purification by flash 
chromatography (cyclohexane/EtOAc = 1:1) yielded 1.11a (63 mg, 0.24 mmol, 47%) as a colorless 
solid. 
1
H NMR (300 MHz, Chloroform-d) δ = 9.90 (s, 1H), 8.36 (ddd, J = 4.1, 1.7 Hz, 1H), 7.20 (td, 
J = 7.8, 1.8 Hz, 1H), 7.13 – 6.99 (m, 4H), 6.90 (m, 2H), 6.82 – 6.73 (m, 1H), 6.59 (dd, J = 2.7,2.7 Hz, 
1H), 2.36 (s, 3H). 
13
C NMR (75 MHz, Chloroform-d) δ = 188.2 (CO), 153.8 (Cq), 149.0 (CH), 138.9 (Cq), 136.6 (Cq), 
134.9 (CH), 133.3 (Cq), 130.4 (CH), 129.9 (CH), 129.1 (Cq), 128.8 (CH), 124.9 (CH), 124.7 (CH), 
124.1 (CH), 121.2 (CH), 113.1 (CH), 19.7 (CH3). 
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MS (GC-MS) m/z (relative intensity) = 262 (33, [M
+
]), 247 (24), 233 (100), 219 (57), 204 (6), 167 
(10), 116 (15), 91 (14). 
HR-MS (EI) m/z calcd for C17H14N2O
+
 [M+H]
+
 262.1100, found 262.1099. 
IR (ATR, neat, cm
-1
): 1734 (w), 1617 (m), 1588 (s), 1488 (m), 1390 (s), 1329 (w), 1230 (w), 1282 
(w), 1240 (w), 1175 (w), 1045 (w), 913 (m), 886 (m), 742 8s), 660 (m). 
Synthesis of [1,1'-biphenyl]-2-yl(3-(pyridin-2-yl)-1H-pyrrol-2-yl)methanone (1.11b) 
 
1.11b was synthesized according to representative procedure B, using 2-iodo-1,1'-biphenyl 
(146 mg, 0.52 mmol) and 2-(1H-pyrrol-3-yl)pyridine (144 mg, 1.00 mmol). Purification by flash 
chromatography (cyclohexane/EtOAc = 1:1) yielded 1.11b (107 mg, 0.33 mmol, 63%) as a colorless 
solid. 
m.p.: 168-169 °C 
1
H NMR (300 MHz, Chloroform-d) δ = 9.87 (s, 1H), 8.25 (ddd, J = 4.9, 1.8, 0.9 Hz, 1H), 7.40 – 7.20 
(m, 8H), 7.17 (dd, J = 7.8, 1.3 Hz, 1H), 7.13 – 6.99 (m, 2H), 6.92 (ddd, J = 7.5, 4.9, 1.2 Hz, 1H), 6.87 
(dd, J = 2.7 Hz, 1H), 6.41 (dd, J = 2.7 Hz, 1H). 
13
C NMR (75 MHz, Chloroform-d) δ = 188.3 (CO), 153.7 (Cq), 148.7 (CH), 140.7 (Cq), 140.3 (Cq), 
139.0 (Cq), 135.2 (CH), 132.7 (Cq), 130.0 (CH), 130.0 (CH), 129.3 (CH), 129.1 (Cq), 129.0 (CH), 
128.2 (CH), 127.3 (CH), 126.5 (CH), 124.1 (CH), 123.9 (CH), 121.1 (CH), 112.6 (CH). 
MS (GC-MS) m/z (relative intensity) = 324 (42, [M
+
]), 295 (100), 280 (17), 247 (13), 219 (36), 152 
(24), 116 (11). 
HR-MS (EI) m/z calcd for C22H16N2O
+
 [M+H]
+
 324.1257, found 324.1252. 
IR (ATR, neat, cm
-1
): 1618 (m), 1498 (w), 1391 (m), 1334 (m), 1180 (w), 1010 (w), 916 (w), 883 (w), 
771 (m), 740 (s), 699 (s), 666 (m), 620 (m). 
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Synthesis of (2-(pyridin-2-yl)thiophen-3-yl)(o-tolyl)methanone (1.12a) 
 
1.12a was synthesized according to representative procedure B, using 2-iodotoluene (108 mg, 
0.49 mmol) and 2-(thiophen-2-yl)pyridine (164 mg, 1.0 mmol). Purification by flash chromatography 
(n-hexane:EtOAc = 10:1 → 7:1) yielded 1.12a (79 mg, 0.0.28 mmol, 57%) as a pale yellow solid. 
m.p.: 60-63 °C 
1
H NMR (500 MHz, Chloroform-d) δ = 8.46 (ddd, J = 4.9, 1.8, 1.0 Hz, 1H), 7.48 (ddd, J = 8.0, 7.4, 
1.8 Hz, 1H), 7.43 (dt, J = 8.0, 1.3 Hz, 1H), 7.36 (d, J = 5.2 Hz, 1H), ), 7.35 (m, 1H), 7.23 (m, 1H), 
7.23 (d, J = 5.2 Hz, 1H), 7.17 (ddd, J = 7.7, 1.5, 0.7 Hz, 1H), 7.06 (ddd, J = 7.4, 4.9, 1.3 Hz, 1H), 
7.02 (ddd, J = 7.4, 7.4, 0.8 Hz, 1H), 2.54 (s, 3H). 
13
C NMR (126 MHz, Chloroform-d) δ = 194.7 (CO), 151.5 (Cq), 149.3 (CH), 147.5 (Cq), 139.3 (Cq), 
138.7 (Cq), 138.4 (Cq), 136.1 (CH), 131.4 (CH), 131.3 (CH), 130.6 (CH), 130.5 (CH), 126.2 (CH), 
125.3 (CH), 123.0 (CH), 122.6 (CH), 20.8 (CH3). 
MS (GC-MS) m/z (relative intensity) = 279 (15, [M
+
]), 250 (80), 236 (100), 218 (24), 188 (25), 116 
(13), 91 (22). 
HR-MS (EI) m/z calcd for C17H14NOS
+
 [M+H]
+
 280.0790, found 280.0789. 
IR (ATR, neat, cm
-1
): 1654 (s), 1582 (m), 1421 (m), 1293 (m), 1273 (s), 1246 (m), 1012 (w), 1003 
(w), 861 (m), 775 (s), 727 (s), 702 (s), 667 (m). 
Synthesis of (4-fluorophenyl)(2-(pyridin-2-yl)thiophen-3-yl)methanone (1.12b) 
 
1.12b was synthesized according to representative procedure B, using K2CO3 (2.0 equiv.) as base, 
1-fluoro-4-iodobenzene (117 mg, 0.53 mmol) and 2-(thiophen-2-yl)pyridine (164 mg, 1.0 mmol). 
Purification by flash chromatography (n-pentane:Et2O = 15:1 → 2:1) yielded 1.12b (67 mg, 
0.24 mmol, 45%) as a pale yellow oil. 
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1
H NMR (300 MHz, Chloroform-d) δ = 8.46 (ddd, J = 4.9, 1.8, 1.0 Hz, 1H), 7.84 (dd, J = 9.0, 5.5 Hz, 
1H), 7.49 (ddd, J = 8.0, 7.5, 1.8 Hz, 1H), 7.44 (d, J = 5.2 Hz, 1H), 7.34 (ddd, J = 8.0, 1.0, 1.0 Hz, 
1H), 7.22 (d, J = 5.2 Hz, 1H), 7.08 (ddd, J = 7.5, 4.9, 1.0 Hz, 1H), 7.01 (dd, J = 9.0, 8.4 Hz, 1H). 
13
C NMR (75 MHz, Chloroform-d) δ = 192.8 (CO), 166.2 (d, J = 255.2 Hz, Cq), 151.7 (Cq), 150.0 
(CH), 146.1 (Cq), 138.2 (CH), 136.9 (CH), 134.6 (d, J = 3.0 Hz, Cq), 133.0 (CH), 132.9 (CH), 130.3 
(CH), 127.3 (CH), 123.0 (d, J = 1.9 Hz, Cq), 116.1 (d, J = 22.0 Hz, CH). 
19
F NMR (282 MHz, Chloroform-d) δ = -104.46 (m). 
MS (EI) m/z (relative intensity) = 283 (13) [M
+
], 254 (100), 188 (20), 116 (5), 95 (15). 
HR-MS (EI) m/z calcd for C16H11FNOS
+
 [M+H]
+
 284.0540, found 284.0544. 
IR (ATR, neat, cm
-1
): 1658 (m), 1594 (s), 1465 (m), 1279 (s), 1230 (s), 1151 (s), 907 (m), 865 (m), 
851 (m), 726 (s), 604 (s). 
Synthesis of (3,5-dimethylphenyl)(2-(pyridin-2-yl)thiophen-3-yl)methanone (1.12c) 
 
1.12c was synthesized according to representative procedure B, using 1-iodo-3,5-dimethylbenzene 
(117 mg, 0.50 mmol) and 2-(thiophen-2-yl)pyridine (170 mg, 1.1 mmol). Purification by flash 
chromatography (n-pentane:Et2O = 15:1 → 2:1) yielded 1.12c (100 mg, 0.34 mmol, 68%) as a pale 
yellow oil. 
1
H NMR (300 MHz, Chloroform-d) δ = 8.51 (ddd, J = 4.9, 1.8, 1.0 Hz, 1H), 7.47 (ddd, J = 8.0, 7.4, 
1.8 Hz, 1H), 7.44 – 7.40 (m, 3H), 7.37 (ddd, J = 8.0, 1.1, 1.0 Hz, 1H), 7.20 (d, J = 5.2 Hz, 1H), 7.13 
(dd, J = 1.8, 0.9 Hz, 1H), 7.08 (ddd, J = 7.4, 4.9, 1.2 Hz, 1H), 2.27 (s, 6H). 
13
C NMR (75 MHz, Chloroform-d) δ = 194.2 (CO), 151.6 (Cq), 149.5 (CH), 145.9 (Cq), 138.2 (Cq), 
138.2 (Cq), 137.7 (Cq), 136.4 (CH), 135.1 (CH), 130.1 (CH), 127.9 (CH), 126.5 (CH), 122.6, (CH), 
122.5 (CH), 21.2 (CH3). 
MS (EI) m/z (relative intensity) = 293 (16) [M
+
], 264 (100), 188 (25), 116 (6), 89 (6). 
HR-MS (EI) m/z calcd for C18H15NOS
+
 [M+H]
+
 294.0947, found 294.0950. 
IR (ATR, neat, cm
-1
): 1654 (m), 1582 (m), 1465 (m), 1304 (s), 1145 (m), 906 (m), 773 (m), 723 (s), 
706 (s). 
Synthesis of [1,1'-biphenyl]-2-yl(2-(pyridin-2-yl)thiophen-3-yl)methanone (1.12d) 
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1.12d was synthesized according to representative procedure B, using 2-iodo-1,1'-biphenyl 
(142 mg, 0.52 mmol) and 2-(thiophen-2-yl)pyridine (174 mg, 1.1 mmol). Purification by flash 
chromatography (n-pentane:EtOAc = 5:1 → 1:1) yielded 1.12d (102 mg, 0.30 mmol, 57%) as a 
colorless oil. 
1
H NMR (300 MHz, Chloroform-d) δ = 8.51 (ddd, J = 4.9, 1.7, 0.9 Hz, 1H), 7.68 (dd, J = 7.6, 1.4 Hz, 
1H), 7.64 – 7.52 (m, 2H), 7.46 (ddd, J = 7.7, 7.5, 1.5 Hz, 1H), 7.38 (ddd, J = 7.6, 7.5, , 1.3 Hz, 1H), 
7.33 – 7.18 (m, 7H), 7.16 – 7.10 (m, 2H), 7.06 (dd, J = 5.3, 0.6 Hz, 1H). 
13
C NMR (75 MHz, Chloroform-d) δ = 194.0 (CO), 151.3 (Cq), 149.1 (CH), 148.7 (Cq), 141.7 (Cq), 
140.3 (Cq), 139.8 (Cq), 138.4 (Cq), 136.0 (CH), 131.3 (CH), 130.9 (CH), 130.3 (CH), 129.9 (CH), 
129.0 (CH), 128.1 (CH), 127.4 (CH), 127.0 (CH), 125.6 (CH), 123.4 (CH), 122.6 (CH). 
MS (EI) m/z (relative intensity) = 341 (24) [M
+
], 312 (100), 280 (30), 236 (74), 188 (30), 152 (36), 
116 (12). 
HR-MS (EI) m/z calcd for C22H15NOS
+
 [M+H]
+
 341.0869, found 341.0868. 
IR (ATR, neat, cm
-1
): 1654 (m), 1581 (w), 1464 (m), 1421 (m), 1279 (s), 858 (m), 777 (m), 742 (m), 
696 (s). 
Synthesis of (2,3-dihydrobenzo[b][1,4]dioxin-6-yl)(2-(pyridin-2-yl)thiophen-3-yl)methanone 
(1.12e) 
 
1.12e was synthesized according to representative procedure B, using 6-iodo-2,3-
dihydrobenzo[b][1,4]dioxine (148 mg, 0.54 mmol) and 2-(thiophen-2-yl)pyridine (161 mg, 1.0 mmol). 
Purification by flash chromatography (n-pentane:EtOAc = 5:1 → 1:1) yielded 1.12e (90 mg, 
0.28 mmol, 57%) as a colorless solid. 
m.p.: 137-138 °C 
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1
H NMR (300 MHz, Chloroform-d) δ = 8.49 (ddd, J = 4.9, 1.7, 0.9 Hz, 1H), 7.49 (ddd, J = 7.9, 7.4, 
1.8 Hz, 1H), 7.44 – 7.31 (m, 4H), 7.15 (d, J = 5.1 Hz, 1H), 7.07 (ddd, J = 7.4, 4.9, 1.1 Hz, 1H), 6.79 
(d, J = 8.5 Hz, 1H), 4.29 – 4.24 (m, 2H), 4.23 – 4.19 (m, 2H). 
13
C NMR (75 MHz, Chloroform-d) δ = 192.7 (CO), 151.4 (Cq), 149.5 (CH), 148.4 (Cq), 145.0 (Cq), 
143.4 (Cq), 138.0 (Cq), 136.5 (CH), 131.2 (Cq), 129.7 (CH), 126.6 (CH), 124.5 (CH), 122.4 (CH), 
122.1 (CH), 119.2 (CH), 117.2 (CH), 64.7 (CH2), 64.1 (CH2). 
MS (GC-MS) m/z (relative intensity) = 323 (31) [M
+
], 294 (100), 238 (9), 210 (9), 188 (20), 107 (8). 
HR-MS (ESI-TOF) m/z calcd for C18H13NOS
+
 [M+H]
+
 324.0689, found 324.0686. 
IR (ATR, neat, cm
-1
): 1641 (m), 1574 (m), 1501 (w), 1464 (m), 1421 (m), 1231 (s), 1279 (s), 1194 
(m), 1118 (m), 1061 (m), 885 (s), 778 (s), 735 (s). 
Synthesis of naphthalen-1-yl(2-(pyridin-2-yl)benzo[b]thiophen-3-yl)methanone (1.14a) 
 
1.14a was synthesized according to the described procedure B, using 1-iodonaphthalene (120 mg, 
0.48 mmol) and 2-(benzothiophen-2-yl)pyridine (211 mg, 1.0 mmol). Purification by flash 
chromatography (n-pentane:Et2O = 20:1 → 5:1) yielded 1.14a (116 mg, 0.32 mmol, 66%) as a 
colorless solid. 
m.p.: 119 °C 
1
H NMR (300 MHz, Chloroform-d) δ = 9.14 (ddd, J = 8.6, 1.0, 1.0 Hz, 1H), 8.26 (ddd, J = 4.9, 1.8, 
1.0 Hz, 1H), 7.97 – 7.90 (m, 1H), 7.86 (ddt, J = 9.2, 7.6, 0.9 Hz, 3H), 7.74 (ddd, J = 8.5, 6.9, 1.4 Hz, 
1H), 7.63 – 7.55 (m, 2H), 7.49 – 7.29 (m, 4H), 7.19 (dd, J = 8.2, 7.2 Hz, 1H), 6.92 (ddd, J = 7.4, 4.8, 
1.0 Hz, 1H). 
13
C NMR (75 MHz, Chloroform-d) δ = 195.8 (CO), 151.3 (Cq), 149.3 (CH), 144.9 (Cq), 140.0 (Cq), 
139.4 (Cq), 136.3 (CH), 135.9 (Cq), 135.5 (Cq), 133.9 (Cq), 133.5 (CH), 131.3 (Cq), 131.1 (CH), 128.5 
(2xCH), 126.7 (CH), 126.3 (CH), 125.9 (CH), 125.5 (CH), 124.4 (CH), 124.1 (CH), 122.8 (CH), 122.7 
(CH), 122.4 (CH). 
MS (GC-MS) m/z (relative intensity) = 365 (29) [M
+
], 336 (100), 304 (19), 287 (24), 238 (14), 209 
(8), 127 (23). 
HR-MS (ESI-TOF) m/z calcd for C24H16NOS
+
 [M+H]
+
 366.0947, found 366.0947. 
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IR (ATR, neat, cm
-1
): 1654 (s), 1581 (m), 1523 (w), 1507 (w), 1226 (m), 1891 (m), 1113 (m), 959 (w), 
881 (m), 735 (s), 746 8s), 723 (s). 
Synthesis of (3,5-dimethylphenyl)(2-(pyridin-2-yl)benzo[b]thiophen-3-yl)methanone (1.14b) 
 
1.14b was synthesized according to representative procedure B, using 1-iodo-3,5-dimethylbenzene 
(120 mg, 0.52 mmol) and 2-(benzothiophen-2-yl)pyridine (211 mg, 1.0 mmol). Purification by flash 
chromatography (n-heptane:EtOAc = 20:1 → 10:1) yielded 1.14b (113 mg, 0.33 mmol, 64%) as a pale 
yellow foam. 
1
H NMR (300 MHz, Chloroform-d) δ = 8.52 (ddd, J = 4.8, 1.7, 0.9 Hz, 1H), 7.91 (dt, J = 8.2, 0.9 Hz, 
1H), 7.60 (ddd, J = 8.2, 8.0, 1.4 Hz, 1H), 7.54 – 7.46 (m, 3H), 7.45 – 7.28 (m, 3H), 7.13 (dq, J = 1.8, 
0.9 Hz, 1H), 7.09 (ddd, J = 7.4, 4.8, 1.3 Hz, 1H), 2.24 (s, 6H). 
13
C NMR (75 MHz, Chloroform-d) δ = 195.4 (CO), 151.4 (Cq), 149.6 (CH), 143.8 (Cq), 139.8 (Cq), 
139.6 (Cq), 138.4 (Cq), 137.5 (Cq), 136.5 (CH), 135.5 (CH), 133.5 (Cq), 127.6 (CH), 125.7 (CH), 125.1 
(CH), 123.8 (CH), 122.9 (CH), 122.7 (CH), 122.4 (CH), 21.2 (CH3). 
MS (GC-MS) m/z (relative intensity) = 343 (32) [M
+
], 314 (100), 300 (25), 282 (16), 238 (36), 209 
(11), 139 (11). 
HR-MS (EI) m/z calcd for C22H18NOS
+
 [M+H]
+
 344.1104, found 344.1106. 
IR (ATR, neat, cm
-1
): 1657 (s), 1583 (s), 1429 (m), 1294 (s), 1176 (s), 1160 (m), 846 (m), 767 (s), 722 
(s). 
Synthesis of (4-methoxyphenyl)(2-(pyridin-2-yl)benzo[b]thiophen-3-yl)methanone (1.14c) 
 
1.14c was synthesized according to the described procedure B, using 4-iodoanisole (118 mg, 
0.50 mmol) and 2-(benzothiophen-2-yl)pyridine (220 mg, 1.0 mmol). Purification by flash 
chromatography (n-pentane:Et2O = 10:1 → 2:1) yielded 1.14c (84 mg, 0.24 mmol, 49%) as a yellow 
oil. 
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1
H NMR (300 MHz, Chloroform-d) δ = 8.52 (ddd, J = 4.9, 1.7, 0.9 Hz, 1H), 7.95 – 7.79 (m, 3H), 
7.58 (ddd, J = 7.8, 1.4, 0.8 Hz, 1H), 7.54 – 7.27 (m, 4H), 7.09 (ddd, J = 7.1, 4.8, 1.4 Hz, 1H), 6.86 – 
6.74 (m, 2H), 3.79 (s, 3H). 
13
C NMR (75 MHz, Chloroform-d) δ = 193.6 (CO), 164.1 (Cq), 151.4 (Cq), 149.7 (CH), 143.3 (Cq), 
139.8 (Cq), 139.6 (Cq), 136.6 (CH), 133.4 (Cq), 132.3 (CH), 130.4 (Cq), 125.7 (CH), 125.1 (CH), 123.7 
(CH), 122.9 (CH), 122.6 (CH), 122.4 (CH), 114.0 (CH), 55.6 (CH3). 
MS (GC-MS) m/z (relative intensity) = 345 (32) [M
+
], 316 (100), 273 (12), 273 (16), 209 (7), 135 (6), 
77 (7). 
HR-MS (ESI-TOF) m/z calcd for C21H15NO2S
+
 [M+H]
+
 345.0818, found 345.0815. 
IR (ATR, neat, cm
-1
): 1649 (m), 1592 (s), 1571 (m), 1507 (m), 1458 (m), 1430 (m), 1420 (m), 1342 
(w), 1251 (m), 1236 (s), 1023 (m), 965 (w), 848 (m), 821 (m), 766 (m), 729 (s), 606 (s). 
Synthesis of (4-fluorophenyl)(2-(pyridin-2-yl)benzothiophen-3-yl)methanone (1.14d) 
 
1.14d was synthesized according to the described procedure B, using 1-fluoro-4-iodobenzene 
(112 mg, 0.50 mmol) and 2-(benzothiophen-2-yl)pyridine (210 mg, 1.0 mmol). Purification by flash 
chromatography (n-heptane:EtOAc = 20:1 → 15:1) yielded 1.14d (88 mg, 0.26 mmol, 53%) as a 
colorless solid. 
m.p.: 109-110 °C 
1
H NMR (300 MHz, Chloroform-d) δ = 8.47 (ddd, J = 4.8, 1.8, 1.0 Hz, 1H), 7.95 – 7.84 (m, 3H), 
7.63 (ddd, J = 7.9, 1.7, 1.4 Hz, 1H), 7.54 (ddd, J = 8.0, 7.5, 1.8 Hz, 1H), 7.43 (ddd, J = 8.0, 1.0, 1.0 
Hz, 3H), 7.39 (dd, J = 2.8, 1.6 Hz, 1H), 7.10 (ddd, J = 7.5, 4.8, 1.2 Hz, 1H), 7.00 (dd, J = 8.9, 8.3 Hz, 
1H). 
13
C NMR (75 MHz, Chloroform-d) δ = 193.1 (CO), 165.9 (d, J = 255.8 Hz, Cq), 151.1 (Cq), 149.5 
(CH), 143.7 (Cq), 139.5 (Cq), 139.4 (Cq), 136.5 (CH), 134.0 (d, J = 2.9 Hz, Cq), 132.8 (Cq), 132.3 (d, 
J = 9.5 Hz, CH), 125.8 (CH), 125.2 (CH), 123.6 (CH), 122.9 (CH), 122.6 (CH), 122.4 (CH), 115.7 (d, 
J = 22.0 Hz, CH). 
19
F NMR (282 MHz, Chloroform-d) δ = -103.88 (m). 
MS (GC-MS) m/z (relative intensity) = 333 (26) [M
+
], 304 (100), 238 (23), 209 (8), 95 (16). 
HR-MS (ESI-TOF) m/z calcd for C20H12FNOS
+
 [M+H]
+
 334.0696, found 334.0699. 
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IR (ATR, neat, cm
-1
): 1664 (s), 1583 (m), 1227 (s), 1157 (s), 856 (m), 823 (m), 757 (m), 729 (s), 606 
(s). 
Synthesis of (4-fluorophenyl)(2-(pyridin-2-yl)benzofuran-3-yl)methanone (1.15a) 
 
1.15a was synthesized according to the described procedure B, using 1-fluoro-4-iodobenzene 
(78 mg, 0.35 mmol) and 2-(benzofuran-2-yl)pyridine (137 mg, 1.0 mmol) and [RuCl2(cod)]n (5.6 mg, 
5.7 mol%). Purification by flash chromatography (n-heptane:EtOAc = 30:1) yielded 1.15a (44 mg, 
0.14 mmol, 40% ) as a colorless solid. 
m.p.: 161-162 °C 
1
H NMR (300 MHz, Chloroform-d) δ = 8.36 (ddd, J = 4.9, 1.8, 0.9 Hz, 1H), 7.90 (dd, J = 8.7, 5.5 Hz, 
2H), 7.82 (dd, J = 8.0, 1.1 Hz, 1H), 7.66 (dd, J = 7.7, 7.7, 1.8 Hz, 1H), 7.60 (ddd, J = 8.3, 0.9, 0.8 Hz, 
1H), 7.52 (ddd, J = 7.9, 1.4, 0.7 Hz, 1H), 7.38 (ddd, J = 8.4, 7.3, 1.4 Hz, 1H), 7.29 – 7.22 (m, 1H), 
7.11 (ddd, J = 7.6, 4.8, 1.1 Hz, 1H), 6.99 (dd, J = 8.7 Hz, 2H). 
13
C NMR (101 MHz, Chloroform-d) δ = 190.9 (Cq), 165.7 (d, J = 254.7 Hz, Cq), 154.3 (Cq), 153.6 
(Cq), 149.7 (Cq), 148.1 (CH), 136.5 (CH), 134.6 (d, J = 2.9 Hz, Cq), 132.1 (d, J = 9.2 Hz, CH), 128.2 
(Cq), 126.2 (CH), 124.1 (CH), 123.5 (CH), 121.8 (CH), 121.2 (CH), 118.1 (Cq), 115.5 (d, J = 21.9 Hz, 
CH), 111.7 (CH). 
19
F NMR (282 MHz, Chloroform-d) δ = -104.78 (p, J = 8.7 Hz). 
MS (EI) m/z (relative intensity) = 317 (34) [M
+
], 288 (100), 222 (16), 140 (5), 95 (15). 
HR-MS (ESI-TOF) m/z calcd for C20H12FNO2
+
 [M+H]
+
 318.0925, found 318.0925. 
IR (ATR, neat, cm
-1
): 1655 (m), 1593 (m), 1558 (m), 1234 (s), 1211 (m), 1126 (m), 891 (m), 738 (s), 
603 (s). 
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Synthesis of (2-(pyridin-2-yl)benzofuran-3-yl)(o-tolyl)methanone (1.15b) 
 
1.15b was synthesized according to the described procedure B, using 2-iodotoluene (110 mg, 
0.50 mmol) and 2-(benzofuran-2-yl)pyridine (195 mg, 1.0 mmol). Purification by flash 
chromatography (PhMe:EtOAc = 20:1) yielded 1.15b (111 mg, 0.354 mmol, 71%) as colorless oil. 
1
H NMR (300 MHz, Chloroform-d) δ = 8.32 (ddd, J = 4.8, 1.7, 0.9 Hz, 1H), 7.64 (dt, J = 7.9, 1.1 Hz, 
1H), 7.60 – 7.47 (m, 3H), 7.34 – 7.12 (m, 5H), 7.01 (ddd, J = 7.6, 4.8, 1.2 Hz, 1H), 6.91 – 6.82 (m, 
1H), 2.57 (s, 3H). 
13
C NMR (75 MHz, Chloroform-d) δ = 194.3 (CO), 155.3 (Cq), 154.0 (Cq), 149.1 (CH), 148.1 (Cq), 
139.1 (Cq), 138.7 (Cq), 136.1 (CH), 131.2 (CH), 131.1 (CH), 129.9 (CH), 129.0 (CH), 126.0 (Cq), 
125.2 (CH), 124.2 (CH), 123.4 (CH), 122.6 (CH), 121.7 (CH), 119.9 (CH), 111.6 (Cq), 20.7 (CH3). 
MS (GC-MS) m/z (relative intensity) = 313 (79) [M
+
], 296 (45), 284 (100), 268 (45), 222 (26), 166 
(16), 140 (23), 91 (37). 
HR-MS (ESI-TOF) m/z calcd for C21H15FO2
+
 [M+H]
+
 313.1097, found 313.1095. 
Synthesis of (2,4-dimethylphenyl)(2-(pyridin-2-yl)benzofuran-3-yl)methanone (1.15c) 
 
1.15c was synthesized according to the described procedure B, using 1-iodo-2,4-dimethylbenzene 
(115 mg, 0.50 mmol) and 2-(benzofuran-2-yl)pyridine (198 mg, 1.0 mmol). Purification by flash 
chromatography (PhMe:EtOAc = 20:1 → 15:1) yielded 1.15c (108 mg, 0.33 mmol, 66%) as a 
colorless oil. 
1
H NMR (300 MHz, Chloroform-d) δ = 8.46 (ddd, J = 4.9, 1.7, 0.9 Hz, 1H), 7.76 (dt, J = 8.0, 1.1 Hz, 
1H), 7.65 – 7.55 (m, 3H), 7.39 (ddd, J = 8.4, 7.2, 1.4 Hz, 1H), 7.34 – 7.26 (m, 2H), 7.11 (ddd, J = 7.5, 
4.8, 1.2 Hz, 1H), 6.06 (d, J = 1.8 Hz, 1H), 6.78 (dd, J = 8.0, 2.2, 1.2 Hz, 1H), 2.67 (s, 3H), 2.27 (s, 
3H). 
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13
C NMR (75 MHz, Chloroform-d) δ = 194.0 (CO), 154.6 (Cq), 154.2 (Cq), 149.6 (CH), 148.2 (Cq), 
141.9 (Cq), 139.2 (Cq), 136.2 (CH), 136.1 (Cq), 132.4 (CH), 130.8 (CH), 128.2 (Cq), 126.0 (CH), 126.0 
(CH), 124.1 (CH), 123.4 (CH), 122.5 (CH), 121.6 (CH), 120.3 (Cq), 111.7 (CH), 21.5 (CH3) 21.0 
(CH)3. 
MS (GC-MS) m/z (relative intensity) = 327 (100, [M
+
]), 310 (75), 298 (98), 284 (70), 254 (9), 222 
(29), 166 (16), 140 (25), 103 (22). 
HR-MS (EI) m/z calcd for C22H17NO2
+
 [M+H]
+
 327.1254, found 327.1252. 
IR (ATR, neat, cm
-1
): 1653 (m), 1608 (m), 1557 (m), 1450 (m), 1424 (m), 1370 (m), 1278 (m), 1123 
(m), 941 (m), 867 (s), 742 (s)611 (w). 
Synthesis of (2-methylphenyl)(1-(pyrimidin-2-yl)-1H-pyrrol-2-yl)methanone (1.16a) 
 
1.16a was synthesized according to the described procedure B, using 2-iodo-toluene (64 µL, 
0.5 mmol) and 2-(1H-pyrrol-1-yl)pyrimidine (145 mg, 1.0 mmol). Purification by flash 
chromatography (n-hexane:EtOAc = 10:1 → 2:1) yielded 1.16a (95 mg, 0.36 mmol, 72%) as a 
colorless solid. 
m.p: 99-100 °C 
1
H NMR (300 MHz, Chloroform-d) δ = 8.55 (d, J = 4.8 Hz, 2H), 7.58 (dd, J = 2.9, 1.7 Hz, 1H), 7.52 
– 7.42 (m, 1H), 7.24 (td, J = 7.5, 1.5 Hz, 1H), 7.11 (m, 2H), 7.05 (d, J = 4.8 Hz, 1H), 6.65 (dd, 
J = 3.6, 1.7 Hz, 1H), 6.26 (dd, J = 3.6, 2.9 Hz, 1H), 2.42 (s, 3H). 
13
C NMR (75 MHz, Chloroform-d) δ = 187.7 (CO), 158.3 (CH), 157.1 (Cq), 138.7 (Cq), 138.5 (Cq), 
134.0 (Cq), 131.2 (CH), 130.8 (CH), 129.8 (CH), 128.5 (CH), 125.1 (CH), 123.2 (CH), 118.7 (CH), 
110.6 (CH), 20.4 (CH3). 
MS (GC-MS) m/z (relative intensity) = 263 (100, [M
+
]), 234 (19), 172 (35), 168 (15), 118 (59), 90 
(34). 
HR-MS (EI) m/z calcd for C16H13N3O+ [M+H]+ 263.1053, found 263.1055. 
IR (ATR, neat, cm
-1
): 1643 (w), 1570 (m), 1437 (m), 1408 (m), 1284 (w), 1254 (w), 1167 (w), 900 
(m), 761 (m), 739 (s), 666 (m), 636 (m). 
Synthesis of (4-methoxyphenyl)(1-(pyrimidin-2-yl)-1H-pyrrol-2-yl)methanone (1.16b) 
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1.16b was synthesized according to the described procedure B, using 4-iodo-anisole (117 mg, 
0.5 mmol) and 2-(1H-pyrrol-1-yl)pyrimidine (145 mg, 1.0 mmol). Purification by flash 
chromatography (n-hexane:EtOAc = 10:1 → 1:1) yielded 1.16b (70 mg, 0.25 mmol, 50%) as a 
colorless solid. 
m.p.: 156-157 °C 
1
H NMR (300 MHz, Chloroform-d) δ = 8.61 (d, J = 4.8 Hz, 2H), 7.95 (d, J = 9.0 Hz, 2H), 7.70 (dd, 
J = 3.0, 1.6 Hz, 1H), 7.11 (dd, J = 4.8, 4.8 Hz, 1H), 6.93 (d, J = 8.9 Hz, 2H), 6.78 (dd, J = 3.6, 1.6 
Hz, 1H), 6.35 (dd, J = 3.6, 3.0 Hz, 1H), 3.87 (s, 3H). 
 13
C NMR (75 MHz, Chloroform-d) δ = 185.0 (CO), 163.2 (Cq), 158.2 (CH), 156.9 (Cq), 132.3 (Cq), 
131.9 (CH), 131.1 (Cq), 127.3 (CH), 121.8 (CH), 118.3 (CH), 113.5 (CH), 110.3 (CH), 55.5 (OMe). 
MS (GC-MS) m/z (relative intensity) = 279 (98, [M
+
]), 250 (28), 236 (13), 172 (100), 135 (19), 117 
(18). 
HR-MS (EI) m/z calcd for C16H13N3O2
+
 [M+H]
+
 279.1002, found 279.1009. 
IR (ATR, neat, cm
-1
): 1636 (m), 1598 (m), 1567 (s), 1436 (s), 1404 (s), 1293 (m), 1257 (s), 1027 (w), 
1018 (w), 897 (w), 852 (w), 811 (w), 752 (s), 635 (m). 
Synthesis of (4-fluorophenyl)(1-(pyrimidin-2-yl)-1H-pyrrol-2-yl)methanone (1.16c) 
 
1.16c was synthesized according to the described procedure B, using 1-fluoro-4-iodobenzene 
(58 µL, 0.5 mmol) and 2-(1H-pyrrol-1-yl)pyrimidine (145 mg, 1.0 mmol). Purification by flash 
chromatography (n-hexane:EtOAc = 10:1 → 2:1) yielded 1.16c (60 mg, 0.22 mmol, 45%) as a 
colorless solid. 
m.p.: 155-156 °C 
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1
H NMR (300 MHz, Chloroform-d) δ = 8.61 (d, J = 4.8 Hz, 2H), 7.97 (dd, J = 9.0, 5.5 Hz, 2H), 7.73 
(dd, J = 3.0, 1.6 Hz, 1H), 7.16 – 7.08 (m, 3H), 6.81 (dd, J = 3.6, 1.6 Hz, 1H), 6.37 (dd, J = 3.6, 3.0 
Hz, 1H). 
13
C NMR (75 MHz, Chloroform-d) δ = 184.5 (CO), 165.4 (d, J = 253.6 Hz, Cq), 158.3 (CH), 134.7 
(CH), 132.1 (d, J = 9.2 Hz, CH), 131.9 (Cq), 128.0 (CH), 122.5 (CH), 118.5 (CH), 115.4 (d, J = 21.7 
Hz, CH), 110.5 (CH). 
19
F NMR (282 MHz, Chloroform-d) δ = –(104.6–107.1) (m). 
MS (GC-MS) m/z (relative intensity) = 267 (79, [M
+
]), 238 (32), 172 (100), 117 (17), 95 (22), 75 (10). 
HR-MS (EI) m/z calcd for C15H10N3F
+
 [M+H]
+
 267.0802, found 267.0809. 
IR (ATR, neat, cm
-1
): 1644 (m), 1571 (m), 1435 (m), 1409 (m), 1302 (m), 1148 (m), 901 8m), 757 (s). 
Synthesis of (1H-indol-5-yl)(1-(pyrimidin-2-yl)-1H-pyrrol-2-yl)methanone (1.16d)  
 
1.16d was synthesized according to the described procedure B, using 5-iodoindole (121 mg, 
0.5 mmol) and 2-(1H-pyrrol-1-yl)pyrimidine (145 mg, 1.0 mmol). Purification by flash 
chromatography (n-pentane:EtOAc = 4:1 → 1:1) yielded 1.16d (99 mg, 0.34 mmol, 69%) as a 
colorless solid. 
m.p.: 195 °C 
1
H NMR (300 MHz, Chloroform-d) δ 8.70 (s, 1H, NH), 8.56 (d, J = 4.8 Hz, 2H), 8.34 (ddd, J = 1.8, 
0.8 Hz, 1H), 7.86 (ddd, J = 8.6, 1.8 Hz, 1H), 7.73 (dd, J = 3.0, 1.7 Hz, 1H), 7.37 (d, J = 8.6 Hz, 1H), 
7.22 (dd, J = 3.2, 2.4 Hz, 1H), 7.04 (dd, J = 4.8 Hz, 1H), 6.82 (dd, J = 3.6, 1.7 Hz, 1H), 6.61 (m, 1H), 
6.37 (dd, J = 3.6, 3.0 Hz, 1H). 
13
C NMR (75 MHz, Chloroform-d) δ 187.0 (CO), 158.3 (CH), 157.1 (Cq), 138.5 (Cq), 132.9 (Cq), 
130.6 (Cq), 127.4 (Cq), 127.3 (CH), 125.7 (CH), 124.8 (CH), 123.8 (CH), 122.1 (CH), 118.3 (CH), 
111.1 (CH), 110.4 (CH), 104.3 (CH). 
MS (GC-MS) m/z (relative intensity) = 288 (100, [M
+
]), 259 (75), 172 (66), 144 (23), 116 (38), 89 
(25). 
HR-MS (EI) m/z calcd for C17H12N4 [M]
+
 288.1006, found 288.1003. 
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IR (ATR, neat, cm
-1
): 1598 (m), 1568 (s), 1426 (s), 1399 (s), 1341 (m), 1302 (m), 1094 (w), 854 (m), 
749 (s). 
Synthesis of (phenyl)(1-(pyrimidin-2-yl)-1H-pyrrol-2-yl)methanone (1.16e) 
 
1.16e was synthesized according to the described procedure B, using iodobenzene (1.28 g, 
6.25 mmol) and 2-(1H-pyrrol-1-yl)pyrimidine (1.81 g, 13.0 mmol, 1.0 equiv.). Purification by flash 
chromatography (n-hexane:EtOAc = 10:1 → 2:1) yielded 1.16e (1.2 g, 4.81 mmol, 77%) as a colorless 
solid. 
m.p.: 120-121 °C 
1
H NMR (300 MHz, Chloroform-d) δ 8.60 (d, J = 4.8 Hz, 2H, 2‘-H, 4‘-H), 7.97 – 7.91 (m, 2H, 7-H, 
12-H), 7.72 (dd, J = 2.9, 1.6 Hz, 1H, 2-H), 7.54 (m, 1H),, 7.43 (m, 2H, 9-H, 11-H), 7.11 (t, J = 4.8 Hz, 
1H, 4‘-H), 6.83 (dd, J = 3.6, 1.6 Hz, 1H, 4-H), 6.37 (dd, J = 3.6, 2.9 Hz, 1H, 3-H). 
13
C NMR (75 MHz, Chloroform-d) δ 186.0 (CO), 158.3 (CH), 157.0 (Cq), 138.4 (Cq), 132.5 (CH), 
132.4 (Cq), 129.8 (CH), 128.3 (CH), 128.0 (CH), 122.7 (CH), 118.6 (CH), 110.6 (CH). 
MS (GC-MS) m/z (relative intensity) = 249 (63) [M
+
], 220 (28), 172 (100), 117 (16), 77 (17). 
HRMS (EI, m/z) calcd. for C15H11ON3 [M]
+
: 249.0897; found: 249.0893. 
IR (ATR, neat, cm
-1
): 3133 (w), 3096 (w), 1644 (m); 1571 (s), 1436 (s), 1406 (m), 1288 (m), 1256 
(m), 1160 (m), 897 (w), 811 (w), 756 (m), 716 (s), 689 (m), 674 (m). 
Synthesisi of (1-(pyridin-2-yl)-indol-2-yl)(o-tolyl)methanone (1.17a) 
 
1.17a was synthesized according to the described procedure A, using 2-iodotoluene (107 mg, 
0.50 mmol) and 1-(pyridin-2-yl)-indol (194 mg, 1.0 mmol). Purification by flash chromatography 
(n-heptane:EtOAc = 20:1 → 10:1) yielded 1.17a (115 mg, 0.37 mmol, 75%) as a colorless oil. 
1
H NMR (300 MHz, Chloroform-d) δ = 8.63 (ddd, J = 4.9, 1.9, 0.8 Hz, 1H), 7.88 (ddd, J = 8.4, 7.8, 
1.9 Hz, 1H), 7.71 (ddd, J = 8.4, 7.8, 1.0 Hz, 2H), 7.53 (ddd, J = 8.5, 1.8, 0.9 Hz, 1H), 7.45 (ddd, 
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J = 8.0, 1.0, 1.0 Hz, 1H), 7.40 (m, 2H), 7.34 (ddd, J = 7.5, 2.6, 1.1 Hz, 1H), 7.29 (d, J = 7.4 Hz, 2H), 
7.23 (ddd, J = 8.4, 7.0, 1.0 Hz, 1H), 7.05 (d, J = 0.9 Hz, 1H), 2.47 (s, 3H). 
13
C NMR (101 MHz, Chloroform-d) δ = 189.0 (Cq), 151.7 (Cq), 149.3 (CH), 140.2 (Cq), 138.5 (Cq), 
138.1 (CH), 137.9 (Cq), 137.3 (Cq), 131.2 (CH), 130.8 (CH), 129.7 (CH), 126.9 (CH), 126.8 (Cq), 
125.1 (CH), 123.1 (CH), 122.5 (CH), 122.0 (CH), 121.4 (CH), 117.0 (CH), 111.7 (CH), 20.2 (CH3). 
MS (GC-MS) m/z (relative intensity) = 312 (100) [M
+
], 283 (43), 221 (21), 118 (17), 91 (18). 
HR-MS (ESI-TOF) m/z calcd for C21H16N2O
+
 [M+H]
+
 313.1335, found 313.1337. 
IR (ATR, neat, cm
-1
): 1642 (m), 1588 (m), 1516 (m), 1466 (s), 1438 (s), 1387 (m), 1217 (m), 905 (s), 
725 (s). 
Synthesisi of (1-(pyrimidin-2-yl)-indol-2-yl)(o-tolyl)methanone (1.18b) 
 
1.18b was synthesized according to the described procedure B, using 2-iodotoluene (107 mg, 
0.50 mmol) and 1-(pyridin-2-yl)-indole (194 mg, 1.0 mmol). Purification by flash chromatography 
(n-heptane:EtOAc = 20:1 → 10:1) yielded 1.18b (83 mg, 0.27 mmol, 54%) as a colorless viscous oil. 
1
H NMR (300 MHz, Chloroform-d) δ = 8.67 (d, J = 4.9 Hz, 2H), 8.31 (dd, J = 8.5, 0.9 Hz, 1H), 7.69 
(ddd, J = 7.9, 1.3, 0.8 Hz, 1H), 7.58 (dd, J = 7.6, 1.3 Hz, 1H), 7.44 (ddd, J = 8.5, 7.1, 1.3 Hz, 1H), 
7.35 (td, J = 7.5, 1.5 Hz, 1H), 7.31 – 7.23 (m, 2H), 7.17 (dddd, J = 8.2, 7.2, 1.5, 0.7 Hz, 1H), 7.08 (d, 
J = 0.8 Hz, 1H), 7.07 (dd, J = 4.8, 4.9 Hz, 1H), 2.58 (s, 3H). 
13
C NMR (75 MHz, Chloroform-d) δ = 189.3 (CO), 158.0 (CH), 157.5 (Cq), 138.8 (Cq), 138.1 (Cq), 
131.3 (CH), 131.2 (CH), 130.0 (CH), 127.9 (Cq), 126.8 (CH), 125.2 (CH), 125.0 (Cq), 122.9 (CH), 
122.7 (CH), 117.7 (CH), 116.3 (CH), 114.1 (CH), 20.5 (CH3). 
MS (GC-MS) m/z (relative intensity) = 313 (100) [M
+
], 295 (29), 284 (26), 233 (15), 222 (40), 193 
(22), 118 (28), 91 (37). 
HR-MS (EI) m/z calcd for C20H15N2O
+
 [M]
+
 313.1210, found 313.1204. 
IR (ATR, neat, cm
-1
): 1642 (m), 1588 (m), 1516 (m), 1466 (s), 1438 (s), 1387 (m), 1217 (m), 905 (s), 
725 (s). 
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Synthesis of (3,5-dimethylphenyl)(1-(pyridin-2-yl)-1H-indol-2-yl)methanone (1.17b)
 
1.17b was synthesized according to the described procedure B, using 5-iodo-m-xylene (113 mg, 
0.50 mmol) and 1-(pyridin-2-yl)-indol (195 mg, 1.0 mmol). Purification by flash chromatography 
(n-pentane:Et2O = 30:1 → 15:1) yielded 1.17b (101 mg, 0.31 mmol, 62%) as a colorless solid. 
m.p.: 165-167 °C 
1
H NMR (300 MHz, Chloroform-d) δ = 8.56 (ddd, J = 4.9, 1.9, 0.8 Hz, 1H), 7.84 (td, J = 7.7, 1.9 Hz, 
1H), 7.77 – 7.72 (m, 1H), 7.63 (d, J = 1.9 Hz, 2H), 7.56 (dd, J = 8.5, 1.2 Hz, 1H), 7.45 – 7.33 (m, 
2H), 7.32 – 7.17 (m, 4H), 2.39 (s, 6H). 
13
C NMR (75 MHz, Chloroform-d) δ = 187.3 (CO), 151.6 (Cq), 149.4 (CH), 139.6 (Cq), 138.3 (Cq), 
138.1 (Cq), 138.1 (CH), 136.4 (Cq), 134.5 (CH), 127.8 (CH), 127.0 (Cq), 126.5 (CH), 123.1 (CH), 
122.2 (CH), 122.0 (CH), 121.1 (CH), 115.9 (CH), 111.6 (CH), 21.4 (CH3). 
MS (GC-MS) m/z (relative intensity) = 326 (77) [M
+
], 297 (58), 221 (100), 192 (21), 105 (10), 78 
(13). 
HR-MS (ESI-TOF) m/z calcd for C22H19N2O
+
 [M+H]
+
 327.1492, found 327.1495. 
IR (ATR, neat, cm
-1
): 1650 (m), 1466 (m), 1444 (m), 1301 (m), 1175 (m), 1145 (m), 964 (w), 750 (s), 
740 (s). 
Synthesis of (4-fluorophenyl)(1-(pyridin-2-yl)-indol-2-yl)methanone (1.17d) 
 
1.17d was synthesized according to the described procedure A, using 1-fluoro-4-iodotoluene 
(112 mg, 0.50 mmol) and 1-(pyridin-2-yl)-indol (200 mg, 1.0 mmol). Purification by flash 
chromatography (n-pentane:Et2O = 10:1 → 5:1) yielded 1.17d (NaHCO3 (2.0 equiv.): 95 mg, 
0.30 mmol, 60%; K2CO3 (2.0 equiv.): 87 mg, 0.28 mmol, 55%) as a colorless solid. 
m.p.: 107-108 °C 
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1
H NMR (300 MHz, Chloroform-d) δ = 8.45 (ddd, J = 5.0, 1.9, 0.9 Hz, 1H), 7.94 (dd, J = 8.7, 5.5 Hz, 
2H), 7.79 – 7.76 (dd, J = 7.7, 7.7, 1.9 Hz, 1H), 7.64 (ddd, J = 7.9, 1.0, 0.9 Hz, 1H), 7.44 (dt, J = 8.5, 
1.0 Hz, 1H), 7.33 (dd, J = 8.0, 0.9 Hz, 1H), 7.28 (ddd, J = 8.4, 7.1, 1.0 Hz, 1H), 7.23 – 7.02 (m, 5H). 
13
C NMR (101 MHz, Chloroform-d) δ = 185.5 (CO), 165.6 (d, J = 254.2 Hz, Cq), 151.4 (Cq), 149.4 
(CH), 139.6 (Cq), 138.2 (CH), 135.9 (Cq), 134.5 (d, J = 3.0 Hz, Cq), 132.5 (CH), 132.4 (CH), 126.9 
(Cq), 126.7 (CH), 123.1 (CH), 122.4 (CH), 122.1 (CH), 121.0 (CH), 115.9 (CH), 115.5 (d, J = 21.9 
Hz, CH), 111.5 (CH). 
19
F NMR (282 MHz, Chloroform-d) δ = -105.32 (td, J = 9.3, 4.4 Hz). 
MS (GC-MS) m/z (relative intensity) = 316 (100) [M
+
], 287 (73), 192 (27), 123 (14), 95 (32). 
HR-MS (ESI-TOF) m/z calcd for C20H13FN2O
+
 [M+H]
+
 317.1085, found 317.1086. 
IR (ATR, neat, cm
-1
): 1665 (m), 1594 (m), 1584 (m), 1532 (w), 1503 (w), 1470 (w), 1411 (w), 1340 
(w), 1228 (s), 1158 (s), 857 (m), 823 (m), 757 (m), 729 (s), 607 (s). 
Synthesis of (2,4-dimethylphenyl)(1-(pyrimidin-2-yl)-1H-indol-2-yl)methanone (1.18b) 
 
1.18b was synthesized according to the described procedure A, using 1-iodo-2,4-dimethylbenzene 
(113 mg, 0.49 mmol) and 1-(pyrimidin-2-yl)-indol (195 mg, 1.0 mmol). Purification by flash 
chromatography (n-pentane:EtOAc = 30:1 → 15:1) yielded 1.18b (101 mg, 0.31 mmol, 62%) as a 
yellowish oil. 
1
H NMR (300 MHz, Chloroform-d) δ = 8.67 (dd, J = 4.8, 0.7 Hz, 2H), 8.34 (dq, J = 8.4, 0.8 Hz, 1H), 
7.69 (ddd, J = 7.9, 1.3, 0.7 Hz, 1H), 7.52 (d, J = 7.8 Hz, 1H), 7.45 (ddt, J = 8.4, 7.1, 1.0 Hz, 1H), 7.35 
– 7.23 (m, 1H), 7.10 – 7.05 (m, 3H), 6.98 (ddt, J = 7.9, 1.5, 0.8 Hz, 1H), 2.57 (s, 3H), 2.35 (s, 3H). 
13
C NMR (75 MHz, Chloroform-d) δ = 189.2 (CO), 158.0 (CH), 157.6 (Cq), 141.7 (Cq), 139.0 (Cq), 
139.0 (Cq), 138.6 (Cq), 135.4 (Cq), 132.3 (CH), 130.6 (CH), 128.0 (Cq), 126.6 (CH), 125.8 (CH), 122.8 
(CH), 122.6 (CH), 117.6 (CH), 115.8 (CH), 114.1 (CH), 21.5 (CH3), 20.6 (CH3). 
MS (GC-MS) m/z (relative intensity) = 327 (100) [M
+
], 309 (28), 247 (13), 222 (33), 193 (20), 132 
(28), 103 (24), 79 (33). 
HR-MS (EI) m/z calcd for C21H17N3
+
 [M+H]
+
 327.1366, found 327.1358. 
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IR (ATR, neat, cm
-1
): 1648 (m), 1563 (m), 1419 (s), 1344 (m), 1210 (m), 1140 (w), 1042 (w), 958 
(m), 801 (w), 765 (s), 745 (s), 705 (w), 599 (m). 
Synthesis of (1H-Pyrrol-2-yl)(o-tolyl)methanone (1.19) 
 
NaOEt (41 mg, 0.60 mmol, 3 equiv.) was added to a stirring solution of (1-(pyrimidin-2-yl)-1H-
pyrrol-2-yl)(o-tolyl)methanone (1.16a) (50 mg, 0.19 mmol, 1.0 equiv.) in DMSO (2 mL) under argon 
atmosphere and the reaction mixture was stirred at 100 °C for 5 h. The reaction was quenched by 
addition of EtOAc (5 mL) and the reaction mixture was portioned between EtOAc and H2O (5 mL). 
The aqueous layer was extracted with EtOAc (3 x 5 mL). The combined organic layer were washed 
with H2O (5 mL) and Brine (5 mL) and dried over Na2SO4. The solvent was removed under reduced 
pressure and the crude product was purified by flash chromatography (n-pentane/Et2O = 5:1). 1.19 
(32 mg, 0.17 mmol, 91%) was obtained as colorless solid. 
m.p.: 64-65 °C 
1
H NMR (300 MHz, Chloroform-d) δ = 10.36 (s, 1H, NH), 7.52 (dd, J = 7.5, 1.5 Hz, 1H), 7.39 (ddd, 
J = 7.5, 1.5 Hz, 1H), 7.32 – 7.21 (m, 2H), 7.16 (ddd, J = 2.8, 1.4 Hz, 1H), 6.63 (ddd, J = 3.8, 2.4, 1.4 
Hz, 1H), 6.29 (ddd, J = 3.8, 2.4 Hz, 1H), 2.44 (s, 3H). 
13
C NMR (75 MHz, Chloroform-d) δ = 187.4 (CO), 138.5 (Cq), 136.8 (Cq), 132.5 (Cq), 131.1 (CH), 
130.1 (CH), 128.6 (CH), 126.1 (CH), 125.2 (CH), 120.6 (CH), 111.1 (CH), 19.9 (CH3). 
MS (GC-MS) m/z (relative intensity) = 185 (100) [M
+
], 168 (27), 156 (15), 128 (11), 94 (20), 91 (22), 
66 (15). 
HR-MS (ESI-TOF) m/z calcd for C12H11NO
+
 [M]
+
 186.0913, found 186.0916. 
IR (ATR, neat, cm
-1
): 3244 (w), 1617 (m), 1605 (m), 1593 (m), 1538 (w), 1391 (m), 1132 (m), 1089 
(w), 1039 (m), 892 (m), 748 (s), 734 (s), 666 (m), 602 (m). 
The analytical data are in accordance with those described in literature.
 
Synthesis of (4,5-dichloro-1H-pyrrol-2-yl)(phenyl)methanone (1.20) 
 
m.p.: 190-191°C 
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1
H NMR (300 MHz, Chloroform-d) δ 10.40 (s, 1H), 7.93 – 7.83 (m, 2H), 7.61 (ddt, J = 8.3, 6.6, 1.3 
Hz, 1H), 7.51 (ddt, J = 8.3, 6.6, 1.3 Hz, 2H), 6.83 (d, J = 2.4 Hz, 1H). 
13
C NMR (75 MHz, Chloroform-d) δ 183.6 (CO), 137.1 (Cq), 132.8 (CH), 129.1 (CH), 128.7 (CH), 
128.3 (Cq), 121.7 (Cq), 118.8 (CH) , 112.2 (Cq). 
MS (GC-MS) m/z (relative intensity) = 239 (100) [M
+
], 204 (26), 162 (38), 105 (61), 77 (80). 
HRMS (EI, m/z) calcd. for C11H7Cl2ON [M]
+
: 240.9870; found: 240.9873. 
IR (ATR, neat, cm
-1
): 3185 (m), 3134 (w), 3068 (w), 1621 (m), 1572 (w), 1467 (m), 1413 (m), 1391 
(m), 1261 (m), 1019 (m), 891 (m), 826 8m), 721 (s), 692 (s), 625 8m), 595 (m). 
Synthesis of 5-methoxy-2-(6-methoxybenzo[b]thiophen-2-yl)pyridine (1.27) 
 
1.27 was synthesized following representative procedure A, using 2-bromo-5-methoxypyridine 
(526 mg, 2.80 mmol, 1.0 equiv.) and (6-methoxybenzo[b]thiophen-2-yl)boronic acid/(4-
methoxybenzo[b]thiophen-2-yl)boronic acid (5.2:1, 700 mg, 3.36 mmol, 1.2 equiv.). Purification by 
flash chromatography (n-pentane/Et2O = 7:1 → 5:1) yielded the title compound 1.27 (555 mg, 
2.05 mmol, 61%) as a colorless solid. 
m.p.: 155-156 °C 
1
H NMR (500 MHz, Chloroform-d) δ = 8.31 (dd, J = 2.8, 0.7 Hz, 1H), 7.68 (dd, J = 8.7, 0.7 Hz, 1H), 
7.64 (d, J = 8.7 Hz, 1H), 7.60 (s, 1H), 7.32 (d, J = 2.3 Hz, 1H), 7.24 (dd, J = 8.7, 3.0 Hz, 1H), 6.97 
(dd, J = 8.7, 2.4 Hz, 1H), 3.89 (s, 3H), 3.89 (s, 3H). 
13
C NMR (126 MHz, Chloroform-d) δ = 157.8 (Cq), 154.8 (Cq), 145.7 (Cq), 141.9 (Cq), 136.6 (CH), 
134.7 (Cq), 124.5 (CH), 121.6 (CH), 119.8 (CH), 119.3 (CH), 114.6 (CH), 104.9 (CH), 55.8 (CH3), 
55.6 (CH3). 
MS (GC-MS) m/z (relative intensity) = 271 (100) [M
+
], 256 (81), 228 (15), 201 (21), 186 (13), 158 
(20), 136 (7). 
HR-MS (EI) m/z calcd for C15H14NO2S
+
 [M+H]
+
 272.0740, found 272.00738. 
IR (ATR, neat, cm
-1
): 1598 (w), 1528 (w), 1477 (m), 1436 (m), 1260 (m), 1220 (m), 1022 (s), 1008 
(s), 844 (m), 833 (s). 
Synthesis of (4-fluorophenyl)(6-methoxy-2-(5-methoxypyridin-2-yl)benzo[b]thiophen-3-
yl)methanone (1.29) 
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1.29 was synthesized according to representative procedure B, using 1-fluoro-4-iodobenzene 
(111 mg, 0.5 mmol) and 2-(benzo[b]thiophen-2-yl)-5-methoxypyridine (5c) (241 mg, 1.0 mmol). 
Purification by flash chromatography (n-heptane:EtOAc = 20:1 → 10:1) yielded 1.29 (92 mg, 
0.27 mmol, 53%) as a pale yellow foam. Crystals were obtained by recrystallization from EtOH. 
1
H NMR (300 MHz, Chloroform-d) δ = 8.17 (dd, J = 3.0, 0.7 Hz, 1H), 7.93 – 7.85 (m, 3H), 7.60 (dd, 
J = 1.6, 0.7 Hz, 1H), 7.42 – 7.29 (m, 3H), 7.36 (d, J = 8.7 Hz, 1H), 7.06 – 6.96 (m, 2H), 7.01 (d, 
J = 8.7 Hz, 2H)3.79 (s, 1H). 
13
C NMR (75 MHz, Chloroform-d) δ = 193.4 (CO), 166.0 (d, J = 255.5 Hz, Cq), 155.3 (Cq), 144.1 
(Cq), 143.7 (Cq), 139.7 (Cq), 139.3 (Cq), 137.5 (CH), 134.2 (d, J = 2.9 Hz, Cq), 132.4 (d, J = 9.5 Hz, 
CH), 131.4 (Cq), 125.3 (CH), 125.2 (CH), 123.4(CH), 123.4 (CH), 122.4 (CH), 120.6 (CH), 115.8 (d, 
J = 21.9 Hz, CH), 55.8 (CH3). 
19
F NMR (282 MHz, Chloroform-d) δ = -102.6 – -105.1 (m). 
MS (GC-MS) m/z (relative intensity) = 363 (47) [M
+
], 334 (100), 291 (14), 268 (22), 225 (10), 181 
(33), 145 (25), 95 (12). 
HR-MS (EI) m/z calcd for C21H14FNO2S
+
 [M+H]
+
 363.0724, found 363.0719. 
IR (ATR, neat, cm
-1
): 1665 (s), 1593 /m), 1578 (m), 1477 (m),1231 (s), 1218 (s), 1159 (m), 751 (s), 
823 (s) 722 (s), 605 (s). 
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Empirical formula  C12H12F2O5 
Formula weight  274.22 
Temperature  150(2) K 
Wavelength  0.71073 Å 
Crystal system  triclinic 
Space group  P-1 
Unit cell dimensions a = 7.9463(7) Å = 104.074(2)°. 
 b = 8.7658(8) Å = 104.446(2)°. 
 c = 10.3812(10) Å  = 112.083(2)°. 
Volume 601.39(10) Å
3 
Z 2 
Density (calculated) 1.514 Mg/m
3 
Absorption coefficient 0.137 mm
-1 
F(000) 284 
Crystal size 0.50 x 0.36 x 0.14 mm
3 
Theta range for data collection 2.19 to 28.00°. 
Index ranges -10<=h<=10, -11<=k<=11, -13<=l<=13 
Reflections collected 16835 
Independent reflections 2911 [R(int) = 0.0389] 
Completeness to theta = 28.00° 100.0 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 1.000 and 0.855 
Refinement method Full-matrix least-squares on F
2 
Data / restraints / parameters 2911 / 0 / 173 
Goodness-of-fit on F
2
 1.054 
Final R indices [I>2sigma(I)] R1 = 0.0412, wR2 = 0.1225 
R indices (all data) R1 = 0.0527, wR2 = 0.1358 
Largest diff. peak and hole 0.374 and -0.271 e
.
Å
-3 
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Synthesis of (4-fluorophenyl)(6-methoxy-2-(5-methoxypyridin-2-yl)benzo[b]thiophen-3-
yl)methanone (1.30) 
 
1.30 was synthesized according to representative procedure B, using 1-fluoro-4-iodobenzene 
(111 mg, 0.5 mmol) and 5-methoxy-2-(6-methoxybenzo[b]thiophen-2-yl)pyridine (1.27) (270 mg, 
1.0 mmol). Purification by flash chromatography (n-heptane:EtOAc = 20:1 → 10:1) yielded 1.30 
(107 mg, 0.27 mmol, 55%) as a pale yellow foam. 
1
H NMR (500 MHz, Chloroform-d) δ = 8.16 (dd, J = 3.0, 0.7 Hz, 1H, 2’-C), 7.88 (dd, J = 8.9, 5.4 
Hz, 2H, A/B), 7.48 (d, J = 8.9 Hz, 1H, 4-C), 7.34 (d, J = 2.4 Hz, 1H, 7-C), 7.30 (dd, J = 8.8, 0.7 Hz, 
1H, 5’-C), 7.00 (d, J = 8.8 Hz, 1H, 6’-C), 6.99 (dd, J = 8.9, 6.4 Hz, 2H, AB), 6.96 (dd, J = 8.9, 2.4 
Hz, 1H, 5-C), 3.88 (s, 3H, OMe), 3.79 (s, 3H, OMe). 
13
C NMR (126 MHz, Chloroform-d) δ = 193.4 (CO), 166.0 (d, J = 255.4 Hz, Cq), 158.4 (Cq), 155.0 
(Cq), 144.0 (Cq), 141.7 (Cq), 140.9 (Cq), 137.4 (CH), 134.2 (d, J = 2.8 Hz, Cq), 133.8 (Cq), 132.4 (d, 
J = 9.4 Hz, CH), 131.1 (Cq), 124.2 (CH), 123.1 (CH), 120.7 (CH), 115.8 (d, J = 22.0 Hz, CH), 115.3 
(CH), 104.8 (CH), 55.8 (2xCH3). 
19
F{
1
H} NMR (282 MHz, Chloroform-d) δ = -104.5 (s). 
MS (GC-MS) m/z (relative intensity) = 393 (75) [M
+
], 364 (100), 298 (20), 283 (6), 240 (6), 197 (6), 
123 (12), 95 (17). 
HR-MS (ESI-TOF) m/z calcd for C22H16FNO3S
+
 [M+H]
+
 393.0829, found 393.0829. 
IR (ATR, neat, cm-1): 3068 (w), 3005 (w), 2961 (w), 2936 (w), 2836 (w), 1734 (w), 1660 (m), 
1594 (m), 1573 (m), 1469 (m), 1436 (m), 1261 (s), 1222 (s), 1150 (m), 1044 (m), 1025 (m), 824 
(s), 609 (m). 
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Synthesis of (6-methoxy-2-(5’-methoxypyridin-2’-yl)benzo[b]thiophen-3-yl)(4-(2-(piperidin-1-
yl)ethoxy) phenyl)methanone (1.31) 
 
1.31 was synthesized according to a procedure described by Schmid
[12]
. A solution of (4-
fluorophenyl)(6-methoxy-2-(5-methoxypyridin-2-yl)benzo[b]thiophen-3-yl)methanone (1.30) (24 mg, 
63 mmol, 1.0 equiv.) in DMF (0.5 mL) was added dropwise to astirring suspension of NaH (60% in 
mineral oil, 6 mg, 0.14 mmol, 2.2 equiv.) and 2-(piperidin-1-yl)ethanol (17 µL, 0.13 mmol, 2.0 equiv.) 
in DMF (1.0 mL) at ambient temperature. The reaction mixture was continuously stirred at ambient 
temperature for 1 h. After complete conversion of the starting material (1h) the reaction was quenched 
by addition of Et2O (1 mL) and sat. aq. NH4Cl (1 mL). The phases were separated via a phase-
separating filter. The supernatant was washed with additional Et2O (5 mL) and DCM (5 mL). The 
organic solvent was removed under reduced pressure and the crude product was purified by flash 
chromatography (n-heptane/EtOAc = 1: 0 → 2:1 → EtOAc/DCM/MeOH = 3:1:0.2). 1.31 (26 mg, 
0.052 mmol, 81%) was obtained as a yellow oil. 
1
H NMR (500 MHz, Chloroform-d) δ = 8.22 (dd, J = 3.0, 0.5 Hz, 1H), 7.83 (d, J = 8.8 Hz, 2H), 7.42 
(d, J = 8.9 Hz, 1H), 7.33 (d, J = 2.4 Hz, 1H), 7.32 (dd, J = 8.8, 0.5 Hz, 2H), 6.99 (dd, J = 8.8, 3.0 Hz, 
1H), 6.92 (dd, J = 8.9, 2.4 Hz, 1H), 6.81 (d, J = 8.9 Hz, 2H), 4.12 (t, J = 5.9 Hz, 2H), 3.88 (s, 4H), 
3.80 (s, 3H), 2.76 (t, J = 5.9 Hz, 2H), 2.59 – 2.43 (m, 4H), 1.60 (ddt, J = 5.7 Hz, 4H), 1.44 (ddt, 
J = 11.8, 8.3, 4.8 Hz, 2H). 
13
C NMR (126 MHz, Chloroform-d) δ = 193.8 (CO), 163.3 (Cq), 158.2 (Cq), 155.0 (Cq), 144.3 (Cq), 
141.1 (Cq), 141.0 (Cq), 137.4 (CH), 134.1 (Cq), 132.4 (CH), 131.6 (Cq), 130.6 (Cq), 124.3 (CH), 123.0 
(CH), 120.8 (CH), 115.1 (CH), 114.6 (CH), 104.7 (CH), 66.3 (CH2), 57.8 (CH2), 55.8 (OCH3), 55.2 
(OCH3), 25.9 (CH2), 24.2 (CH2). 
MS (GC-MS) m/z (relative intensity) = 502 (13) [M
+
], 404 (6), 374 (4), 281 (10), 253 (9), 98 (100). 
HR-MS (ESI-TOF) m/z calcd for C29H30O4N2S
+
 [M+H]
+
 502.1921, found 502.1922. 
IR (ATR, neat, cm-1): 2931 (w), 2834 (w), 2781 (w), 1651 (w), 1594 (m), 1570 (m), 1466 (m), 
1259 (m), 1222 (s), 1162 (m), 1026 (m), 825 (m). 
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Synthesis of (6-hydroxy-2-(5-hydroxypyridin-2-yl)benzo[b]thiophen-3-yl)(4-(2-(piperidin -1-
yl)ethoxy)-phenyl)methanone hydrochloride (1.32) 
 
(6-methoxy-2-(5-methoxypyridin-2-yl)benzo[b]thiophen-3-yl) (4-(2-(piperidin-1-yl) ethoxy) 
phenyl)methanone hydrochloride (1.31HCl) (13 mg, 24.1 µmol, 1.0 equiv.) was dissolved in DCM 
(2.0 mL). At 0 °C, BBr3 (1 M in DCM, 100 µL, 4.0 equiv.) was added dropwise over 30 min. The 
reaction mixture was slowly warmed to ambient temperature and heated to 35 °C for 2 h. The mixture 
was cooled to 0 °C and MeOH (1 mL) was added dropwise over 10 min. The sluggish, red reaction 
mixture turned into a clear, yellow solution that was refluxed at 40 °C for 45 min. The volatiles were 
removed under reduced pressure. The crude product was purified by flash chromatography (washed 
with n-pentane, product was eluted with MeOH), yielding the title compound 1.32 (12 mg, 24 µL, 
99%) as a pale yellow solid. 
1
H NMR (300 MHz, Methanol-d4) δ = 8.08 (t, J = 3.3 Hz, 1H), 7.80 – 7.70 (m, 2H), 7.53 – 7.26 (m, 
3H), 7.18 (ddd, J = 8.8, 2.7, 2.6 Hz, 1H), 7.01 – 6.79 (m, 3H), 4.14 (t, J = 5.5 Hz, 2H), 3.88 (s, 1H, 
OH), 3.79 (m, 3H), 2.79 (t, J = 5.5 Hz, 2H), 2.55 (m, 4H), 1.62 (p, J = 5.5 Hz, 4H), 1.47 (p, J = 5.5 
Hz, 2H). 
13
C NMR (75 MHz, Methanol-d4) δ = 194.6 (CO), 163.6 (Cq), 156.5 (Cq), 155.6 (Cq), 144.1 (Cq), 
142.9 (Cq), 141.1 (Cq), 139.9 (Cq), 137.3 (CH), 133.0 (Cq), 132.2 (CH), 130.8 (Cq), 124.0 (CH), 123.3 
(CH), 120.8 (CH), 115.4 (CH), 114.5 (CH), 107.0 (CH), 104.7 (CH), 100.0 (CH), 65.5 (CH)2, 57.5 
(CH2), 55.3 (CH2), 54.8 (CH2), 25.3 (CH2), 23.8 (CH2). 
IR (ATR, neat, cm-1): 3356 (w), 2935 (w), 2650 (w), 1642 (w), 1594 (m), 1548 (m), 1308 (w), 
1224 (s), 1168 (s), 1007 (m), 840 (m), 795 (m). 
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H/D-Exchange Experiments 
 
General procedure B was followed, using 2-(thiophen-3-yl)pyridine 1.8 (160 mg, 1.0 mmol, 
2.0 equiv.) and 2-iodotoluene 1.2b (115 mg, 0.53 mmol) in D2O (1.0 mL). The reaction mixture was 
stirred for the indicated time at 120 °C under 30 bar of carbon monoxide pressure. Purification by 
flash chromatography (n-pentane/Et2O = 10:1 → 4:1) yielded 1.9a (134 mg, 0.48 mmol, 91%) as 
yellow oil and d-1.8 (71 mg, 0.44 mmol, 83% based on A) as colorless oil. 
According to 
1
H-NMR spectroscopy the deuterium incorporation at C-2 amounted 65% after 3 
hours and 95% after 20 hours, respectively. After 20 hours 15% H/D-exchange was found at C-4 and 
<7% in 3ba. 
1
H NMR (300 MHz, Chloroform-d) δ = 8.52 (ddd, J = 4.8, 1.7, 0.8 Hz, 1H), 7.62 – 7.54 (m, 2H), 
7.50 (dq, J = 8.0, 1.0 Hz, 1H), 7.29 (dd, J = 5.0, 2.5 Hz, 1H), 7.05 (ddd, J = 7.1, 4.8, 1.0 Hz, 1H). 
13
C NMR (75 MHz, Chloroform-d) δ = 153.6 (Cq), 149.7 (CH), 142.2 (Cq), 136.8 (CH), 126.3 (CH), 
126.2 (CH), 123.4 (t, J = 28 Hz, CD), 121.9 (CH), 120.3 (CH). 
MS (GC-MS) m/z (relative intensity) = 162 (100) [M+], 136 (11), 118 (20), 105 (6), 91 (6), 81 (5). 
HR-MS (ESI-TOF) m/z calcd for C9H6DNS+ [M+H]+ 163.0435, found 163.0434. 
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Evidence for Competitive Attack of the Ru-Acyl species 
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Following a modified representative procedure B, 4-(pyridin-2-yl)phenol (86 mg, 0.5 mmol, 
1.0 equiv.) and 2-iodophenol (218 mg, 1.0 mmol, 2.0 equiv.) were reacted. The crude products were 
purified by flash chromatography (n-heptane/EtOAc = 10:1 → 5:1), yielding 1.33a (90 mg, 
0.31 mmol, 62%), 1.33b (24 mg, 0.06 mmol, 12%) and 1.1c (7 mg, 0.03 mmol, 5%) besides re-
isolated 1.1b (10 mg, 0.06 mmol, 12%). 
 
1
H NMR (300 MHz, Chloroform-d) δ = 9.58 (s, 1H), 8.46 (ddd, J = 5.1, 1.7, 0.9 Hz, 1H), 7.61 (dd, 
J = 7.7, 1.7 Hz, 1H), 7.48 (d, J = 8.4 Hz, 1H), 7.41 – 7.35 (m, 1H), 7.24 (dd, J = 9.8, 7.4 Hz, 2H), 
7.16 – 7.05 (m, 3H), 7.05 – 6.97 (m, 1H), 6.95 (dd, J = 8.4, 2.5 Hz, 1H), 2.60 (s, 3H). 
13
C NMR (75 MHz, Chloroform-d) δ = 200.1 (CO), 157.7 (Cq), 157.6 (Cq), 148.2 (CH), 141.5 (Cq), 
139.2 (Cq), 137.7 (Cq), 136.7 (CH), 131.3 (CH), 131.2 (CH), 131.1 (Cq), 130.9 (CH), 130.9 (CH), 
125.0 (CH), 123.4 (CH), 121.7 (CH), 118.3 (CH), 117.5 (CH), 21.1 (CH3). 
MS (GC-MS) m/z (relative intensity) = 289 (41) [M
+
], 260 (100), 246 (97), 198 (63), 115 (30), 91 
(42), 65 (32). 
HR-MS (EI) m/z calcd for C19H15NO2
+
 [M]
+
 288.1019, found 288.1016. 
IR (ATR, neat, cm-1): 1660 (m), 1560 (w), 1467 (w), 1312 (w), 1216 (w), 862 (m), 780 8m), 
742 (s). 
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1
H NMR (300 MHz, Chloroform-d) δ = 8.42 (dt, J = 4.7, 1.2 Hz, 1H), 8.19 (dd, J = 8.4, 1.5 Hz, 1H), 
7.77 – 7.69 (m, 1H), 7.60 – 7.39 (m, 5H), 7.34 (m, 2H), 7.24 (dd, J = 7.7, 1.4 Hz, 1H), 7.18 (dd, 
J = 7.4, 1.4 Hz, 1H), 7.12 – 7.06 (m, 1H), 7.04 – 6.92 (m, 2H), 2.69 (s, 3H), 2.60 (s, 3H). 
13
C NMR (75 MHz, Chloroform-d) δ = 198.5 (CO), 165.4 (Cq), 156.7 (Cq), 151.0 (Cq), 148.8 (CH), 
142.0 (Cq), 141.5 (Cq), 139.4 (Cq), 137.7 (Cq), 137.6 (Cq), 136.3 (CH), 133.0 (CH), 132.0 (CH), 131.3 
(CH), 131.1 (CH), 130.5 (CH), 130.2 (CH), 128.1 (Cq), 126.0 (CH), 124.9 (CH), 123.9 (CH), 123.1 
(CH), 122.5 (CH), 121.8 (CH), 22.0 (CH3), 21.1 (CH3). 
MS (GC-MS) m/z (relative intensity) = 407 (4) [M
+
], 364 (8), 288 (15), 272 (15), 119 (100), 91 (54). 
HR-MS (ESI-TOF) m/z calcd for C27H22NO3
+
 [M+H]
+
 408.1594, found 408.1596. 
 
1
H NMR (300 MHz, Chloroform-d) δ = 8.73 – 8.67 (m, 1H), 8.23 – 8.16 (m, 1H), 8.07 (d, J = 8.6 Hz, 
2H), 7.82 – 7.71 (m, 2H), 7.49 (dd, J = 7.3, 1.5 Hz, 1H), 7.33 (dd, J = 6.8, 6.8 Hz, 2H), 7.32 (d, 
J = 8.7 Hz, 2H), 7.25 – 7.21 (m, 1H), 2.70 (s, 3H). 
13
C NMR (75 MHz, Chloroform-d) δ = 165.8 (CO2), 156.8 (Cq), 151.8 (Cq), 149.8 (CH), 141.5 (Cq), 
137.2 (Cq), 137.0 (CH), 132.9 (CH), 132.1 (CH), 131.4 (CH), 128.6 (Cq), 128.2 (CH), 126.1 (CH), 
122.3 (CH), 122.3 (CH), 120.6 (CH), 22.1 (CH3). 
MS (GC-MS) m/z (relative intensity) = 289 (4) [M+], 170 (3), 141 (12), 119 (100), 91 (38). 
HR-MS (ESI-TOF) m/z calcd for C19H16NO2
+
 [M+H]+ 290.1176, found 290.1175. 
Intermolecular Competition Experiment 
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The intermolecular competition experiment was conducted using 2-(thiophen-3-yl)pyridine (1.8) 
(80 mg, 0.5 mmol, 1 equiv.), 1-iodo-4-methoxybenzene (1.2c) (234 mg, 1.0 mmol, 2.0 equiv.), 1-
fluoro-4-iodobenzene (1.2d) (222 mg, 1.0 mmol, 2.0 equiv.), [RuCl2(cod)]n (7 mg, 0.025 mmol, 
5 mol%), NaHCO3 (84 mg, 1.0 mmol), KOAc (10 mg, 20 mol%) in H2O (1 mL). The reaction mixture 
was pressurized with CO (30 bar) and stirred for 4 h at 120 °C. After cooling to 0 °C, the pressure was 
released and the autoclave was purged with N2 (2 x 10 bar). The reaction mixture was quenched with 
DCM. The phases were separated using a silicon impregnated filter paper. The supernatant was 
washed with DCM and the organic phase was removed under reduced pressure. A 
1
H-NMR spectrum 
was recorded after thorough drying. Integration of relevant peaks revealed the formation of the desired 
reaction products 3bf and 3bg in a 1.2 to 1.0 ratio after 7% conversion. 
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6.2.2 Experimental part to Chapter 2 
Synthesis of (S)-methyl 2-phenyl-2-(1,3,5-trioxan-2-yl)acetate (2.3a): 
 
A solution of methyl 2-phenyl-2-diazoacetate (2.1a) (89 mg, 0.5 mmol, 1.0 equiv.) in 1,2-
dichloroethane (5.0 mL) was added dropwise to a styrring solution of Rh2(S-DOSP)4 (9.5 mg, 
1.0 mol%) and 1,3,5-trioxane (450 mg, 5 mmol, 10 equiv.) in 1,2-dichloroethane (5.0 mL) at 0°C 
within 90 min. The reaction mixture was stirred for additional 30 min. Volatiles were removed under 
reduced pressure. Mesitylene (20 L) was added as internal standard. Purification by flash 
chromatography (n-pentane:EtOAc = 30:1 → 20:1) yielded the title compound (S)-2.3a (43 mg, 
0.18 mmol, 36%)as translucent oil. 
A racemic sample was prepared using Rh2(esp)2 (3.6 mg, 1.0 mol%) at 40°C under otherwise 
identical reaction conditions, yielding 2.3a (44 mg, 0.18 mmol, 37%). 
1
H NMR (300 MHz, Chloroform-d) δ 7.43 – 7.29 (m, 5H), 5.47 (d, J = 8.3 Hz, 1H), 5.24 (dd, J = 6.3, 
1.2 Hz, 1H), 5.16 (d, J = 6.3 Hz, 1H), 5.13 (dd, J = 6.3, 1.2 Hz, 1H), 5.00 (d, J = 6.3 Hz, 1H), 3.95 (d, 
J = 8.3 Hz, 1H), 3.70 (s, 3H). 
13
C NMR (75 MHz, Chloroform-d) δ 170.8 (CO2R), 133.1 (Cq), 128.9 (CH), 128.8 (CH), 128.3 (CH), 
101.8 (CH), 93.5 (CH2), 93.4 (CH2), 56.3 (CH), 52.5 (CH3). 
MS (GC-MS) m/z (relative intensity) = 316 (1) [M
+
], 230 (14), 196 (14), 134 (11), 89 (100). 
HRMS (EI, m/z) calcd. For C12H14O5 [M]
+
: 238.0836; found: 238.0830. 
IR (ATR, neat, cm
-1
): 2953 (w), 2862 (w), 1734 (s), 1434 (m), 1316 (m), 1215 (m), 1161 (s), 1136 (s), 
1060 (s), 990 (m), 971 (m), 953 (m), 735 (m), 700 (m), 529 (m). 
HPLC: Chiracel OD-H, n-heptane/i-PrOH = 99.7:0.3, 1.0 mL/min, 220 nm, 92% ee (tR 
(minor) = 15.6 min, tR (major) = 18.0 min). 
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Synthesis of (S)- and (R)-methyl 2-(4-bromophenyl)-2-(1,3,5-trioxan-2-yl)acetate (2.3b) 
 
A solution of methyl 2-(4-bromophenyl)-2-diazoacetate (2.1b) (126 mg, 0.5 mmol, 1.0 equiv.) in 
1,2-dichloroethane (5.0 mL) was added dropwise to a styrring solution of Rh2(S-DOSP)4 (9.5 mg, 
1.0 mol%) and 1,3,5-trioxane (450 mg, 5 mmol, 10 equiv.) in 1,2-dichloroethane (5.0 mL) at 0°C 
within 90 min. The reaction mixture was stirred for additional 30 min. Volatiles were removed under 
reduced pressure. Mesitylene (20 L) was added as internal standard. Purification by flash 
chromatography (n-pentane:EtOAc = 30:1 → 20:1) yielded the title compound (S)-2.3b (67 mg, 
0.21 mmol, 42%) as translucent oil. Recrystallization from MeOH afforded an analytically pure 
sample. 
A racemic sample was prepared using Rh2(esp)2 (3.6 mg, 1.0 mol%) at 40°C under otherwise 
identical reaction conditions, yielding 2.3b (86 mg, 0.27 mmol). 
m.p.: 114 °C (recrystallized from MeOH) 
1
H NMR (300 MHz, Chloroform-d) δ 7.47 (d, J = 8.5 Hz, 2H), 7.26 (d, J = 8.4 Hz, 2H), 5.42 (d, 
J = 8.0 Hz, 1H), 5.23 (dd, J = 6.3, 1.2 Hz, 1H), 5.16 – 5.11 (m, 2H), 5.00 (d, J = 6.3 Hz, 1H), 3.90 (d, 
J = 8.0 Hz, 1H), 3.70 (s, 3H). 
13
C NMR (75 MHz, Chloroform-d) δ 170.4 (CO2R), 132.1 (Cq), 132.0 (CH), 130.7 (CH), 122.5 (Cq), 
101.4 (CH), 93.5 (CH2), 93.4 (CH2), 55.7 (CH), 52.6 (CH3). 
MS (GC-MS) m/z (relative intensity) = 316 (1) [M
+
], 228 (14), 196 (14), 169 (9), 134 (11), 89 (100). 
HRMS (EI, m/z) calcd. For C12H13O5Br [M]
+
: 315.9941; found: 315.9948. 
IR (ATR, neat, cm
-1
): 3013 (w), 2958 (w), 2884 (w), 1736 (s), 1488 (m), 1210 (m), 1136 (s), 1054 (s), 
1009 (s), 988 (s), 956 (m), 943 (s), 828 (m), 767 (m), 542 (s). 
(S)-2.3b: 
HPLC: Chiracel OD-H, n-heptane/i-PrOH = 99:1, 0.5 mL/min, 220 nm, 95% ee (tR 
(minor) = 20.5 min, tR (major) = 26.0 min). 
[]28 = -41.28° (c = 1.00, CHCl3) 
(R)-2.3b: 
HPLC: Chiracel OD-H, n-heptane/i-PrOH = 99.5:0.5, 1.0 mL/min, 220 nm, 99% ee (tR 
(major) = 8.83 min). 
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Synthesis of (S)-ethyl 2-(4-bromophenyl)-2-(1,3,5-trioxan-2-yl)acetate (2.3c) 
 
A solution of ethyl 2-(4-bromophenyl)-2-diazoacetate (2.1c) (135 mg, 0.5 mmol, 1.0 equiv.) in 1,2-
dichloroethane (5.0 mL) was added dropwise to a styrring solution of Rh2(R-DOSP)4 (9.5 mg, 
1.0 mol%) and 1,3,5-trioxane (450 mg, 5 mmol, 10 equiv.) in 1,2-dichloroethane (5.0 mL) at ambient 
temperature within 90 min. The reaction mixture was stirred for additional 30 min. Volatiles were 
removed under reduced pressure. Mesitylene (20 L) was added as internal standard. Purification by 
flash chromatography (n-pentane:EtOAc = 30:1 → 20:1) yielded the title compound (R)-2.3c (63 mg, 
0.19 mmol, 38%) as translucent oil. Recrystallization from MeOH afforded a colorless solid. 
A racemic sample was prepared using Rh2(esp)2 (3.6 mg, 1.0 mol%) at 40°C under otherwise 
identical reaction conditions, yielding 2.3c (53 mg, 0.16 mmol, 32%). 
m.p.: 148-149 °C (recrystallized from MeOH) 
1
H NMR (300 MHz, Chloroform-d) δ 7.47 (d, J = 8.5 Hz, 2H), 7.26 (d, J = 8.5 Hz, 2H), 5.41 (d, 
J = 8.0 Hz, 1H), 5.23 (dd, J = 6.3, 1.2 Hz, 1H), 5.16 – 5.11 (m, 2H), 5.00 (d, J = 6.3 Hz, 1H), 4.25 – 
4.15 (m, 2H), 3.87 (d, J = 8.1 Hz, 1H), 1.22 (t, J = 7.1 Hz, 3H). 
13
C NMR (75 MHz, Chloroform-d) δ 169.8 (-CO2R), 132.1 (Cq), 131.8 (CH), 130.6 (CH), 122.3 (Cq), 
101.4 (CH), 93.4 (CH2), 93.2 (CH2), 61.5 (CH2), 55.7 (CH), 14.0 (CH3). 
MS (GC-MS) m/z (relative intensity) = 332 (2) [M
+
], 256 (4), 244 (12), 198 (14), 169 (13), 89 (100). 
HRMS (EI, m/z) calcd. For C12H13O5Br [M]
+
: 315.9941; found: 315.9948. 
HPLC: Chiracel OD-H, n-heptane/i-PrOH = 99:1, 0.5 mL/min, 220 nm, 95% ee (tR 
(minor) = 20.5 min, tR (major) = 25.9 min). 
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Empirical formula  C13H15BrO5 
Formula weight  331.16 
Temperature  150(2) K 
Wavelength  0.71073 Å 
Crystal system  Orthorhombic 
Space group  P212121 
Unit cell dimensions a = 5.7276(3) Å = 90°. 
 b = 7.9566(3) Å = 90°. 
 c = 30.6039(13) Å  = 90°. 
Volume 1394.69(11) Å
3 
Z 4 
Density (calculated) 1.577 Mg/m
3 
Absorption coefficient 2.960 mm-1 
F(000) 672 
Crystal size 0.43 x 0.38 x 0.08 mm
3 
Theta range for data collection 2.65 to 28.00°. 
Index ranges -7<=h<=7, -5<=k<=10, -38<=l<=40 
Reflections collected 19233 
Independent reflections 3372 [R(int) = 0.0321] 
Completeness to theta = 28.00° 99.9 %  
Max. and min. transmission 0.789 and 0.361 
Refinement method Full-matrix least-squares on F
2
 
Data / restraints / parameters 3372 / 0 / 173 
Goodness-of-fit on F
2
 1.070 
Final R indices [I>2sigma(I)] R1 = 0.0240, wR2 = 0.0514 
R indices (all data) R1 = 0.0268, wR2 = 0.0525 
Absolute structure parameter 0.002(7) 
Largest diff. peak and hole 0.384 and -0.409 e
.
Å
-3
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Synthesis of (S)-methyl 2-(4-fluorophenyl)-2-(1,3,5-trioxan-2-yl)acetate (2.3d) 
 
A solution of methyl 2-(4-fluorophenyl)-2-diazoacetate (2.1d) (97 mg, 0.5 mmol, 1.0 equiv.) in 1,2-
dichloroethane (5.0 mL) was added dropwise to a styrring solution of Rh2(S-DOSP)4 (9.5 mg, 
1.0 mol%) and 1,3,5-trioxane (450 mg, 5 mmol, 10 equiv.) in 1,2-dichloroethane (5.0 mL) at 0°C 
within 90 min. The reaction mixture was stirred for additional 30 min. Volatiles were removed under 
reduced pressure. Mesitylene (20 L) was added as internal standard. Purification by flash 
chromatography (n-pentane:EtOAc = 30:1) yielded the title compound (S)-2.3d (53 mg, 0.21 mmol, 
41%) as translucent oil. 
A racemic sample was prepared using Rh2(esp)2 (3.6 mg, 1.0 mol%) at 40°C under otherwise 
identical reaction conditions, yielding 2.3d (70 mg, 0.28 mmol). 
1
H NMR (300 MHz, Chloroform-d) δ 7.36 (dd, J = 8.8, 5.3 Hz, 2H), 7.03 (t, J = 8.7 Hz, 2H), 5.41 (d, 
J = 8.1 Hz, 1H), 5.23 (dd, J = 6.2, 1.4 Hz, 1H), 5.14 (dd, J = 6.3, 1.4 Hz, 2H), 5.01 (d, J = 6.3 Hz, 
1H), 3.92 (d, J = 8.1 Hz, 1H), 3.70 (s, 3H). 
13
C NMR (75 MHz, Chloroform-d) δ 170.7 (CO), 162.7 (d, 2JC-F = 247.0 Hz, Cq), 130.6 (d, 
3
JC-F = 8.1 
Hz, CH), 128.8 (d, 
4
JC-F = 3.3 Hz, Cq), 115.8 (d, 
3
JC-F = 21.6 Hz, CH), 101.6 (CH), 93.5 (CH2), 93.4 
(CH2), 55.4 (CH3), 52.5 (CH). 
19
F NMR (282 MHz, Chloroform-d) δ -113.6 (m). 
MS (GC-MS) m/z (relative intensity) = 256 (2) [M
+
], 225 (1), 168 (44), 136 (47), 109 (75), 89 (100), 
61 (36). 
HRMS (EI, m/z) calcd. For C12H13O5F1 [M]
+
: 256.0742; found: 256.0743. 
[𝜶]𝑫
𝟐𝟐 = -45.25° (c = 1.5, CH2Cl2) 
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Synthesis of (R)-methyl 2-(4-(trifluoromethyl)phenyl)-2-(1,3,5-trioxan-2-yl)acetate (2.3e)
 
A solution of methyl 2-(4-trifluoromethylphenyl)-2-diazoacetate (2.1e) (122 mg, 0.5 mmol, 
1.0 equiv.) in 1,2-dichloroethane (5.0 mL) was added dropwise to a styrring solution of Rh2(R-DOSP)4 
(9.5 mg, 1.0 mol%) and 1,3,5-trioxane (450 mg, 5 mmol, 10 equiv.) in 1,2-dichloroethane (5.0 mL) at 
0°C within 90 min. The reaction mixture was stirred for additional 30 min. Volatiles were removed 
under reduced pressure. Mesitylene (20 L) was added as internal standard. Purification by flash 
chromatography (n-pentane:EtOAc = 20:1) yielded the title compound (R)-2.3e (55 mg, 0.18 mmol, 
36%) as translucent oil. Recrystallization from MeOH afforded a colorless solid. 
A racemic sample was prepared using Rh2(esp)2 (3.6 mg, 1.0 mol%) at 40°C under otherwise 
identical reaction conditions, yielding 2.3e (67 mg, 0.22 mmol, 44%). 
m.p.: 74 °C 
1
H NMR (300 MHz, Chloroform-d) δ 7.60 (d, J = 8.0 Hz, 2H), 7.51 (d, J = 8.2 Hz, 2H), 5.47 (d, 
J = 7.9 Hz, 1H), 5.24 (dd, J = 6.3, 1.3 Hz, 1H), 5.15 (d, J = 6.3 Hz, 1H), 5.13 (dd, J = 6.3, 1.3 Hz, 
1H), 5.01 (d, J = 6.3 Hz, 1H), 4.01 (d, J = 7.9 Hz, 1H), 3.71 (s, 3H). 
13
C NMR (75 MHz, Chloroform-d) δ 170.1(Cq) , 137.0 (Cq), 130.5 (q, 
2
JC‒F = 32.6 Hz, Cq), 129.5 , 125.7 
(q, 
3
JC‒F = 3.8 Hz, CH), 124.1 (q, 
1
JC‒F = 272.1 Hz), 101.4 (CH), 93.5 (CH2), 93.4 (CH2), 56.1 (CH3), 
52.7 (CH). 
19
F NMR (282 MHz, Chloroform-d) δ -62.3 (s). 
MS (GC-MS) m/z (relative intensity) = 247 (2) [M
+
], 218 (24), 186 (39), 159 (29), 127 (10), 89 (100), 
61 (37). 
HRMS (EI, m/z) calcd. For C11H10O3F3 [M]
+
: 247.0577; found: 247.0582. 
IR (ATR, neat, cm
-1
): 2961 (w), 2861 (w), 1732 (m), 1320 (s), 1159 (s), 1110 (s), 1063 (s), 1018 (m), 
1992 (m), 944 (m), 838 (m), 761 (w), 600 (w). 
HPLC: Cellulose2, n-heptane/EtOH = 90:10, 0.3 mL/min, 220 nm, 94% ee (tR (major) = 10.2 min, tR 
(minor) = 12.5 min). 
[𝜶]𝑫
𝟐𝟐 = +36.74° (c = 2.5, CHCl3) 
Synthesis of (R)-methyl 2-(4-((methylsulfonyl)oxy)phenyl)-2-(1,3,5-trioxan-2-yl)acetate (2.3f) 
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A solution of methyl 2-(4- methylsulfonylphenyl)-2-diazoacetate (2.1f) (135 mg, 0.5 mmol, 
1.0 equiv.) in 1,2-dichloroethane (5.0 mL) was added dropwise to a styrring solution of Rh2(R-DOSP)4 
(9.5 mg, 1.0 mol%) and 1,3,5-trioxane (450 mg, 5 mmol, 10 equiv.) in 1,2-dichloroethane (5.0 mL) at 
0°C within 90 min. The reaction mixture was stirred for additional 30 min. Volatiles were removed 
under reduced pressure. Mesitylene (20 L) was added as internal standard. Purification by flash 
chromatography (n-pentane:EtOAc = 10:1 → 5:1 → 2:1) yielded the title compound (R)-2.3f 
(63 mmg, 0.19 mmol, 38%) as colorless solid. Recrystallization from MeOH afforded a colorless 
solid. 
A racemic sample was prepared using Rh2(esp)2 (3.6 mg, 1.0 mol%) at 40°C under otherwise 
identical reaction conditions, yielding 2.3f (86 mg, 0.26 mmol, 52%). 
m.p.: 144 °C (recrystallized from MeOH) 
1
H NMR (300 MHz, Chloroform-d) δ 7.44 (d, J = 8.7 Hz, 2H), 7.25 (d, J = 8.7 Hz, 2H), 5.42 (d, 
J = 8.0 Hz, 1H), 5.22 (d, J = 6.3 Hz, 1H), 5.14 (d, J = 6.3 Hz, 1H), 5.13 (d, J = 6.3 Hz, 1H), 5.00 (d, 
J = 6.3 Hz, 1H), 3.95 (d, J = 7.9 Hz, 1H), 3.70 (s, 3H), 3.14 (s, 3H). 
13
C NMR (75 MHz, Chloroform-d) δ 170.1 (CO2), 148.8 (Cq), 132.2 (Cq), 130.5 (CH), 122.1 (CH), 
101.2 (CH), 93.3 (CH2), 93.2 (CH2), 55.4 (CH3), 52.5 (CH), 37.4 (CH3). 
MS (GC-MS) m/z (relative intensity) = 332 (1) [M
+
], 256 (16), 244 (60), 165 (100), 133 (42), 89 (64). 
HRMS (EI, m/z) calcd. For C13H16O8S1 [M]
+
: 332.0560; found: 332.0569. 
IR (ATR, neat, cm
-1
): 3018 (w), 3001 (w), 2877 (w), 1722 (m), 1508 (w), 1366 (m), 1144 (s), 1061 
(m), 969 (m), 876 (s), 789 (m), 523 (s). 
[𝜶]𝑫
𝟐𝟐 = +42.63° (c = 1.0, CH2Cl2) 
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Synthesis of (S)-methyl 2-(4-((tosylsulfonyl)oxy)phenyl)-2-(1,3,5-trioxan-2-yl)acetate (2.3g) 
 
A solution of methyl 2-(4-tosylsulfonylphenyl)-2-diazoacetate (173 mg, 0.5 mmol, 1.0 equiv.) in 
1,2-dichloroethane (5.0 mL) was added dropwise to a styrring solution of Rh2(S-DOSP)4 (9.5 mg, 
1.0 mol%) and 1,3,5-trioxane (450 mg, 5 mmol, 10 equiv.) in 1,2-dichloroethane (5.0 mL) at 0°C 
within 90 min. The reaction mixture was stirred for additional 30 min. Volatiles were removed under 
reduced pressure. Mesitylene (20 L) was added as internal standard. Purification by flash 
chromatography (n-pentane:EtOAc = 20:1) yielded the title compound (S)-2.3g (110 mg, 0.27 mmol, 
54%) as colorless solid. Recrystallization from MeOH afforded a colorless solid. 
A racemic sample was prepared using Rh2(esp)2 (3.6 mg, 1.0 mol%) at 40°C under otherwise 
identical reaction conditions, yielding 2.3g (124 mg, 0.31 mmol, 61%). 
m.p.: 112-113 °C 
1
H NMR (300 MHz, Chloroform-d) δ 7.71 (d, J = 8.3 Hz, 2H), 7.35 – 7.27 (m, 4H), 6.95 (d, J = 8.6 
Hz, 2H), 5.37 (d, J = 8.0 Hz, 1H), 5.20 (d, J = 6.5, 1.2 Hz, 1H), 5.11 (d, J = 6.2 Hz, 1H), 5.09 (d, 
J = 6.5, 1.2 Hz, 1H), 4.98 (d, J = 6.3 Hz, 1H), 3.89 (d, J = 8.0 Hz, 1H), 3.68 (s, 2H), 2.44 (s, 3H). 
13
C NMR (75 MHz, Chloroform-d) δ 170.3 (Cq), 149.4 (Cq), 145.5 (Cq), 132.6 (Cq), 132.0 (Cq), 130.3 
(CH), 129.9 (CH), 128.5 (CH), 122.6 (CH), 101.4 (CH), 93.4 (CH2), 93.3 (CH2), 55.6 (CH3), 52.6 
(CH), 21.8 (CH3). 
MS (GC-MS) m/z (relative intensity) = 408 (1) [M
+
], 332 (15), 320 (41), 289 (5), 165 (100), 137 (21), 
91 (43). 
HRMS (EI, m/z) calcd. For C19H20O8S1 [M]
+
: 408.0873; found: 408.0877. 
IR (ATR, neat, cm
-1
): 2958 (w), 2871 (w), 1733 (m), 1470 (w), 1367 (m), 1177 (m), 1153 (s), 10681 
(m), 862 (s), 657 (m), 550 (s). 
[𝜶]𝑫
𝟐𝟐 = -31.97° (c = 3.5, CHCl3) 
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Synthesis of (S)-Methyl 2-(4-(cyclopropanecarbonyl)phenyl)-2-(1,3,5-trioxan-2-yl)acetate 
(2.3h) 
 
A solution of methyl 2-(4-(cyclopropanecarbonyl)phenyl)-2-diazoacetate (2.1h) (73 mg, 0.3 mmol, 
1.0 equiv.) in 1,2-dichloroethane (5.0 mL) was added dropwise to a styrring solution of Rh2(S-DOSP)4 
(5.6 mg, 1.0 mol%) and 1,3,5-trioxane (286 mg, 3.18 mmol, 10 equiv.) in 1,2-dichloroethane (5.0 mL) 
at 0°C within 90 min. The reaction mixture was stirred for additional 30 min. Volatiles were removed 
under reduced pressure. Mesitylene (20 L) was added as internal standard. Purification by flash 
chromatography (n-pentane:EtOAc = 10:1 → 7:1 → 5:1) yielded the title compound 2.3h (21 mg, 
0.07 mmol, 23%) as translucent oil. 
A racemic sample was prepared using 2-(4-(cyclopropanecarbonyl)phenyl)-2-diazoacetate (110 mg, 
0.45 mmol, 1.0 equiv.) and Rh2(esp)2 (3.6 mg, 1.0 mol%) at 40°C under otherwise identical reaction 
conditions, yielding 2.3h (47 mg, 0.153 mmol, 34%). 
1
H NMR (300 MHz, Chloroform-d) δ 7.98 (d, J = 8.3 Hz, 2H), 7.49 (d, J = 8.3 Hz, 2H), 5.49 (d, 
J = 8.0 Hz, 1H), 5.23 (dd, J = 6.1, 1.3 Hz, 1H), 5.15 (d, J = 6.3 Hz, 1H), 5.12 (dd, J = 6.4, 1.3 Hz, 
1H), 5.00 (d, J = 6.3 Hz, 1H), 4.01 (d, J = 8.0 Hz, 1H), 3.70 (s, 3H), 2.64 (tt, J = 7.9, 4.5 Hz, 1H), 
1.22 (d, J = 7.2 Hz, 0H), 1.22 (dt, J = 4.5, 3.3 Hz, 2H), 1.03 (dt, J = 7.9, 3.3 Hz, 2H).  
13
C NMR (75 MHz, Chloroform-d) δ 200.1 (Cq), 170.2 (Cq), 137.8 (Cq), 129.2 (CH), 128.4 (CH), 
101.4 (CH), 93.5 (CH2), 93.4 (CH2), 56.2 (CH), 52.6 (CH3), 17.3 (CH), 11.8 (CH2). 
MS (GC-MS) m/z (relative intensity) = 306 (3) [M
+
], 276 (4), 218 (63), 186 (15), 145 (46), 89 (100), 
61 (29). 
HRMS (EI, m/z) calcd. For C16H18O6 [M+H]
+
: 307.1176; found: 307.1179. 
HPLC: Cellulose2, n-heptane/EtOH = 95:5, 1.0 mL/min, 220 nm, 91% ee (tR (minor) = 15.30 min, tR 
(major) = 20.32 min). 
[𝜶]𝑫
𝟐𝟏 = -47.85° (c = 0.5, i-PrOH) 
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Synthesis of (S)-methyl 2-(3,4-dichlorophenyl)-2-(1,3,5-trioxan-2-yl)acetate (2.3i) 
 
A solution of methyl 2-(3,4-dichlorophenyl)-2-diazoacetate (2.1i) (123 mg, 0.5 mmol, 1.0 equiv.) in 
1,2-dichloroethane (5.0 mL) was added dropwise to a styrring solution of Rh2(S-DOSP)4 (9.5 mg, 
1.0 mol%) and 1,3,5-trioxane (450 mg, 5 mmol, 10 equiv.) in 1,2-dichloroethane (5.0 mL) at 0°C 
within 90 min. The reaction mixture was stirred for additional 30 min. Volatiles were removed under 
reduced pressure. Mesitylene (20 L) was added as internal standard. Purification by flash 
chromatography (n-pentane:EtOAc = 20:1) yielded the title compound (S)-3i (54 mg, 0.18 mmol, 
35%) as translucent oil. Recrystallization from MeOH afforded a colorless solid. 
A racemic sample was prepared using Rh2(esp)2 (3.6 mg, 1.0 mol%) at 40°C under otherwise 
identical reaction conditions, yielding 2.3i (80 mg, 0.26 mmol, 52%). 
1
H NMR (300 MHz, Chloroform-d) δ 7.49 (d, J = 2.1 Hz, 1H), 7.41 (d, J = 8.3 Hz, 1H), 7.22 (dd, 
J = 8.3, 2.1 Hz, 1H), 5.40 (d, J = 7.8 Hz, 1H), 5.22 (dd, J = 6.3, 1.2 Hz, 1H), 5.18 – 5.08 (m, 2H), 
5.01 (d, J = 6.3 Hz, 1H), 3.89 (d, J = 7.8 Hz, 1H), 3.71 (s, 3H). 
13
C NMR (75 MHz, Chloroform-d) δ 170.0 (CO), 133.1 (Cq), 132.8 (Cq), 132.6 (Cq), 131.0 (Cq), 130.6 
(CH), 128.6 (CH), 101.1 (CH), 93.4 (CH2), 93.3 (CH2), 55.3 (CH), 52.7 (CH3). 
MS (GC-MS) m/z (relative intensity) = 306 (1) [M
+
], 247 (1), 218 (23), 186 (25), 159 (19), 123 (22), 
89 (100). 
HPLC: Chiracel OD-H, n-heptane/i-PrOH = 99.5:0.5, 1.0 mL/min, 220 nm, 77% ee (tR 
(minor) = 13.1 min, tR (major) = 16.3 min). 
[𝜶]𝑫
𝟐𝟖 = -23.14° (c = 1.25, CHCl3) 
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Synthesis of (R)-methyl 2-(3-methoxyphenyl)-2-(1,3,5-trioxan-2-yl)acetate (2.3j) 
 
A solution of methyl 2-(3-methoxyphenyl)-2-diazoacetate (2.1j) (103 mg, 0.5 mmol, 1.0 equiv.) in 
1,2-dichloroethane (5.0 mL) was added dropwise to a styrring solution of Rh2(R-DOSP)4 (9.5 mg, 
1.0 mol%) and 1,3,5-trioxane (450 mg, 5 mmol, 10 equiv.) in 1,2-dichloroethane (5.0 mL) at 0°C 
within 90 min. The reaction mixture was stirred for additional 30 min. Volatiles were removed under 
reduced pressure. Mesitylene (20 L) was added as internal standard. Purification by flash 
chromatography (n-pentane:EtOAc = 20:1 → 10:1) yielded the title compound (R)-2.3j (27 mg, 
0.10 mmol, 20%) as translucent oil. 
A racemic sample was prepared using Rh2(esp)2 (3.6 mg, 1.0 mol%) at 40°C under otherwise 
identical reaction conditions, yielding 2.3j (64 mg, 0.24 mmol, 48%). 
1
H NMR (300 MHz, Chloroform-d) δ 7.63 – 7.51 (m, 1H), 7.32 – 7.21 (m, 2H), 7.17 (ddd, J = 8.3, 
2.6, 1.0 Hz, 1H), 5.77 (d, J = 8.3 Hz, 1H), 5.55 (dd, J = 6.3, 1.2 Hz, 1H), 5.47 (d, J = 6.2 Hz, 1H), 
5.45 (dd, J = 6.3, 1.2 Hz, 1H), 5.32 (d, J = 6.4 Hz, 1H), 4.22 (d, J = 8.3 Hz, 1H), 4.12 (s, 3H), 4.01 (s, 
3H). 
13
C NMR (75 MHz, Chloroform-d) δ 170.7 (Cq), 159.8 (Cq), 134.5 (Cq), 129.8 (CH), 121.2 (CH), 
114.7 (CH), 113.6 (CH), 101.7 (CH), 93.6 (CH2), 93.4 (CH2), 56.3 (CH), 55.3 (CH3), 52.5 (CH3). 
MS (GC-MS) m/z (relative intensity) = 268 (8) [M
+
], 192 (63), 180 (22), 148 (100), 121 (29), 89 (30), 
61 (28). 
HRMS (EI, m/z) calcd. For C13H16O6 [M]
+
: 268.0941; found: 268.0940. 
HPLC: Chiracel OD-H, n-heptane/i-PrOH = 99.5:0.5, 1.0 mL/min, 220 nm, 76% ee (tR 
(major) = 29.8 min, tR (minor) = 34.4 min). 
[𝜶]𝑫
𝟐𝟖 = +53.5° (c = 1.0, CHCl3) 
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Synthesis of (S)-ethyl 2-ethoxy-4-(2-methoxy-2-oxo-1-(1,3,5-trioxan-2-yl)ethyl)benzoate (2.3k) 
 
A solution of methyl ethyl 2-ethoxy-4-(2-methoxy-2-oxoethyl)-2-diazoacetate (2.1k) (146 mg, 
0.5 mmol, 1.0 equiv.) in 1,2-dichloroethane (5.0 mL) was added dropwise to a styrring solution of 
Rh2(S-DOSP)4 (9.5 mg, 1.0 mol%) and 1,3,5-trioxane (450 mg, 5 mmol, 10 equiv.) in 1,2-
dichloroethane (5.0 mL) at 0°C within 90 min. The reaction mixture was stirred for additional 30 min. 
Volatiles were removed under reduced pressure. Mesitylene (20 L) was added as internal standard. 
Purification by flash chromatography (n-pentane:EtOAc = 20:1 → 10:1 → 5:1) yielded the title 
compound as (S)-2.3k (60 mg, 0.17 mmol, 34%) pale yellow oil. 
A racemic sample was prepared using Rh2(esp)2 (3.6 mg, 1.0 mol%) at 40°C under otherwise 
identical reaction conditions, yielding 2.3k (98 mg, 0.28 mmol, 55%). 
1
H NMR (300 MHz, Chloroform-d) δ 7.71 (d, J = 8.3 Hz, 1H), 7.00 – 6.92 (m, 2H), 5.42 (d, J = 8.1 
Hz, 1H), 5.22 (dd, J = 6.3, 1.2 Hz, 1H), 5.13 (d, J = 6.4 Hz, 1H), 5.10 (dd, J = 6.3, 1.2 Hz, 1H), 4.98 
(d, J = 6.4 Hz, 1H), 4.32 (q, J = 7.1 Hz, 2H), 4.11 (q, J = 7.0 Hz, 2H), 3.91 (d, J = 8.1 Hz, 1H), 3.69 
(s, 3H), 1.44 (t, J = 7.0 Hz, 3H), 1.34 (t, J = 7.1 Hz, 3H). 
13
C NMR (75 MHz, Chloroform-d) δ 170.2 (Cq), 166.2 (Cq), 158.5 (Cq), 138.3 (Cq), 131.7 (CH), 120.7 
(Cq), 120.5 (CH), 114.1 (CH), 101.4 (CH), 93.5 (CH2), 93.4 (CH2), 64.7 (CH2), 60.9 (CH2), 56.3 (CH), 
52.6 (CH3), 14.8 (CH3), 14.4 (CH3). 
MS (GC-MS) m/z (relative intensity) = 354 (6) [M
+
], 309 (22), 278 (69), 220 (100), 187 (13), 161 
(30), 89 (59). 
HRMS (EI, m/z) calcd. For C17H22O8 [M+H]
+
: 355.13874; found: 355.13879. 
IR (ATR, neat, cm
-1
): 2976 (w), 2866 (w), 1734 (m), 1611 (w), 1297 (m), 1267 (m), 1162 (s), 1114 
(s), 1067 (s), 947 (m), 746 (w). 
HPLC: Cellulose2, n-heptane/EtOH = 98:2, 0.8 mL/min, 220 nm, 67% ee (tR (minor) = 24.7 min, tR 
(major) = 32.5 min). 
[𝜶]𝑫
𝟐𝟐 = -35.9° (c = 1.0, CHCl3) 
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Synthesis of (S)-Methyl 2-(2,5-difluorophenyl)-2-(1,3,5-trioxan-2-yl)acetate (2.3l) 
 
A solution of methyl 2-(2,5-difluorophenyl)-2-diazoacetate (2.1l) (106 mg, 0.5 mmol, 1.0 equiv.) in 
1,2-dichloroethane (5.0 mL) was added dropwise to a styrring solution of Rh2(S-DOSP)4 (9.5 mg, 
1.0 mol%) and 1,3,5-trioxane (450 mg, 5 mmol, 10 equiv.) in 1,2-dichloroethane (5.0 mL) at 0°C 
within 90 min. The reaction mixture was stirred for additional 30 min. Volatiles were removed under 
reduced pressure. Mesitylene (20 L) was added as internal standard. Purification by flash 
chromatography (n-pentane:EtOAc = 20:1 → 10:1 → 5:1) yielded the title compound 2.3l (30 mg, 
0.11 mmol, 21%) as pale yellow oil. 
A racemic sample was prepared using Rh2(esp)2 (3.6 mg, 1.0 mol%) at 40°C under otherwise 
identical reaction conditions, yielding 3l (72 mg, 0.26 mmol, 53%). 
m.p.: 69-70 °C 
13
C NMR (75 MHz, Chloroform-d) δ 169.5 (Cq), 158.5 (dd, 
1
JC-F 242.3, 
4
JC-F = 2.4 Hz), 157.1 (dd, 
1
JC-F = 243.8, 
4
JC-F  = 2.5 Hz), 116.8 (dd, 
2
JC-F = 25.2, 
3
JC-F = 3.5 Hz, CH), 116.4 (dd, 
3
JC-F = 8.6, 
4
JC-F = 
3.6 Hz), 122.0 (dd, 
2
JC-F = 17.2, 
3
JC-F = 8.4 Hz), 116.4 (dd, J = 53.3, 8.7 Hz), 100.8 (d, J = 1.7 Hz), 
93.4 , 93.3 , 52.7, 48.2 , 49.2 – 46.7 (m). 
19
F NMR (282 MHz, Chloroform-d) δ -117.4 – -118.3 (m), -122.1 – -123.1 (m). 
MS (GC-MS) m/z (relative intensity) = 274 (1) [M
+
], 215 (2), 186 (40), 154 (63), 127 (62), 89 (100), 
61 (38). 
IR (ATR, neat, cm
-1
): 3008 (w), 2928 (w), 2823 (w), 1664 (m), 1381 (m), 1224 (w), 1096 (s), 991 (s), 
825 (m), 742 (m). 
HPLC: Chiracel OD-H, n-heptane/iPrOH = 99.5:0.5, 1.5 mL/min, 220 nm, 70% ee (tR 
(minor) = 11.4 min, tR (major) = 13.1 min). 
[𝜶]𝑫
𝟐𝟐 = -36.2° (c = 1.25, CHCl3) 
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Empirical formula  C12H12F2O5 
Formula weight  274.22 
Temperature  150(2) K 
Wavelength  0.71073 Å 
Crystal system  triclinic 
Space group  P1̅ 
Unit cell dimensions a = 7.9463(7) Å = 104.074(2)°. 
 b = 8.7658(8) Å = 104.446(2)°. 
 c = 10.3812(10) Å  = 112.083(2)°. 
Volume 601.39(10) Å
3 
Z 2 
Density (calculated) 1.514 Mg/m
3 
Absorption coefficient 0.137 mm
-1 
F(000) 284 
Crystal size 0.50 x 0.36 x 0.14 mm 
Theta range for data collection 2.19 to 28.00°. 
Index ranges -10<=h<=10, -11<=k<=11, -13<=l<=13 
Reflections collected 16835 
Independent reflections 2911 [R(int) = 0.0389] 
Completeness to theta = 28.00° 100.0 %  
Max. and min. transmission 1.000 and 0.855 
Refinement method Full-matrix least-squares on F
2
 
Data / restraints / parameters 2911 / 0 / 173 
Goodness-of-fit on F
2
 1.054 
Final R indices [I>2sigma(I)] R1 = 0.0412, wR2 = 0.1225 
R indices (all data) R1 = 0.0527, wR2 = 0.1358 
Largest diff. peak and hole 0.374 and -0.271 e
.
Å
-3
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Synthesis of (R)-methyl 2-(3,5-dimethoxyphenyl)-2-(1,3,5-trioxan-2-yl)acetate (2.3m) 
 
A solution of methyl 2-(3,5-dimethoxyphenyl)-2-diazoacetate (2.1m) (118 mg, 0.50 mmol, 
1.0 equiv.) in 1,2-dichloroethane (5.0 mL) was added dropwise to a styrring solution of Rh2(R-DOSP)4 
(9.5 mg, 1.0 mol%) and 1,3,5-trioxane (450 mg, 5 mmol, 10 equiv.) in 1,2-dichloroethane (5.0 mL) at 
0°C within 90 min. The reaction mixture was stirred for additional 30 min. Volatiles were removed 
under reduced pressure. Mesitylene (20 L) was added as internal standard. Purification by flash 
chromatography (n-pentane:EtOAc = 20:1 → 10:1) yielded the title compound as (R)-2.3m (26 mg, 
0.87 mmol, 17%) translucent oil. Recrystallization from MeOH afforded a colorless solid. 
A racemic sample was prepared using 1m (113 mg, 0.48 mol), Rh2(esp)2 (3.6 mg, 1.0 mol%) at 
40°C under otherwise identical reaction conditions, yielding 2.3m (80 mg, 0.27 mmol, 56%). 
m.p.: 101-102 °C 
1
H NMR (300 MHz, Chloroform-d) δ 6.53 (d, J = 2.3 Hz, 2H), 6.40 (dd, J = 2.3 Hz, 1H), 5.43 (d, 
J = 8.3 Hz, 1H), 5.22 (dd, J = 6.3, 1.2 Hz, 1H), 5.14 (m, 2H), 5.00 (d, J = 6.3 Hz, 1H), 3.85 (d, 
J = 8.3 Hz, 1H), 3.77 (s, 6H), 3.68 (s, 3H). 
13
C NMR (75 MHz, Chloroform-d) δ 170.5 (Cq), 160.9 (Cq), 135.0 (Cq), 107.0 (CH), 101.6 (CH2), 
100.1 (CH2), 56.4 (CH3), 55.4 (CH3), 52.4 (CH). 
MS (GC-MS) m/z (relative intensity) = 298 (29) [M
+
], 222 (97), 178 (100), 151 (28), 121 (18), 89 
(43). 
HRMS (EI, m/z) calcd. For C14H18O7 [M+H]
+
: 298.1047; found: 298.1041. 
IR (ATR, neat, cm
-1
): 2966 (w), 2864 (w), 1729 (m), 1597 (m), 1463 (w), 1323 (w), 1202 (m), 1161 
(s), 1137 (s), 1051 (s), 947 (m), 835 (m), 688 (m), 531 (m). 
HPLC: Cellulose2, n-heptane/iPrOH = 98:2, 1.0 mL/min, 220 nm, 53% ee (tR (major) = 25.25 min, tR 
(minor) = 29.07 min). 
[𝜶]𝑫
𝟐𝟐 = -17.0° (c = 0.5, CHCl3) 
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Synthesis of rac-methyl 2-(4-bromophenyl)-2-2,4,6-trimethyl-1,3,5-trioxan-2-yl)acetate (2.5) 
 
A solution of methyl 2-(4-bromophenyl)-2-diazoacetate (2.1b) (127 mg, 0.5 mmol, 1.0 equiv.) in 
1,2-dichloroethane (5.0 mL) was added dropwise to a styrring solution of Rh2(esp)2 (3.6 mg, 
1.0 mol%) and 1,3,5-trioxane (450 mg, 5 mmol, 10 equiv.) in 1,2-dichloroethane (5.0 mL) at 40°C 
within 90 min. The reaction mixture was stirred for additional 30 min. Volatiles were removed under 
reduced pressure. Mesitylene (20 L) was added as internal standard. Purification by flash 
chromatography (n-pentane:EtOAc = 40:1) yielded the title compound 2.5 (90 mg, 0.25 mmol, 50%) 
as colorless oil. 
1
H NMR (500 MHz, Chloroform-d) δ 7.44 (d, J = 8.5 Hz, 2H, H-3’, H-5’), 7.31 (d, J = 8.5 Hz, 2H, 
H-2’, H-6’), 5.56 (q, J = 5.0 Hz, 1H), 5.52 (q, J = 5.0 Hz, 1H), 4.88 (s, 3H, H-2), 1.43 (s, 3H, H-4), 
1.36 (d, J = 5.0 Hz, 3H), 1.34 (d, J = 5.0 Hz, 3H). 
13
C NMR (126 MHz, Chloroform-d) δ 170.2 (CO), 133.1 (Cq), 131.5 (CH), 131.2 (CH), 122.0 (Cq), 
100.9 (Cq), 93.0 (CH), 92.4 (CH), 52.2 (CH3), 50.6 (CH), 24.3 (CH3), 21.1 (CH3), 21.0 (CH3). 
MS (GC-MS) m/z (relative intensity) = 359 (0) [M
+
], 315 (1), 272 (5), 228 (56), 196 (17), 131 (48), 87 
(58), 43 (100). 
HRMS (EI, m/z) calcd. For C15H19BrO5 [M+Na]
+
: 381.0308; found: 381.0307. 
IR (ATR, neat, cm
-1
): 2995 (w), 2950 (w), 1738 (m), 1490 (m), 1391 (m), 1178 (s), 1094 (s), 979 (s), 
951 (m), 845 (m), 527 (m). 
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Synthesis of (S)-2-(4-bromophenyl)-2-(1,3,5-trioxan-2-yl)ethanol (2.6) 
 
(R)-methyl 2-(4-bromophenyl)-2-(1,3,5-trioxan-2-yl)acetate (2.3b) ( 200 mg, 0.63 mmol) was 
dissolved in THF (12 mL) and treated with a suspension of LiAlH4 (120 mg, 2 M in THF, 5 equiv.) at 
0°C. The conversion was monitored by TLC and judged complete after 30-45 min. The reaction 
mixture was quenched by dropwise addition of MeOH (2 mL), followed by a saturated, aqueous 
solution of NH4Cl (5 mL). The layers were separated and the aqueous layer was extracted with 
dichloromethane (3x15 mL). The combined organic layer were washed with brine and dried over 
Na2SO4. Purification by flash chromatography (n-pentane:EtOAc = 5:1 → 2:1) and drying under 
reduced pressure yielded the title compound 2.6 (164 mg, 0.57 mmol, 90%) as colorless solid. 
m.p.: 84-85 °C 
1
H NMR (500 MHz, Chloroform-d) δ 7.45 (d, J = 8.4 Hz, 2H, C-8, C-10), 7.17 (d, J = 8.4 Hz, 2H, C-
7, C-11), 5.27 (dd, J = 6.2, 1.2 Hz, 1H), 5.2 (dd, J = 6.3, 1.3 Hz, 1H), 5.2 (d, J = 5.0 Hz, 1H), 5.10 (d, 
J = 6.2 Hz, 1H), 5.05 (d, J = 6.3 Hz, 1H), 4.09 (ddd, J = 11.2, 7.0, 5.0 Hz, 1H, H-1b), 3.86 (ddd, 
J = 11.2, 7.3, 5.2, 2.1 Hz, 1H, H-1a), 3.13 (dt, J = 7.0, 5.0 Hz, 1H, H-2), 2.13 (dd, J = 7.3, 5.2 Hz, 1H, 
OH). 
13
C NMR (126 MHz, Chloroform-d) δ 136.4 (Cq, C-9), 131.8 (C-H, C-8, C-10), 130.7 (CH, C-7,C-
11), 121.6 (C-6), 103.2 (CH, C-3), 93.6 (C4/5), 93.5 (C4/5), 63.0 (CH2, C-1), 51.5 (CH, C-2). 
MS (GC-MS) m/z (relative intensity) = 288 (1) [M
+
+H], 229 (1), 212 (7), 198 (68), 182 (76), 169 
(87), 120 (38), 89 (100), 61 (70). 
HRMS (EI, m/z) calcd. For C11H13O4Br [M]
+
: 287.9992; found: 287.9992. 
IR (ATR, neat, cm
-1
): 3244 (w, OH), 2870 (w), 2855 (w), 1488 (m), 1392 (w), 1189 (m), 1160 (s), 
1123 (m), 1041 (s), 952 (s), 820 (m), 733 (m), 544 (m). 
HPLC: Chiralpak AD-H, n-heptane/EtOH = 90:10, 1.0 mL/min, 220 nm, 97% ee (tR 
(major) = 20.99 min, tR (minor) = 27.26 min). 
[𝜶]𝑫
𝟐𝟐 = +27.52° (c = 0.6, CHCl3) 
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Synthesis of (S)-2-(4-Bromophenyl)-N,N-dimethyl-2-(1,3,5-trioxan-2-yl)ethanamine (2.7) 
 
(S)-2-(4-bromophenyl)-2-(1,3,5-trioxan-2-yl)ethanol (2.6) (40 mg, 0.14 mmol) was dissolved in 
dichloromethane (2 mL) and cooled to 0 °C. Pyridine (0.1 L, 0.21 mmol, 1.5 equiv.) was added via 
syringe followed by dropwise addition of triflic anhydride (25 L, 0.15 mmol, 1.1 equiv.). The 
reaction mixture was stirred for 1 h at 0 °C; conversion was monitored by TLC. NaI (25 mg, 
0.16 mmol, 1.2 equiv.) was added followed by dimethylamine (2 M in THF, 0.35 mL, 5.0 equiv.). The 
resulting mixture was stirred for additional 90 min at 0 °C at which point full conversion was reached 
judged by TLC. The reaction mixture was quenched with H2O and extracted with dichloromethane 
(3 x 15 mL), combined organic layer were washed with sat. NaHCO3 (10 mL) and dried over Na2SO4. 
Purification by flash chromatography afforded 2.7 (31 mg, 0.1 mmol, 71%) as yellowish solid. 
m.p.: 84-85 °C 
1
H NMR (300 MHz, Chloroform-d) δ 7.43 (d, J = 8.4 Hz, 1H), 7.18 (d, J = 8.4 Hz, 1H), 5.19 (ddd, 
J = 6.2, 3.1, 1.2 Hz, 2H), 5.07 (d, J = 4.0 Hz, 1H), 5.04 (d, J = 6.3 Hz, 1H), 3.09 (ddd, J = 8.7, 6.2, 
4.0 Hz, 1H), 2.83 (dd, J = 12.5, 6.2 Hz, 1H), 2.66 (dd, J = 12.5, 8.7 Hz, 1H), 2.23 (s, 4H). 
13
C NMR (75 MHz, Chloroform-d) δ 137.7 (Cq), 131.5 (CH), 131.0 (CH), 121.2 (Cq), 102.7 (CH), 
93.5 (CH2), 93.4 (CH2), 59.5 (CH2), 47.7 (CH), 46.0 (CH3). 
MS (GC-MS) m/z (relative intensity) = 315 (0) [M
+
], 254 (1), 198 (1), 184 (2), 169 (3), 103 (4), 89 
(4), 58 (100). 
HRMS (ESI
+
, m/z) calcd. For C13H18BrNO3 [M+H]
+
: 316.0543; found: 316.0545. 
IR (ATR, neat, cm
-1
): 2943 (w), 2856 (w), 2782 (w), 1489 (m), 1378 (m), 1265 (m), 1164 (s), 1106 
(s), 1056 (s), 1011 (s), 930 (s), 854 (m), 524 (s). 
HPLC: Chiralpak OD-H, n-heptane/EtOH = 99:1, 1.0 mL/min, 220 nm, 94% ee (tR 
(major) = 20.99 min, tR (minor) = 27.26 min). 
[𝜶]𝑫
𝟐𝟓 = -23.3° (c = 0.5, CHCl3) 
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Synthesis of (S)-2-(4-bromophenyl)-2-(1,3,5-trioxan-2-yl)ethanol (2.8) 
 
(S)-2-(4-bromophenyl)-2-(1,3,5-trioxan-2-yl)ethanol (2.6) (84 mg, 0.29 mmol, 1.0 equiv.) was 
dissolved in THF (5 mL); NaH (60wt% in mineral oil, 35 mg, 0.87 mmol, 3 equiv.) and MeI (247 mg, 
108 µL, 6 equiv.) were added at 0 °C. The reaction mixture was stirred over night at ambient 
temperature. The reaction mixture was quenched with H2O and extracted with dichloromethane 
(3 x 15 mL), combined organic layer were washed with sat. NaHCO3 (10 mL) and dried over Na2SO4. 
Purification by flash chromatography (n-pentane/EtOAc = 2:1) afforded 2.8 (75 mg, 0.25 mmol, 85%) 
as colorless solid. 
1
H NMR (300 MHz, Chloroform-d) δ 7.44 (d, J = 8.4 Hz, 1H), 7.21 (d, J = 8.4 Hz, 1H), 5.20 (ddd, 
J = 6.1, 4.4, 1.2 Hz, 2H), 5.16 (d, J = 5.0 Hz, 1H), 5.06 (dd, J = 9.1, 6.4 Hz, 2H), 3.82 – 3.63 (m, 1H), 
3.31 (s, 3H), 3.14 (dt, J = 6.9, 5.3 Hz, 1H). 
13
C NMR (75 MHz, Chloroform-d) δ 136.9  (Cq), 131.5 (CH), 131.1 (CH), 121.3 (Cq), 101.7 (CH), 
93.5 (CH2), 93.5 (CH2), 71.8 (CH), 59.2 (CH3), 49.6 (CH3). 
MS (GC-MS) m/z (relative intensity) = 303 (1) [M
+
], 213 (6), 184 (54), 171 (13), 134 (32), 89 (100), 
61 (28). 
HRMS (ESI
+
, m/z) calcd. For C12H15O4Br [M+Na]
+
: 325.0046; found: 325.0048. 
Synthesis of (R)-methyl 2-(4-bromophenyl)-3-hydroxypropanoate (2.9) 
 
(R)-methyl 2-(4-bromophenyl)-2-(1,3,5-trioxan-2-yl)acetate (2.3b) (75 mg, 0.24 mmol, 1.0 equiv.) 
was dissolved in THF/H2O (1:1, 3 mL); NaBH4 (45 mg, 1.2 mmol, 5 equiv.) and LiOH (7 mg, 
0.3 mmol, 1.2 equiv.) were consecutively added at 0 °C. The reaction mixture was stirred for 3 hours 
at 0 °C. The reaction was quenched by addition of saturated aqueous NH4Cl solution (2 mL) and 
diluted with CH2Cl2 (3 mL). The aqueous phase was extracted with CH2Cl2 (3 x 3 mL). Phases were 
separated and the organic layer was dried over Na2SO4. Purification of the crude product by flash 
chromatography (n-pentane/EtOAc = 4:1, KMnO4-stain) yielded the title compound 2.9 (40 mg, 
0.154 mmol, 65%) as a colorless oil. 
Experimental section 
161 
 
1
H NMR (500 MHz, Chloroform-d) δ 7.47 (d, J = 8.4 Hz, 2H), 7.15 (d, J = 8.4 Hz, 2H), 4.10 (dd, 
J = 12.8, 10.1 Hz, 1H), 3.82 (dd, J = 12.9, 5.2 Hz, 1H), 3.81 (dd, J = 10.1, 5.2 Hz, 1H), 3.71 (s, 3H). 
13
C NMR (126 MHz, Chloroform-d) δ 173.3 (CO), 134.8 (Cq), 132.2 (CH), 130.1 (CH), 122.0 (Cq), 
64.5 (CH2), 53.4 (CH), 52.5 (CH3). 
MS (GC-MS) m/z (relative intensity) = 258 (3) [M
+
], 240 (3), 228 (100), 196 (37), 169 (17), 134 (27), 
120 (31), 89 (51). 
HRMS (HR(EI), m/z) calcd. For C10H11O3Br [M
+
]: 257.98861; found: 257.98813. 
IR (ATR, neat, cm
-1
): 3424 (w), 2950 (w), 2876 (w), 1734 (s), 1490 (m), 1436 (m), 1251 (w), 1199 
(w), 1167 (m), 1072 (m), 1011 (s). 
[𝜶]𝑫
𝟐𝟒 = -1.4° (c = 1.5, CHCl3) 
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6.2.3 Experimental part to Chapter 3 
Synthesis of (Z)-7-(methylsulfonyl)-9-(phenyl)-6,7-dihydro-1,3,5,7-trioxazonine (3.3a) 
 
Following general procedure E, 3.3a (103 mg, 0.36 mmol, 72%) was isolated as colorless solid. 
Purification was performed by flash chromatograohy (n-pentane:EtOAc = 20:1). 
1
H NMR (300 MHz, Chloroform-d) δ 7.47 – 7.41 (m, 2H, CH), 7.41 – 7.31 (m, 3H, CH), 6.51 (s, 1H, 
CH), 5.54 (s, 2H, CH2), 5.00 (s, 2H, CH2), 4.93 (s, 2H, CH2), 3.13 (s, 3H, CH3). 
13
C NMR (75 MHz, Chloroform-d) δ 142.5 (Cq), 133.4 (Cq), 128.9 (CH), 128.9 (CH), 125.9 (CH), 
113.8 (CH), 96.7 (CH2), 93.9 (CH2), 77.9 (CH2), 41.9 (CH3). 
MS (GC-MS) m/z (relative intensity) = 285 (13) [M
+
], 255 (8), 225 (6), 146 (100), 105 (78), 91 (83), 
77 (37). 
HRMS (ESI-TOF, m/z) calcd. For C12H15NSO5 [M+Na]
+
 calc.: 308.0563; found: 308.0566. 
IR (ATR, neat, cm
-1
): 2964 (w), 2936 (w), 2895 (w), 1343 (s), 1147 (s), 1100 (m), 1056 (s), 929 (s), 
773 (s), 697 (m), 509 (s). 
Synthesis of (Z)-7-(methylsulfonyl)-9-(p-tolyl)-6,7-dihydro-1,3,5,7-trioxazonine (3.3b) 
 
Following general procedure E, 3.3b (108 mg, 0.36 mmol, 72%) was isolated as colorless solid. 
Purification was performed by flash chromatograohy (n-pentane:EtOAc = 30:1). 
m.p.: 122-123 °C 
1
H NMR (300 MHz, Chloroform-d) δ 7.33 (d, J = 8.2 Hz, 2H, CH), 7.17 (d, J = 7.8 Hz, 1H, CH), 
6.45 (s, 1H, CH), 5.50 (s, 2H, CH2), 5.00 (s, 2H, CH2), 4.94 (s, 2H, CH2), 3.13 (s, 3H, CH3), 2.36 (s, 
3H, CH3). 
13
C NMR (75 MHz, Chloroform-d) δ 143.5 (Cq), 139.1 (Cq), 130.4 (Cq), 129.6 (CH), 126.0 (CH), 
113.2 (CH), 96.6 (CH2), 93.9 (CH2), 77.8 (CH2), 41.8 (CH3), 21.4 (CH3). 
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MS (GC-MS) m/z (relative intensity) = 299 (6) [M
+
], 269 (3), 160 (71), 119 (59), 105 (100), 91 (38). 
HRMS (ESI-TOF, m/z) calcd. For C13H17NSO5 [M]
+
 calc.: 299.0822; found: 299.0823. 
IR (ATR, neat, cm
-1
): 2956 (w), 2901 (w), 1332 (m), 1323 (m), 1145 (m), 1145 (s). 1109 (s), 1072 (s), 
927 (s), 814 (s), 767 (m), 516 (s). 
 
Empirical formula  C13H17NO5S 
Formula weight  299.33 
Temperature  150(2) K 
Wavelength  0.71073 Å 
Crystal system  triclinic 
Space group  P1̅ 
Unit cell dimensions a = 5.6464(2) Å = 71.157(1)°. 
 b = 11.2363(4) Å = 80.731(1)°. 
 c = 11.4977(4) Å  = 85.869(1)°. 
Volume 681.20(4) Å
3 
Z 2 
Density (calculated) 1.459 Mg/m
3 
Absorption coefficient 0.257 mm-1 
F(000) 316 
Crystal size 0.433 x 0.233 x 0.120 mm 
Theta range for data collection 1.892 to 27.996°. 
Index ranges -7<=h<=7, -14<=k<=14, -15<=l<=15 
Reflections collected 24709 
Independent reflections 3289 [R(int) = 0.0204] 
Completeness to theta = 25.242° 100.0 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.97 and 0.90 
Data / restraints / parameters 3289 / 0 / 183 
Goodness-of-fit on F
2
 1.065 
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Final R indices [I>2sigma(I)] R1 = 0.0305, wR2 = 0.0807 
R indices (all data) R1 = 0.0333, wR2 = 0.0835 
Largest diff. peak and hole 0.394 and -0.376 e
.
Å
-3
 
 
 
Synthesis of (Z)-7-(methylsulfonyl)-9-(p-anisyl)-6,7-dihydro-1,3,5,7-trioxazonine (3.3c) 
 
Following general procedure E, 3.3c (95 mg, 0.3 mmol, 60%) was isolated as colorless solid. 
Purification was performed by flash chromatograohy (n-pentane:EtOAc = 20:1 → 10:1). 
1
H NMR (300 MHz, Chloroform-d) δ 7.29 (d, 2H, CH), 6.84 (d, 2H, CH), 6.28 (s, 1H, CH), 5.38 (s, 
2H, CH2), 4.92 (d, J = 12,7 Hz, 4H, CH2), 3.76 (s, 3H, CH3), 3.05 (s, 3H, CH3). 
13
C NMR (75 MHz, Chloroform-d) δ 160.36, 144.50, 127.55, 125.33, 114.22, 112.47, 96.42, 93.69, 
78.09, 55.40, 41.66. 
MS (GC-MS) m/z (relative intensity) = 315 (10) [M
+
], 252 (19), 250 (13), 235 (11), 207 (21), 177 
(19), 176 (100), 175 (69).  
HRMS (EI, m/z) calcd. For C13H17NO6S1 [M]
+
: 316.3422; found: 316.0849.  
IR (ATR, neat, cm
-1
): 2962 (w), 2840 (w), 1683 (m), 1599 (s), 1511 (s), 1147 (s), 830 (w), 506 (m).  
Synthesis of (Z)-7-(methylsulfonyl)-9-(4-bromophenyl)-6,7-dihydro-1,3,5,7-trioxazonine (3.3d) 
 
Following general procedure E, 3.3d (108 mg, 0.36 mmol, 77%) was isolated as colorless solid. 
Purification was performed by flash chromatograohy (n-pentane:EtOAc = 20:1). 
m.p.: 141-142 °C 
1
H NMR (300 MHz, Chloroform-d) δ 7.49 (d, J = 8.7 Hz, 1H, CH), 7.30 (d, J = 8.7 Hz, 1H, CH), 
6.53 (s, 1H, CH), 5.56 (s, 2H, CH2), 5.01 (s, 2H, CH2), 4.90 (s, 2H, CH2), 3.13 (s, 3H, CH3). 
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13
C NMR (75 MHz, Chloroform-d) δ 140.4 (Cq), 132.6 (Cq), 132.1 (Cq), 127.3 (CH), 122.8 (CH), 
114.2 (CH), 96.9 (CH2), 94.0 (CH2), 77.8 (CH2), 42.0 (CH3). 
MS (GC-MS) m/z (relative intensity) = 363 (6) [M
+
], 333 (5), 303 (2), 224 (100), 183 (57), 169 (99), 
155 (33). 
HRMS (ESI-TOF, m/z) calcd. For C12H14BrNO5S [M]
+
: 303.0571; found: 303.0568. 
IR (ATR, neat, cm
-1
): 2961 (w), 2895 (w), 1670 (w), 1478 (w), 1341 (s), 1219 (m), 1145 (s), 1049 (s), 
998 (s), 969 (s), 904 (s), 832 (s). 812 (s), 512 (s), 475 (m). 
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Empirical formula  C12H14BrNO5S 
Formula weight  364.21 
Temperature  150(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P21/c 
Unit cell dimensions a = 16.4002(6) Å = 90°. 
 b = 6.0352(2) Å = 118.104(1)°. 
 c = 16.0983(6) Å  = 90°. 
Volume 1405.51(9) Å
3
 
Z 4 
Density (calculated) 1.721 Mg/m
3
 
Absorption coefficient 3.091 mm
-1
 
F(000) 736 
Crystal size 0.404 x 0.139 x 0.096 mm 
Theta range for data collection 2.531 to 27.998°. 
Index ranges -21<=h<=21, -7<=k<=7, -20<=l<=21 
Reflections collected 15921 
Independent reflections 3380 [R(int) = 0.0508] 
Completeness to theta = 25.242° 100.0 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.76 and 0.57 
Refinement method Full-matrix least-squares on F
2
 
Data / restraints / parameters 3380 / 0 / 182 
Goodness-of-fit on F
2
 1.030 
Final R indices [I>2sigma(I)] R1 = 0.0320, wR2 = 0.0623 
R indices (all data) R1 = 0.0538, wR2 = 0.0683 
Largest diff. peak and hole 0.499 and -0.506 e
.
Å
-3
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Synthesis of (Z)-7-(methylsulfonyl)-9-(4-chlorophenyl)-6,7-dihydro-1,3,5,7-trioxazonine (3.3e) 
 
Following general procedure E, 3.3e (108 mg, 0.36 mmol, 77%) was isolated as colorless solid. 
Purification was performed by flash chromatograohy (n-pentane:EtOAc = 20:1). 
1
H NMR (300 MHz, Chloroform-d) δ 7.29 (m, 4H), 6.45 (s, 1H), 5.49 (s, 2H), 4.94 (s, 2H), 4.84 (s, 
2H), 3.06 (s, 3H). 
13
C NMR (75 MHz, Chloroform-d) δ 140.54, 134.59, 132.04, 129.05, 127.01, 114.08, 96.79, 93.85, 
41.90. 
MS (GC-MS) m/z (relative intensity) = 319 (5) [M
+
], 180 (82), 139 (61), 125 (100), 111 (36).  
HRMS (EI, m/z) calcd. For C12H14NO5S1 [M]
+
: 319.0281; found: 319.0274. 
IR (ATR, neat, cm
-1
): 2975 (w), 2795 (w), 1636 (w), 1488 (m), 1325 (s), 1151 (s), 833 (m), 688 (w), 
511 (m).  
Synthesis of (Z)-9-(3-fluorophenyl)-7-(methylsulfonyl)-6,7-dihydro-1,3,5,7-trioxazonine (3.3f) 
 
Following general procedure E, 3.3f (121 mg, 0.4 mmol, 80%) was isolated as colorless solid. 
Purification was performed by flash chromatograohy (n-pentane:EtOAc = 20:1). 
m.p.: 118-119 °C 
1
H NMR (300 MHz, Chloroform-d) δ 7.33 (td, J = 8.0, 5.8 Hz, 1H, CH), 7.22 (ddd, J = 7.8, 1.7, 1.1 
Hz, 1H, CH), 7.15 – 7.09 (m, 1H, CH), 7.01 (tdd, J = 8.3, 2.6, 1.1 Hz, 1H, CH), 6.59 (s, 1H, CH), 5.59 
(d, J = 2.1 Hz, 2H, CH2), 5.02 (s, 2H, CH2), 4.92 (s, 2H, CH2), 3.13 (s, 3H, CH3). 
13
C NMR (75 MHz, Chloroform-d) δ 163.2 (d, 1JC-F = 246.3 Hz, Cq), 139.8 (d, 
4
JC-F = 2.7 Hz, Cq), 
136.2 (d, 
3
JC-F = 7.6 Hz, Cq), 130.5 (d, 
3
JC-F = 8.4 Hz, CH), 121.4 (d, 
4
JC-F = 2.9 Hz, CH), 115.6 (d, 
2
JC-
F = 21.4 Hz, CH), 114.7 (CH), 112.6 (d, 
2
JC-F = 23.1 Hz, CH), 97.0 (CH2), 94.1 (CH2), 77.8 (CH2), 
42.0 (CH3). 
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19
F NMR (282 MHz, Chloroform-d) δ -111.9 (dd, J = 9.5, 6.0 Hz). 
MS (GC-MS) m/z (relative intensity) = 303 (3) [M
+
], 273 (4), 164 (89), 123 (53), 109 (100), 95 (42). 
HRMS (ESI-TOF, m/z) calcd. For C12H14NFSO5 [M]
+
: 303.0571; found: 303.0568. 
IR (ATR, neat, cm
-1
): 3015 (w), 2925 (w), 1361 (m), 1347 (m), 1146 (s), 1052 (m), 968 (m), 906 8s), 
795 8m), 768 (s). 508 (s). 
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6.2.4 Experimental part to Chapter 4 
Synthesis of methyl 2-(4-bromophenyl)-2,3,3-trimethoxypropanoate (4.3a) 
 
Following general procedure F, the title compound 4.3a (123 mg, 0.33 mmol, 83%) was isolated as 
colorless solid. Purification was performed by flash chromatograohy (n-pentane:EtOAc = 20:1). 
m.p.: 83 °C 
1
H NMR (300 MHz, Chloroform-d) δ 7.48 (d, J = 8.9 Hz, 1H, CH), 7.41 (d, J = 8.9 Hz, 1H, CH), 
4.78 (s, 1H, CH3), 3.83 (s, 3H, CH3), 3.50 (s, 3H, CH3), 3.41 (s, 3H, CH3), 3.37 (s, 3H, CH3). 
13
C NMR (75 MHz, Chloroform-d) δ 170.3 (CO2R), 134.0 (Cq), 130.9 (CH), 130.1 (CH), 122.6 (Cq), 
108.4 (CH), 87.0 (Cq), 58.6 (CH3), 58.0 (CH3), 54.7 (CH3), 52.5 (CH3). 
MS (GC-MS) m/z (relative intensity) = 301 (1) [M
+
-31], 275 (2), 201 (7), 183 (10), 155 (5), 105 (3), 
75 (100). 
HRMS (ESI-TOF, m/z) calcd. For C13H17Br2O2 [M+Na]
+
: 355.01516; found: 355.01527. 
IR (ATR, neat, cm
-1
): 2956 (w), 2935 (w), 1741 (s), 1226 (m), 1175 (m), 1097 (m), 1076 (s), 1008 
(m), 975 (m), 910 (m), 800 (m). 
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Empirical formula  C13H17BrO5 
Formula weight  333.17 
Temperature  150(2) K 
Wavelength  0.71073 Å 
Crystal system  orthorhombic 
Space group  Pna21 
Unit cell dimensions a = 14.3578(16) Å = 90°. 
 b = 11.7005(14) Å = 90°. 
 c = 8.2619(9) Å  = 90°. 
Volume 1387.9(3) Å
3
 
Z 4 
Density (calculated) 1.594 Mg/m
3
 
Absorption coefficient 2.975 mm
-1
 
F(000) 680 
Crystal size 0.490 x 0.298 x 0.145 mm 
Theta range for data collection 2.245 to 28.701°. 
Index ranges -19<=h<=19, -15<=k<=15, -11<=l<=10 
Reflections collected 21187 
Independent reflections 3366 [R(int) = 0.0327] 
Completeness to theta = 25.242° 100.0 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.67 and 0.48 
Data / restraints / parameters 3366 / 1 / 176 
Goodness-of-fit on F
2
 1.018 
Final R indices [I>2sigma(I)] R1 = 0.0219, wR2 = 0.0472 
R indices (all data) R1 = 0.0262, wR2 = 0.0483 
Absolute structure parameter 0.021(5) 
Largest diff. peak and hole 0.377 and -0.281 e
.
Å
-3 
Experimental section 
171 
 
Synthesis of ethyl 2-(4-bromophenyl)-2,3,3-trimethoxypropanoate (4.3b)
 
 
Following general procedure F, the title compound 4.3b (75 mg, 0.21 mmol, 54%) was isolated as a 
colorless oil. Purification was performed by preparative TLC (n-pentane:EtOAc = 40:1). 
1
H NMR (300 MHz, Chloroform-d) δ 7.48 (d, J = 9.0 Hz, 2H, CH), 7.42 (d, J = 8.9 Hz, 2H, CH), 
4.78 (s, 1H, CH), 4.31 (d, J = 7.1 Hz, 2H, CH2), 3.51 (s, 3H, CH3), 3.41 (s, 3H, CH3), 3.38 (s, 3H, 
CH3), 1.33 (t, J = 7.1 Hz, 3H, CH3). 
13
C NMR (75 MHz, Chloroform-d) δ 169.7 (CO), 134.1 (Cq), 130.9 (CH), 130.2 (CH), 122.5 (Cq), 
108.4 (CH), 86.9 (Cq), 61.6 (CH2), 58.6 (CH3), 57.9 (CH3), 54.6 (CH3), 14.3 (CH3). 
MS (GC-MS) m/z (relative intensity) = 317 (1) [M
+
-31], 273 (3), 244 (1), 227 (1), 199 (8), 183 (9), 75 
(100). 
HRMS (ESI-TOF, m/z) calcd. For C14H19BrO5 [M+Na]
+
: 369.0308; found: 369.0307. 
IR (ATR, neat, cm
-1
): 2937 (w), 2833 (w), 1734 (m), 1488 (m), 1181 (m), 1072 (s), 1009 (m), 937 
(m), 731 (m), 503 (m). 
Synthesis of ethyl 2-(4-chlorophenyl)-2,3,3-trimethoxypropanoate (4.3c) 
 
Following general procedure F, the title compound 4.3c (82 mg, 0.27 mmol, 68%) was obtained as 
a colorless solid. Purification was performed by flash chromatograohy (n-pentane:EtOAc = 20:1). 
m.p.: 122-123 °C 
1
H NMR (300 MHz, Chloroform-d) δ 7.48 (d, J = 8.9 Hz, 1H, CH), 7.32 (d, J = 8.8 Hz, 1H, CH), 
4.78 (s, 1H, CH), 4.32 (qd, J = 7.1, 1.0 Hz, 2H, CH2), 3.51 (s, 3H, CH3), 3.41 (s, 3H, CH3), 3.38 (s, 
3H, CH3), 1.33 (t, J = 7.1 Hz, 3H, CH3). 
13
C NMR (75 MHz, Chloroform-d) δ 169.8 (Cq), 134.2 (Cq), 133.5 (Cq), 129.8 (CH), 127.9 ,(CH) 
108.4 (CH), 86.8 (Cq), 61.6 (CH2), 58.6 (CH3), 57.9 (CH3), 54.6 (CH3), 14.3 (CH3). 
MS (GC-MS) m/z (relative intensity) = 271 (1) [M
+
-31], 229 (5), 183 (3), 155 (16), 139 (16), 111 
(11), 75 (100). 
HRMS (ESI-TOF, m/z) calcd. For C14H19Cl2O5 [M+Na]
+
: 325.0813; found: 325.0815. 
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IR (ATR, neat, cm
-1
): 2938 (w), 2834 (w), 1731 (m), 1491 (m), 1181 (m), 1076 (s), 1038 (m), 1014 
(s), 963 (m). 733 (m), 507 (m). 
Synthesis of methyl 2-(3,4-dichlorophenyl)-2,3,3-trimethoxypropanoate (4.3d) 
 
Following general procedure F, the title compound 4.3d (92 mg, 0.28 mmol, 71%) was obtained as 
colorless solid. Purification was performed by flash chromatograohy (n-pentane:EtOAc = 20:1). 
m.p.: 78 °C 
1
H NMR (300 MHz, Chloroform-d) δ 7.65 (dd, J = 2.1, 0.5 Hz, 1H, CH), 7.42 (dd, J = 8.5, 0.5 Hz, 
1H, CH), 7.37 (dd, J = 8.5, 2.1 Hz, 1H, CH), 4.77 (s, 1H, CH), 3.85 (s, 3H, CH3), 3.53 (s, 3H, CH3), 
3.42 (s, 3H, CH3), 3.37 (s, 3H, CH3). 
13
C NMR (75 MHz, Chloroform-d) δ 169.9 (CO), 135.1 (Cq), 132.4 (Cq), 132.0 (Cq), 130.6 (CH), 
129.6 (CH), 128.0 (CH), 108.2 (CH), 86.6 (Cq), 58.9 (CH3), 57.9 (CH3), 54.7 (CH3), 52.7 (CH3). 
MS (GC-MS) m/z (relative intensity) = 324 (1) [M
+
], 291 (2), 263 (3), 219 (2), 189 (12), 173 (13), 75 
(100). 
HRMS (ESI-TOF, m/z) calcd. For C13H16Cl2O5 [M+Na]
+
: 345.0267; found: 345.0268. 
IR (ATR, neat, cm
-1
): 2935 (w), 1898 (w), 2834 (w), 1742 (s), 1225 (m), 1191 (m), 1180 (m), 1106 
(s), 1084 (s), 1049 (m), 979 (m), 921 (m), 797 (m), 718 (m), (674 (m), 517 (m). 
Synthesis of ethyl 2-(4-fluorophenyl)-2,3,3-trimethoxypropanoate (4.3e) 
 
Following general procedure F, the title compound 4.3e (104 mg, 0.38 mmol, 76%) was obtained as 
colorless oil. Purification was performed by flash chromatograohy (n-pentane:EtOAc = 20:1). 
1
H NMR (300 MHz, Chloroform-d) δ 7.51 (dd, J = 9.0, 5.4 Hz, 1H, CH), 7.04 (dd, J = 9.0, 8.5 Hz, 
1H, CH), 4.78 (s, 1H, CH), 3.84 (s, 3H, CH3), 3.50 (s, 3H, CH3), 3.42 (s, 3H, CH3), 3.37 (s, 3H, CH3). 
13
C NMR (75 MHz, Chloroform-d) δ 170.6 (CO), 162.7 (d, J = 246.9 Hz, Cq), 130.7 (d, J = 3.5 Hz, 
Cq), 130.1 (d, J = 8.1 Hz, CH), 114.8 (d, J = 21.3 Hz, CH), 108.5 (CH), 86.9 (Cq), 58.5 (CH3), 58.0 
(CH3), 54.6 (CH3), 52.5 (CH3). 
19
F NMR (282 MHz, Chloroform-d) δ -112.7 – -117.0 (m). 
Experimental section 
173 
 
MS (GC-MS) m/z (relative intensity) = 271 (1) [M
+
-31], 229 (5), 183 (3), 155 (16), 139 (16), 111 
(11), 75 (100). 
HRMS (ESI-TOF, m/z) calcd. For C14H19Cl2O5 [M+Na]
+
: 325.0813; found: 325.0815. 
IR (ATR, neat, cm
-1
): 2952 (w), 2836 (w), 1735 (m), 1508 (m), 1225 (m), 1076 (s), 911 (m), 727 (s). 
Synthesis of methyl 2-(2,5-difluorophenyl)-2,3,3-trimethoxypropanoate (4.3f) 
 
Following general procedure F, the title compound 4.3f (120 mg, 0.41 mmol, 83%) was obtained as 
colorless solid. Purification was performed by flash chromatograohy (n-pentane:EtOAc = 20:1). 
1
H NMR (300 MHz, Chloroform-d) δ 7.39 – 7.27 (m, 1H, CH), 7.06 – 6.90 (m, 2H, CH), 4.95 (d, 
J = 1.2 Hz, 1H, CH), 3.82 (s, 3H), 3.55 (s, 3H), 3.54 (s, 3H), 3.36 (d, J = 0.5 Hz, 3H). 
13
C NMR (75 MHz, Chloroform-d) δ 169.5 (Cq), 158.4 (dd, J = 241.6, 2.0 Hz, Cq), 156.7 (dd, 
J = 244.3, 2.5 Hz, Cq), 125.0 (dd, J = 14.6, 7.8 Hz, Cq), 117.1 (dd, J = 26.6, 4.0 Hz, CH), 116.7 (dd, 
J = 27.0, 8.8 Hz, CH), 116.7 (dd, J = 24.3, 9.3 Hz, CH), 106.5 (d, J = 2.7 Hz, CH), 83.9 (d, J = 3.2 
Hz, Cq), 58.3 (CH3), 57.9 (CH3), 54.1 (CH3), 52.6 (CH3). 
19
F NMR (282 MHz, Chloroform-d) δ -115.8 – -116.2 (m), -118.0 – -118.8 (m). 
MS (GC-MS) m/z (relative intensity) = 259 (1) [M
+
-31], 228 (2), 197 (8), 159 (10), 138 (18), 75 
(100). 
IR (ATR, neat, cm
-1
): 3087 (w), 2954 (w), 2834 (w), 1733 (s), 1491 (m), 1248 (m), 1166 (m), 1069 
(s), 986 (m), 818 (m), 768 (m), 718 (m). 
Synthesis of methyl 2-ethoxy-4-(1,1,2,3-tetramethoxy-3-oxopropan-2-yl)benzoate (4.3g) 
 
Following general procedure F, the title compound 4.3g (123 mg, 0.33 mmol, 83%) was isolated as 
a colorless oil. Purification was performed by flash chromatograohy (n-pentane:EtOAc = 10:1 → 5:1). 
1
H NMR (300 MHz, Chloroform-d) δ 7.73 (d, J = 8.2 Hz, 1H, CH), 7.22 (d, J = 1.6 Hz, 1H, CH), 
7.11 (dd, J = 8.2, 1.6 Hz, 1H, CH), 4.80 (s, 1H, CH), 4.34 (q, J = 7.1 Hz, 2H, CH2), 4.13 (q, J = 7.0 
Hz, 2H, CH2), 3.82 (s, 3H, CH3), 3.48 (s, 3H, CH3), 3.42 (s, 3H, CH3), 3.39 (s, 3H, CH3), 1.44 (t, 
J = 7.0 Hz, 3H, CH3), 1.36 (t, J = 7.1 Hz, 3H, CH3). 
Experimental section 
174 
 
13
C NMR (75 MHz, Chloroform-d) δ 170.4 (Cq), 166.4 (Cq), 158.1 (Cq), 140.9 (Cq), 130.8 (CH), 120.6 
(Cq), 119.6 (CH), 113.4 (CH), 108.7 (CH), 86.9 (Cq), 64.8 (CH2), 60.9 (CH2), 58.4 (CH3), 58.2 (CH3), 
55.1 (CH3), 52.5 (CH3), 14.8 (CH3), 14.4 (CH3). 
MS (GC-MS) m/z (relative intensity) = 370 (1) [M
+
-31], 311 (2), 237 (6), 221 (4), 147 (3), 119 (5), 75 
(100). 
HRMS (ESI-TOF, m/z) calcd. For C18H26O8 [M+H]
+
: 371.17004; found: 371.17003. 
IR (ATR, neat, cm
-1
): 2981 (w), 2938 (w), 2835 (w), 1728 (s), 1610 (m), 1417 (m) 1293 (m), 1240 (s), 
1074 (s), 1040 (m), 982 (m), 770 (m). 
Synthesis of methyl 2,3,3-trimethoxy-2-phenylpropanoate (4.3h) 
 
Following general procedure F, the title compound 4.3h (67 mg, 0.26 mmol, 66%) as colorless oil. 
Purification was performed by flash chromatograohy (n-pentane:EtOAc = 20:1). 
1
H NMR (300 MHz, Chloroform-d) δ 7.58 – 7.48 (m, 2H), 7.42 – 7.28 (m, 3H), 4.83 (s, 1H, CH), 3.83 
(s, 3H, CH3), 3.49 (s, 3H, CH3), 3.42 (s, 3H, CH3), 3.40 (s, 3H, CH3). 
13
C NMR (75 MHz, Chloroform-d) δ 170.9 (Cq), 135.2 (Cq), 128.3 (CH), 128.0 (CH), 128.0 (CH), 
108.8 (CH), 87.2 (Cq), 58.3 (CH3), 58.0 (CH3), 54.8 (CH3), 52.4 (CH3) 
MS (GC-MS) m/z (relative intensity) = 223 (1) [M
+
-31], 195 (5), 179 (2), 149 (4), 121 (20), 105 (25), 
75 (100). 
HRMS (ESI-TOF, m/z) calcd. For C13H18O5 [M+Na]
+
: 277.1046; found: 277.1046. 
IR (ATR, neat, cm
-1
): 2951 (w), 2834 (w), 1733 (m), 1190 (m), 1106 (m), 1076 (s), 910 (m), 726 (s), 
698 (m), 646 (m). 
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Synthesis of dimethyl (E)-4-(dimethoxymethyl)-4-methoxypent-2-enedioate (4.6a) 
 
Following general procedure F on a 0.2 mmol scale, the title compound 4.6a (28 mg, 0.11 mmol, 
53%) was obtained as colorless solid. Purification was performed by flash chromatograohy (n-
pentane:EtOAc = 5:1). 
1
H NMR (500 MHz, Chloroform-d) δ 7.09 (d, J = 16.1 Hz, 1H, CH), 6.17 (d, J = 16.1 Hz, 1H, CH), 
4.54 (s, 1H, CH), 3.82 (s, 3H, CH3), 3.76 (s, 3H, CH3), 3.53 (s, 3H, CH3), 3.45 (s, 3H, CH3), 3.33 (s, 
3H, CH3). 
13
C NMR (126 MHz, Chloroform-d) δ 169.5 (Cq), 166.4 (Cq), 141.2 (CH), 124.5 (CH), 108.1 (CH), 
86.3 (Cq), 58.6 (CH3), 57.6 (CH3), 54.2 (CH3), 52.7 (CH3), 51.9 (CH3). 
MS (GC-MS) m/z (relative intensity) = 230 (2) [M
+
-31], 199 (8), 171 (4), 113 (13), 75 (100). 
HRMS (ESI-TOF, m/z) calcd. For C11H18O7 [M+Na]
+
: 285.0945; found: 285.0946. 
Synthesis of methyl 2-(4-bromophenyl)-2-methoxy-3-oxopropanoate (4.7a) 
 
Dimethylacetale 4.3a (50 mg, 0.15 mmol, 1.0 equiv.) was dissolved in acetone (3 mL). Iodine 
(114 mg, 0.45 mmol, 3.0 equiv.) was added. The reaction mixture was stirred for 2 hours at 60 °C. The 
crude mixture was concentrated and quenched with Na2S2O3 and extracted with Et2O (3 x 20 mL). The 
combined organic layers were washed with brine (25 mL), dried over Na2SO4 and concentrated under 
reduced pressure. Purification by flash chromatography (n-pentane/EtOAc = 20:1) yielded the title 
compound 4.7a (42 mg, 0.15 mmol, 99%) as colorless oil. 
1
H NMR (300 MHz, Chloroform-d) δ 9.77 (s, 1H), 7.55 (d, J = 8.47 Hz, 2H), 7.35 (d, J = 8.51 Hz, 
2H), 3.88 (s, 3H, CH3), 3.49 (s, 3H, CH3). 
13
C NMR (75 MHz, Chloroform-d) δ 194.1 (CHO), 168.9 (CO2R), 132.7 (CH), 132.5 (Cq), 129.0 
(CH), 124.3 (Cq), 89.0 (Cq), 55.6 (CH3), 54.8 (CH3). 
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Synthesis of 2-(4-Bromophenyl)-2,3,3-trimethoxypropan-1-ol (4.8a) 
 
Dimethylacetale 4.3a (50 mg, 0.15 mmol, 1.0 equiv.) was dissolved in dry THF (3 mL) and cooled 
to 0 °C. LiAlH4 (23 mg, 0.6 mmol, 4.0 equiv.) was added in two portions. The reaction mixture was 
stirred for 0 °C for 30 min. The crude mixture was quenched by dropwise addition of MeOH (2 mL) 
and extracted with EtOAc (3 x 10 mL). The combined organic layers were washed with brine (25 mL), 
dried over Na2SO4 and concentrated under reduced pressure. Purification by flash chromatography (n-
pentane/EtOAc = 20:1) yielded the title compound 4.8a (42 mg, 0.15 mmol, 99%) as translucid oil. 
1
H NMR (300 MHz, Chloroform-d) δ 7.41 (d, J = 8.5 Hz, 1H), 7.17 (d, J = 8.5 Hz, 2H), 4.35 (d, 
J = 11.9 Hz, 1H), 4.23 (d, J = 0.7 Hz, 1H), 3.85 (d, J = 11.9 Hz, 1H), 3.46 (s, 3H), 3.17 (s, 3H), 3.16 
(s, 3H). 
13
C NMR (75 MHz, Chloroform-d) δ 137.4 (Cq), 131.3 (CH), 129.0 (CH), 121.9 (Cq), 110.8 (CH), 
81.5 (Cq), 61.7 (CH2), 58.3 (2CH3), 50.9 (CH3). 
MS (GC-MS) m/z (relative intensity) = 273 (1) [M
+
-31], 229 (2), 199 (8), 183 (6), 155 (5), 118 (7), 75 
(100). 
HRMS (ESI-TOF, m/z) calcd. For C12H17BrO4 [M+Na]
+
: 327.0202; found: 327.0208. 
IR (ATR, neat, cm
-1
): 3456 (w), 2934 (w), 2832 (w), 1488 (w), 1189 (w), 1098 (m), 1071 (s), 1008 
(m), 969 (w), 823 (w). 
Synthesis of 2-(4-Bromophenyl)-2,3,3-trimethoxypropanoic acid (4.9a) 
 
Dimethylacetale 4.3a (50 mg, 0.15 mmol, 1.0 equiv.) and LiOH were dissolved in THF/H2O (3 mL) 
and stirred at 80 °C for 16 hours. The reaction mixture was allowed to cool to ambient temperature 
and extracted with Et2O (3 x 10 mL). The aqueous layer was acidified to pH 1 with 1M HCl (2 mL) 
and extracted with Et2O (3 x 10 mL). The combined organic layer were washed with brine (25 mL), 
dried over Na2SO4 and concentrated under reduced pressure. The title compound 4.9a (42 mg, 
0.15 mmol, 99%) was obtained as colorless solid. 
1
H NMR (300 MHz, Acetone-d6) δ 7.46 (m, 4H, 2 CH3), 4.87 (s, 1H, CH), 3.46 (s, 3H, CH3), 3.36 (s, 
3H, CH3), 3.34 (s, 3H, CH3). 
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13
C NMR (75 MHz, Acetone-d6) δ 170.7 (CO), 136.2 (Cq) , 131.4 (CH), 131.0 (CH), 122.1 (Cq), 109.0 
(CH), 87.0 (Cq), 58.7 (CH3), 57.6 (CH3), 54.5 (CH3). 
MS (GC-MS) m/z (relative intensity) = 287 (1) [M
+
-31], 275 (2), 242 (11), 227 (8), 183 (12), 148 
(14), 75 (100). 
HRMS (ESI-TOF, m/z) calcd. For C12H15BrO5 [M-H]
+
: 317.0030; found: 317.0035. 
Synthesis of methyl -2-(4-(benzo[d][1,3]dioxol-5-yl)phenyl)-2,3,3-trimethoxypropanoate (4.11) 
 
Benzo[d][1,3]dioxol-5-ylboronic acid 4.10 (52.3 mg, 0.32 mmol, 1.2 equiv.), Na2CO3 (89 mg, 
0.84 mmol,4.0 equiv.) and Pd(PPh3)4 (24 mg, 10 mol%) were dissolved in DME (3.8 mL) and H2O 
(0.8 mL). Methyl 2-(4-bromophenyl)-2,3,3-trimethoxypropanoate (4.3a) (70 mg, 0.21 mmol, 
1.0 equiv.) was added in one portion. The reaction mixture was placed in a pre-heated oil bath and 
stirred at 100 °C for 5 hrs. The reaction mixture was quenched with EtOAc/H2O (10 mL) and 
extracted with Et2O (3 x 20 mL). The combined organic layers were washed with brine (25 mL), dried 
over Na2SO4 and concentrated under reduced pressure. Purification by flash chromatography (n-
hexane/EtOAc = 20:1) yielded the title compound 4.11 (71 mg, 0.19 mmol, 90%) as colorless solid. 
m.p.: 122 °C 
1
H NMR (300 MHz, Chloroform-d) δ 7.6 (d, J = 8.8 Hz, 2H), 7.5 (d, J = 8.8 Hz, 2H), 7.1 – 7.0 (m, 
2H), 6.9 (d, J = 8.6 Hz, 1H), 6.0 (s, 2H), 4.9 (s, 1H), 3.9 (s, 3H), 3.5 (s, 3H), 3.5 (s, 3H), 3.4 (s, 3H). 
13
C NMR (75 MHz, Chloroform-d) δ 170.8 (Cq), 148.2 (Cq), 147.2 (Cq), 140.7 (Cq), 135.1 (Cq), 133.7 
(Cq), 128.6 (CH), 126.3 (CH), 125.1 (Cq), 120.8 (CH), 108.7 (CH), 107.7 (CH), 101.3 (CH2), 87.2 
(Cq), 58.5 (CH3), 58.0 (CH3), 54.7 (CH3), 52.4 (CH3). 
MS (GC-MS) m/z (relative intensity) = 374 (1) [M
+
], 343 (2), 299 (6), 241 (8), 139 (25), 75 (100). 
HRMS (ESI-TOF, m/z) calcd. For C20H22O7 [M+Na]
+
: 397.1258; found: 397.1259. 
IR (ATR, neat, cm
-1
): 2884 (w), 2827 (w), 1741 (s), 1477 (m), 1227 (s), 1178 (m), 1103 (s), 1085 (s), 
1036 (m), 935 (m), 911 (m), 811 (s), 799 (s), 535 (m). 
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Empirical formula  C20H22O7 
Formula weight  374.37 
Temperature  150(2) K 
Wavelength  0.71073 Å 
Crystal system  monoclinic 
Space group  P21/n 
Unit cell dimensions a = 9.7096(3) Å = 90°. 
 b = 7.1009(2) Å = 100.031(1)°. 
 c = 26.6401(7) Å  = 90°. 
Volume 1808.67(9) Å
3 
Z 4 
Density (calculated) 1.375 Mg/m
3 
Absorption coefficient 0.104 mm
-1
 
F(000) 792 
Crystal size 0.478 x 0.440 x 0.162 mm 
Theta range for data collection 2.136 to 28.000°. 
Index ranges -12<=h<=12, -9<=k<=9, -35<=l<=35 
Reflections collected 35963 
Independent reflections 4368 [R(int) = 0.0314] 
Completeness to theta = 25.242° 100.0 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.98 and 0.91 
Data / restraints / parameters 4368 / 0 / 248 
Goodness-of-fit on F
2
 1.034 
Final R indices [I>2sigma(I)] R1 = 0.0445, wR2 = 0.1103 
R indices (all data) R1 = 0.0555, wR2 = 0.1182 
Largest diff. peak and hole 0.515 and -0.231 e
.
Å
-3 
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